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PREFACE 
This thesis is the result of a four-year project funded by the Faculty of 
Medical Sciences, University of Nijmegen. In this project the author was 
appointed as 'assistent-in-opleiding (AIO)' (junior researcher) from 
01.01.91 to 01.01.95. The aim of this investigation was to study the cell 
biological and clinical aspects of the expression of the serine proteinase 
inhibitor skin-derived antileukoproteinase (SKALP) by human 
keratinocytes. Four main parts can be distinguished: part I (chapters 2 
and 3) deals with the basic and molecular studies, part II (chapters 4 and 
5) comprises the histological localization studies in normal and psoriatic 
tissue, part III (chapters 6 and 7) deals with the use of SKALP 
measurements in urine or serum for monitoring disease activity in 
psoriasis, and part IV (chapters 8 and 9) with the histological studies in 
human epidermal tumors. 
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INTRODUCTION 
Polymorphonuclear leukocytes and proteinases 
Polymorphonuclear leukocytes (PMN) are inflammatory cells with the 
potential to destroy tissues due to reactive oxygen metabolites and 
proteolytic enzymes. This destructive potential may be used beneficially 
as a defense mechanism against the environment, i.e. bacterial and 
fungal infection, but it may also be directed against the organism itself. 
PMN are known to cause tissue damage in many diseases [1]: arthritis 
[2-4], glomerulonephritis [5,6], cutaneous vasculitis [7], emphysema 
[8,9], adult respiratory distress syndrome [10,11], the allergic late phase 
asthmatic response [12], sepsis [13,14], bullous dermatoses [15-17], and 
tumor invasion and metastasis [18]. Most of the damage results from 
proteinases that degrade proteins in physiological and pathological 
processes [19,20]. PMN aré known to contain several proteinases such as 
elastase, cathepsin G, collagenase, plasminogen activator, and proteinase 
3. 
The major PMN-derived proteinase in humans is human leukocyte 
elastase (E.C. 3.4.21.37), a serine proteinase with a broad range of 
substrates such as elastin, proteoglycans, collagen, fibrinogen, 
fibronectin, and keratins [8,21,22]. PMN contain 3 pg elastase per cell 
[23], which results in a daily turnover of more than 250 mg elastase 
[24], which has to be counteracted to prevent damage to normal tissue. 
Other elastases or elastase-like enzymes have been described in different 
cell types such as monocytes, eosinophils, basophils and mast cells 
[25-27]. 
Proteinase 3 has a substrate specificity similar to that of human 
leukocyte elastase [28]; it can induce emphysema in hamsters [29], and 
was shown to be the target antigen of anti-neutrophil cytoplasm auto-
antibodies associated with Wegener's granulomatosis [30]. Furthermore, 
it may have a microbicidal action based on a nonproteolytic mechanism 
[31,32]. 
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Proteinase inhibitors 
Because of the nature of the function of the proteinases, a balanced 
homeostatic control of their activities is needed, and three principal in 
vivo mechanisms that prevent unwanted proteolytic tissue damage are 
known [21,33,34]. First, compartmentalization of enzymes by 
membranes provides a way to store injurious agents and prevents 
damage of tissues. Second, enzymes may be secreted in latent, inactive 
forms that require activation to degrade proteins, as is the case for 
metalloproteinases, and most of the serine proteinases and cysteine 
proteinases. Third, and relevant for this thesis, proteinase inhibitors are 
present as regulatory elements that counteract proteolytic activity by 
forming an inactive complex with their target proteinases. 
The epidermis is an avascular tissue compartment to which nutrients 
and plasma proteins are supplied via diffusion from the dermal papillary 
vessels. During inflammation plasma protein levels are rapidly increased 
in epidermis [35], and diffusion of proteinase inhibitors together with 
other plasma components to the tissue site may occur [36]. However, in 
normal epidermis hardly any anti-elastase activity can be found [37], 
although the presence of αϊ-proteinase inhibitor (αϊ-PI) and a2-
macroglobulin has been noticed in small quantities in normal skin 
[38,39]. 
Inflammation can be defined as the non-specific response of tissue 
following injury in order to restore homeostasis and tissue integrity. A 
destructive phase can be distinguished during which the stimulus is 
counteracted, followed by a phase of repair of the tissue in which 
hyperproliferation plays a role. Inflammatory mediators that are locally 
produced diffuse into the circulation and initiate a systemic reaction: the 
acute phase response [40]. This reaction includes fever, activation of the 
clotting system, and a change of cytokine production, which 
subsequently leads to the activation of inflammatory cells such as PMN, 
and an increased hepatic production of proteinase inhibitors [41]. This 
increased production of proteinase inhibitors such as al-PI and a2-
macroglobulin is thought to anticipate and prevent excessive proteolysis 
by PMN/monocyte-derived proteinases such as elastase, proteinase 3, 
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and cathepsin G. Some of these proteinase inhibitors may be present 
systemically, such as al-PI, al-antichymotrypsin, inter-a-trypsin 
inhibitor, and a2-macroglobulin, which are abundantly present in human 
blood plasma [33,42,43]. Inhibitors may also be produced locally such as 
SKALP (as is described in this thesis), the plasminogen activator 
inhibitors PAI-1 and PAI-2 [44], and ALP (antileukoprotease) [45,46], 
also known as SLPI (secretory leukocyte proteinase inhibitor) [47], as 
HUSI-I (human seminal plasma inhibitor) [48], as BSI-TE (bronchial 
secretion inhibitor with activity against trypsin, chymotrypsin, elastase 
and cathepsin G) [49], as BrPI (bronchial proteinase inhibitor) [50], and 
as MPI (mucous proteinase inhibitor) [51]. 
Inflammatory skin diseases 
The cutaneous inflammatory response to injury, either trauma-induced or 
in skin diseases such as psoriasis or eczema, comprises mediators that 
are partly derived from activated keratinocytes [52]. These activated 
keratinocytes may produce cytokines that cause directional migration of 
leukocytes towards the site of inflammation [53] and activation of 
leukocyte function in situ [54]. This may result in a mixed accumulation 
of inflammatory cells such as macrophages, lymphocytes, and 
neutrophils [55]. Subsequently, the activated neutrophils and 
macrophages degranulate, and proteinases such as elastase and cathepsin 
G are released into the environment, i.e. the inflammatory site [56]. 
In normal skin, proteinases play an important physiological role in the 
process of keratinization by catalyzing the breakdown of nuclei and cell 
organdis during transition from granular cells to horny cells. However, 
proteinases are also responsible for blister formation and acantholysis in 
pathological conditions such as several bullous diseases [16,44]. Naito et 
al reported that bullous pemphigoid blister formation was caused by 
PMN-proteinases, which were released after complement activation with 
production of chemotactic peptides that initiated PMN migration to 
basement membranes [57]. In patients with dermatitis herpetiformis high 
levels of elastase activity were present, probably derived from PMN that 
were abundantly present in the lesions [15]. In vitro experiments 
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demonstrated involvement of PMN elastase in the degradation of the 
basement membrane [58,59], and also in vivo the basement membrane 
appeared to be the target for human leukocyte elastase [60]. Eczema and 
psoriasis are other skin diseases in which PMN elastase is implicated 
[61-63]. In vitro, human leukocyte elastase appeared to impair epidermal 
intercellular cohesion, resembling in vivo findings in eczema such as 
spongiosis and acantholysis [64]. 
Epithelial cells produce not only plasminogen activators (urokinase and 
tissue plasminogen activator) under physiological conditions, but also the 
plasminogen inhibitors 1 and 2, that balance the activity of these 
proteolytic enzymes [44]. In psoriasis plasminogen activators are 
increased, especially the tissue type, which may activate the complement 
cascade and induce inflammation [65-67]. Furthermore, plasminogen 
activators appear to be associated with cell migration [68,69] and cell 
division [66,70], and may be involved in the increased rate of 
proliferation of the epidermal cells in psoriasis [71]. At inflammatory 
loci, proteinases may leak into surrounding normal tissue, and proteins 
need to be protected against destruction. 
The serine proteinase inhibitors αϊ-PI and al-antichymotrypsin are 
acute phase proteins that increase during inflammation, and that may 
fulfill this protective function [41]. 
Psoriasis 
As mentioned above, PMN play a role in many diseases, and psoriasis is 
a skin disorder in which PMN invasion of the epidermis is an important 
and early feature [72,73]. Psoriasis is a common skin disease in the 
Western world, affecting about 2% of the people, men and women alike. 
Patients have sharply demarcated, erythematous lesions with a silvery 
white scaling, which may be minimal in size (pinpoint lesions), may be 
plaque-like, or may fuse and cover large areas of the skin [74]. A wide 
spectrum of involved area of the skin is seen, from solitary lesions that 
are restricted in size, to the most extensive form with (nearly) whole 
body involvement (erythroderma). Pustular forms are seen as well, both 
localized (palmoplantar pustulosis) or generalized (von Zumbusch type). 
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In addition, extracutaneous manifestations of psoriasis affecting nails, 
mucosal membranes, and joints may be present [75]. 
Histologically, psoriasis is characterized by inflammatory changes in 
dermis and epidermis such as dilation of the capillaries in the papillary 
dermis with extravasation of lymphocytes, erythrocytes, macrophages, 
and PMN; edema of the papillary dermis, hyperkeratosis, parakeratosis, 
disappearance of the granular layer, spongiosis and pustule formation in 
the epidermis are seen as well. Reports on the sequence of the events 
conflict [76-80]. Most groups agree that dermal inflammatory events 
precede epidermal changes, although altered keratinocyte differentiation 
preceding vascular abnormalities during the spread of psoriatic plaques 
has been described [76]. PMN involvement is regarded as an important 
feature of psoriasis [63,73]. While both in the early phase of the 
psoriatic lesion and in the pustular forms of psoriasis PMN invasion of 
the epidermis is the histologically predominant event [72,74], in chronic 
stable plaque psoriasis the intra-epidermal PMN accumulation is less 
impressive [81]. 
Skin-derived antileukoproteinase (SKALP): review of the data 
available at the start of the project 
In 1988, elastase-inhibiting activity could be demonstrated in lesionai 
psoriatic epidermis and scales of lesionai epidermis, whereas extracts 
from normal human skin showed hardly any inhibition of elastase 
[82-84]. The inhibiting activity was caused by a low molecular weight 
endogeneous inhibitor that was heat stable and resistant to extremes of 
pH. Furthermore, the inhibitor could be induced by experimental 
inflammation. Psoriatic scales were used as a source to purify the 
inhibitor for characterization experiments. The inhibiting activity 
appeared to be caused by two species of new inhibitors with molecular 
weights of 10 and 20 kDa, as was shown on SDS-PAGE and by gel 
permeation experiments [37]. The inhibitors expressed a strong specific 
inhibition towards human leukocyte elastase with a K,<10'10 M, since 
there was no interference with cathepsin G, which is inhibited by other 
elastase inhibitors. Sellotape stripping as an in vivo model for wound 
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healing, yielding an inflammatory reaction of the skin and 
hyperproliferation of keratinocytes [85], induced elastase-inhibiting 
activity [86]. In view of the kinetics with maximal inhibiting activity 48 
hours after injury, it was suggested that the inhibitor might function as 
an off-switch of epidermal inflammation [83]. Because amino acid 
sequencing demonstrated partial homology with the elastase inhibitor 
antileukoprotease (ALP) this new elastase inhibitor was named skin-
derived antileukoproteinase (SKALP). 
Two inhibitors derived from bronchial secretions were similar to 
SKALP with respect to inhibition of human leukocyte elastase, but were 
different with respect to the interference with trypsin, chymotrypsin or 
cathepsin G. Hochstrasser et al reported a low molecular weight inhibitor 
specific to human leukocyte elastase and porcine pancreatic elastase, but 
with other inhibiting characteristics (Κ;=5·10"'0Μ for HLE) and another 
iso-electric point (pl>ll) than SKALP [83,87]. Rasche et al [88] 
described the same elastase-specific inhibitor in human bronchial mucus 
(BSI-E), which might be present in a masked form, probably in complex 
with proteases. The rapid oxidative inactivation of the inhibitor made it 
unlikely that this molecule was identical to SKALP. Kramps et al 
described an elastase-specific inhibitor from human bronchial secretion, 
which was named LMI-5000 because of its low molecular weight of 
5000 Da. The lower molecular weight, the elastase-inhibiting activity 
under reducing conditions, and the amino acid composition were 
different from the known properties of SKALP [89]. However, our own 
antisera raised against SKALP isolated from psoriatic scales did react 
with this LMI-5000. 
The elastase-inhibiting activity was demonstrated not only in psoriasis 
and after sellotape stripping, but also in other scaling skin disorders [90]. 
In the erythrodermic form of autosomal recessive lamellar ichthyosis and 
in Netherton syndrome, elastase-inhibiting activity was significantly 
increased. These monogenic disorders of keratinization are also 
accompanied by inflammation. Non-inflammatory monogenic disorders 
of keratinization and atopic dermatitis showed only a slight increase in 
elastase-inhibiting activity as compared to normal skin [90]. 
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In the spreading psoriatic lesion SKALP activity was maximal in the 
center and decreased towards the marginal zone as measured by a 
functional assay; more than 4 mm outside the edge of the lesion SKALP 
activity was similar to that in normal skin [91]. Intra-epidermal PMN 
accumulation is increasing from the center of the psoriatic lesion towards 
the periphery where psoriasis is active [91,92]. 
SKALP was further characterized and appeared to be a very cationic 
molecule, which could be present in an intact form or in a degraded 
form with a lower molecular weight [93]. The intact molecule with a 
molecular weight of approximately 18 kDa was the main form in 
cultured keratinocytes, whereas the 11 kDa fragment was the 
predominant form in psoriatic scales. The latter was subjected to N-
terminal gas-phase sequencing, and within a stretch of 16 amino acids, a 
40% homology was found with the C-terminal half of ALP (comprising 
the reactive site). Apart from human leukocyte elastase, porcine 
pancreatic elastase (PPE) was also inhibited, and the iso-electric point 
appeared to be pl>10.5 [93]. 
At the same time, elafin, an elastase-specific inhibitor of human skin 
was described by Wiedow et al [94]. Complete N-terminal sequencing 
showed that the inhibitor was composed of 57 amino acids, and a 
molecular weight of 7017 Da was reported. Wiedow et al performed 
experiments that proved elafin not only to inhibit human leukocyte 
elastase and porcine pancreatic elastase, but also proteinase 3, an elastin-
degrading proteinase from neutrophils [95]. 
The presence of an elastase-specific inhibitor in lung tissue as 
described by Hochstrasser et al, Rasche et al, and Kramps and Klasen 
[87-89], was confirmed and described in greater detail by Sallenave et 
al. They reported an elastase-specific inhibitor with a molecular weight 
of 2.5 kDa [96], which was very similar to a portion of elafin and which 
showed some homology with ALP, especially around the reactive site fo 
human leukocyte elastase. 
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Aim of this project 
At the start of the project only biochemical data were available. Two 
related projects were set up for the molecular and functional 
characterization of SKALP: the project described here, and the project 
900-512-146 of the 'Netherlands Organization for Scientific Research 
(NWO)' which deals with the molecular structure and regulation of the 
expression of SKALP. The aims of the project described in this thesis 
were: 
1. To study cell biological aspects of SKALP such as distribution and 
localization in vivo, and the expression by cultured keratinocytes. 
2. To investigate the clinical applications of SKALP measurement in 
human tissues. 
Specific questions of this project were: 
1. Which cells are responsible for the production of SKALP in skin? 
2. Is SKALP expression restricted to skin, or is SKALP also produced 
in other issues? 
3. Which factors induce SKALP expression in vivo and in vitro? 
4. What is the expression pattern in skin diseases? 
5. Can SKALP be used as a marker for disease activity in psoriasis? 
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ABSTRACT 
SKALP/Elafin is a proteinase inhibitor found in psoriatic epidermis as a 
short polypeptide of 6 kDa. Here we present evidence that this protein is 
synthesized as a larger precursor molecule with distinct biological 
features. Purification and NH2-terminal sequencing of SKALP/elafin 
from cultured human keratinocytes and the cloning of its cDNA revealed 
the existence of a mature protein, which upon cleavage of a hydrophobic 
signal sequence of 22 amino acids has a calculated molecular mass of 
9.9 kDa (95 amino acids). In addition to the known proteinase inhibitor 
domain, the mature protein contains a domain with 4 repeats which are 
homologous to putative transglutaminase substrate motifs. We were able 
to demonstrate on Western blots that immunoreactive SKALP is present 
in high molecular weight proteins extracted from psoriatic skin. This 
suggests that SKALP is covalently attached to epidermal proteins. In 
addition it was found that both the complete SKALP molecule and a 
synthetic peptide of the NH2-terminal portion of SKALP could be used 
as a transglutaminase substrate. We therefore speculate that 
SKALP/elafin, secreted by epidermal keratinocytes in inflamed skin, 
exists both as a free 6-kDa form and as an immobilized 9.9-kDa form 
covalently attached to the comified envelopes by transglutaminase cross-
linking. 
INTRODUCTION 
Elastase is a serine proteinase derived from polymorphonuclear 
leukocytes [1]. When secreted at sites of inflammation this enzyme can 
cause severe tissue damage, since it is active at neutral pH and can 
degrade a broad range of connective tissue components such as elastin 
[2], proteoglycans [3] and collagen [4,5]. The action of elastase, like that 
of many other proteinases, is controlled by proteinase inhibitors which 
are found in the extracellular fluids [6]. A crucial role for proteinases 
and their inhibitors has been suggested for several pathologic conditions, 
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such as emphysema [2,7], arthritis [3,8], nephritis [9], and certain skin 
diseases [10,11]. 
Recently we have described a new, low molecular weight elastase 
inhibitor derived from psoriatic skin [12,13] termed SKALP (skin-
derived antileukoproteinase). We demonstrated that this inhibitor can be 
found in the epidermis of several inflammatory skin diseases, but not in 
normal human epidermis. SKALP, also termed elafm by Wiedow et al. 
[14], was found both in the epidermis and in the urine of psoriatic 
patients [15]. Immunohistochemical studies showed that SKALP/elafin is 
found in the suprabasal differentiated keratinocytes of psoriatic epidermis 
[16]. 
In previous studies [12,13] we have shown that cultured human 
keratinocytes contain an elastase inhibitor with an apparent molecular 
mass of 18 kDa on SDS-PAGE, which is otherwise indistinguishable 
from SKALP/elafin derived from psoriatic epidermis using biochemical 
and immunochemical criteria. Here we describe the purification, NH2-
terminal sequencing, and cDNA sequence analysis of this elastase 
inhibitor from cultured keratinocytes. We conclude that this protein with 
a molecular mass of 9.9 kDa represents the precursor molecule of the 6-
kDa form of SKALP/elafin found in psoriatic epidermis. The NH2-
terminal part of this precursor was also shown to contain a domain with 
putative transglutaminase substrate motifs. Here we present evidence that 
transglutaminase-mediated cross-linking of SKALP can occur in human 
epidermis in vitro and in vivo. 
EXPERIMENTAL PROCEDURES 
Keratinocyte culture and extraction 
Human epidermal keratinocytes were cultured according to the 
Rheinwald-Green system [17] as previously described [18]. Cells were 
grown to confluence and lysed in 20 ml 0.025 mM triethylamine per 
100-ml tissue culture flask, containing approximately 20 χ 106 cells. Cell 
extracts were prepared by sonication on ice followed by centrifugation 
for 1 h at 40,000 χ g. The supernatant was concentrated by vacuum 
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centrifugation in a Speed-Vac concentrator (AS 160, Savant). The sample 
was dialyzed against distilled water, again centrifuged, and used for 
chromatography. Using this procedure, 100-200 ng of SKALP was 
obtained per 106 cells, assuming that all antielastase activity measured in 
the crude extract represents SKALP with a molecular mass of 9.9 kDa. 
Biopsies 
Human skin biopsies (0.3 mm thickness) from healthy volunteers and 
psoriatic patients were taken with a keratotome as previously described 
[12] and used for keratinocyte cultures and RNA extraction. 
Purification of SKALP 
Extracts from cultured keratinocytes were either directly used for 
reversed-phase chromatography or first purified on a РВЕ 118 
chromatofocusing column as described before [13]. Samples were 
chromatographed on а цЯРС C2/C18 PC 3.2/3 reversed-phase column 
using the SMART chromatography system (Pharmacia LKB 
Biotechnology INC.) at a flow of 240 μΐ per min. The gradient was 10 
min of 100% buffer A (0.1% trifluoroacetic acid in distilled water), then 
100% buffer A to 70% buffer В (0.1% trifluoroacetic acid in acetonitril) 
in 30 min (linear gradient) followed by a 5-min gradient to 100% buffer 
B. UV absorption was continuously recorded at 215 nm. The anti­
elastase activity of all fractions was measured fluori metrically using a 
synthetic substrate as described before [13], and active fractions of 
several runs were pooled and rechromatographed using the same 
conditions. The fraction containing peak activity was freeze-dried, 
dissolved in phosphate-buffered saline, and subjected to gel permeation 
chromatography on a Superdex 75 PC 3.2/30 column (Pharmacia) using 
the SMART chromatography system. The column was equilibrated with 
phosphate-buffered saline, and a flow rate of 80 μΐ per min was applied. 
The column was calibrated with Blue dextran (void volume), ovalbumin 
(43 kDa), cytochrome с (12 kDa), and L-dopa (total volume) as 
molecular mass markers (Sigma). Fractions were collected and 
antielastase activity was found in the major peak eluting from the 
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column. This material was analyzed (Eurosequence Inc., Groningen, The 
Netherlands) on a gas-phase sequenator (Model 477A) and an on-line 
HPLC (Model 120A), from Applied Biosystems. The material was not 
alkylated or otherwise modified prior to sequencing. 
Synthesis of a specific cDNA hybridization probe 
Total RNA was isolated from psoriatic epidermis by the single-step 
guanidinium thiocyanate method of Chomczynski and Sacchi [19]. First 
strand cDNA was generated from total RNA with Moloney murine 
leukemia virus RNase H- reverse transcriptase (GIBCO-BRL Life 
Technologies) under conditions as suggested by the supplier, using 
excess oligo(dT) primers. Part of the total reverse transcriptase (RT) 
reaction was used for mixed oligonucleotide-primed amplification of 
cDNA [20] to generate a SKALP-specific hybridization probe. Based on 
amino acid sequence data of elafin [14] degenerate PCR-primers were 
synthesized on a Gene Assembler Plus (Pharmacia). As the sense primer 
the degenerate codons for amino acids 1 to 7 were taken. The antisense 
primer represents amino acids 40 to 46, and the internal antisense primer 
contains the possible sequences encoding amino acids 33 to 39 in elafin 
(see also Fig. 2). All primers contained an additional BamHl site to 
facilitate subcloning of the amplified DNA. PCR-reactions were carried 
out using a DNA thermal Cycler (Perkin Elmer/Cetus) in 50-μ1 mixtures 
covered with mineral oil. The following buffer conditions were used: 
16.5 mM ammonium sulfate, 65 mM Tris-HCl, pH 8.8, 0.065 mM 
EDTA, 0.17 mg/ml bovine serum albumin, 10 mM (3-mercaptoethanol, 3 
mM magnesium chloride, 0.2 mM of each dNTP and 500 ng of each 
primer. After an initial boiling of 10 min the temperature was lowered to 
80°C, and 1 unit of Taq polymerase was added. Amplification was for 
30 cycles as follows: 60 s at 94°C, 90 s at 42°C, 90 s at 72°C. An 
additional 10 min at 72°C was used for the last cycle. To determine the 
specificity of the resulting PCR product, the DNA was purified from 
agarose gel and used as a template in a second PCR reaction under the 
same conditions with the sense primer and the internal antisense primer. 
To rescue the original amplified cDNA, purified cDNA was treated with 
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Proteinase К [21], digested with BamUl, subcloned into the 5a/nHI-sites 
of a pGEM-4 vector (Promega) and sequenced using the dideoxy chain 
termination procedure [22]. 
Library screening 
To determine the hybridization conditions for library screening with a 
243-base pair PCR-generated cDNA, this cDNA was initially used as a 
probe for Southern blot analysis of human blood cell genomic DNA 
following standard procedures [23]. Based on the results of this analysis, 
a random primed human keratinocyte cDNA library in the vector Xgtll 
(HLlllOb, Clonetech) was screened with replica filters (Hybond N+, 
Amersham Сотр.) at 65°C in hybridization buffer (500 mM sodium, 250 
mM phosphate, pH 7.2, 7% SDS, 1 mM EDTA). Washing of the filters 
was performed at 65°C in wash buffer (250 mM sodium, 125 mM 
phosphate, 1% SDS, 1 mM EDTA). The probe was labeled with 3 2P by 
random priming following standard procedures [23]. Hybridizing phage 
plaques were purified and XDNA was isolated. A Sacl/Kpnl-'msert from 
one positive λ clone was subcloned into pGEM-4 and used for further 
analysis. Based on the results of Southern blot analysis of this clone, 
using the 243-base pair PCR-generated cDNA as a probe, an 0.5-
kilobase pair EcoRl fragment was subcloned into pGEM-4, and both 
strands were completely sequenced. 
Computer analysis 
DNA sequence gel readings were recorded and edited using the IG-suite 
5.35 package (Intelligenetics, Inc.) on a SUN computer. Protein analysis 
was carried out using the CAMMSA software package on a VAX 
computer as provided by the Dutch CAOS/CAMM center. 
Antisera 
Antisera were raised against the 6-kDa form of SKALP/elafin which 
lacks the transglutaminase substrate domain. We used both recombinant 
elafin (a kind gift of Dr. N. Russell, ICI, United Kingdom) or SKALP 
purified from psoriatic scales [13]. Protein (50 μg) was cross-linked with 
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glutaraldehyde, dialysed against distilled water and emulsified with 
Freund's complete adjuvant [13]. Rabbits were immunized 
intracutaneously in the back, followed by two subcutaneous boosters at 
week 2 and 4. Preimmune serum was drawn before the experiments and 
immune serum was collected after 6 weeks. Titers in enzyme-linked 
immunosorbent assay were 1/20000. On Western blots, dilutions between 
1/100 and 1/1000 were used. The antisera were negative with extracts of 
normal human skin and human plasma proteins. Antisera raised against 
recombinant material and against purified protein from scales yielded 
identical staining patterns. 
SDS-PAGE and Western blotting 
Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel 
electroforesis (SDS-PAGE) on a 16 % gel, using tricine as a trailing ion 
instead of Tris-glycine [24], or on a 12% gel using the conventional 
SDS-PAGE [25]. Molecular mass markers used were: broad range 
prestained markers from Bio-rad (myosin (205 kDa), ß-galactosidase 
(116 kDa), bovine serum albumin (80 kDa), ovalbumin (49.5 kDa), 
carbonic anhydrase (32.5 kDa), soybean trypsin inhibitor (27.5 kDa), 
lysozyme (18.5 kDa), and aprotinin (6.5 kDa)), and l4C-methylated 
proteins from Amersham (myosin (200 kDa), phsophorylase b (92 kDa), 
bovine serum albumin (69 kDa), ovalbumin (46 kDa), carbonic 
anhydrase (30 kDa), and lysozyme (14.3 kDa)). Molecular masses 
according to the manufacturers. Gels were electroblotted on 
polyvinylidenedifluoride (PVDF) membranes (Millipore), and protein 
staining was performed with Amido Black according to standard 
procedures. Immunological detection of proteins was performed using 
the antisera described above, followed by biotinylated swine-anti-rabbit 
Ig and avidin-conjugated alkaline phosphatase using a colorimetrie 
detection system [15]. Preimmune serum of the same rabbits was used as 
a control. 
Preparation of a biotinylated peptide 
A peptide comprising amino acids 23 to 36 of SKALP (see also Fig. 2), 
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containing a glutamine which is part of a GQDXVK motif, putatively 
involved in cross-linking, was synthesized (Eurosequence Ine, 
Groningen, The Netherlands). The peptide (250 μg) was biotinylated 
with 500 μg of NHS-LC-biotin (Pierce) for 2 h at 37°C in 300 μΐ of 0.1 
M Na2C03 pH 8.0. The reaction was stopped by the addition of 20 μΐ of 
1 M Tris, pH 8.0 [26]. 
Cross-linking of the biotinylated peptide to stratum corneum 
proteins by endogenous and exogenous tranglutaminase 
Scales from a psoriatic patient (1 gram) were homogenized in 20 ml of 
phosphate buffered saline and centrifuged for 30 min at 40,000 χ g. The 
supernatant (2 mg of protein per ml) was sterilized through a 0.2-μιτι 
filter and stored at -20°C until further use. For cross-linking experiments 
10 μΐ of scale extract was used with 8 μΐ of biotinylated peptide solution 
[26]; either 0.01 unit of guinea pig liver transglutaminase (Sigma) or 
water (to measure the endogenous transglutaminase activity of the scale 
extract) was added. The reaction was initiated by the addition of CaCl2 
at a concentration of 8.7 mM, in a final reaction volume of 20 μΐ. A 
reaction mixture containing 50 mM of EDTA was used as a control. 
After 16 h at 37°C the reaction mixtures were diluted with SDS-sample 
buffer (containing dithiothreitol) and boiled for 2 min. Samples were 
subjected to SDS-PAGE (12% gel) and blotted onto PVDF membrane. 
Biotinylated proteins were detected with the Western Light kit (Tropix) 
according to the manufacturer's instructions. This assay uses avidin-
conjugated alkaline phosphatase and chemiluminescence of a sensitive 
alkaline phosphatase substrate. Positive bands were printed on x-ray 
film. 
Labeling of purified SKALP with [l4C]methylamine; detection of 
14C-labeled protein 
SKALP purified from cultured keratinocytes as described above, was 
assayed to act as an amine acceptor using [14C]-methylamine as a probe 
[27]. SKALP (1 μg) was dissolved in 50 mM Tris, 100 mM NaCl, pH 
7.5, containing 20% glycerol, 2 mM leupeptin, 1 mM 
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phenylmethanesulfonylfluoride, 8.7 mM CaCl2, 0.01 unit guinea pig liver 
transglutaminase, and 1 MBq of [l4C]methylamine (specific activity, 2.04 
GBq per mmol) in a final volume of 25 μΐ. After 2 h at 37°C the 
reaction was terminated by the addition of EDTA (20 mM final 
concentration). From this mixture 250 ng of SKALP was run on SDS-
PAGE (16% gel) and blotted onto PVDF membrane as described above. 
l4C-Labeled proteins (Amersham) were used as molecular mass markers. 
The dried blot was used for autoradiography on x-ray film, with two 
intensifying screens, for 62 h. 
RESULTS 
Purification and NH2-terminal sequencing of SKALP 
Reversed-phase chromatography of soluble proteins extracted from 
cultured keratinocytes yielded one peak of antielastase activity as shown 
in Fig. la. Pooled fractions were, after rechromatography, finally 
purified on a Superdex 75 gel permeation column which gave a peak of 
antielastase activity coinciding with the major peak recorded at 215 nm 
(Fig. lb). A K
av
 of 0.28 corresponding with an apparent molecular mass 
of 22 kDa was calculated. NH2-terminal gas-phase sequencing of this 
material identified 26 amino acids (see Fig. 2) of which the 7 COOH-
terminal amino acids overlap with the NH2-terminal sequence of the 76-
amino acid form of elafin purified from psoriatic scales [28]. In Fig. 2 
the amino acid sequence of SKALP from cultured keratinocytes is 
compared with the known sequence data of elafin from psoriatic scales. 
cDNA probe synthesis, library screening, and sequence analysis 
In order to verify and extend the protein sequence data we cloned and 
sequenced the SKALP-encoding cDNA. Amplification of cDNA reverse-
transcribed from psoriatic epidermis total RNA with the sense and 
antisense primer (Fig. 2) resulted in 2 distinct cDNAs. The largest cDNA 
of about 250 base pairs was used for a second PCR reaction with the 
sense primer and the internal antisense primer (Fig. 2). This resulted in a 
shorter PCR product of about 230 base pairs. The 250-base pair product 
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from the initial PCR reaction was subsequently subcloned into the 
BamHl site of a pGEM-4 vector. 
Fig. 1. a, reversed-phase chromatography (цЯРС C2/C18) of soluble proteins from 
cultured keratinocytes. Solid line, absorban« at 215 nm. Bars, antielastase activity 
expressed as units per fraction. 1 unit is the amount of inhibitor that gives 50% inhibition 
of 1 nmol of human leukocyte elastase [13]. b, gel permeation chromatography 
(Superdex 75) of partially purified SKALP obtained by reversed-phase chromatography. 
Solid line, absorbance at 215 nm. One fraction per minute was collected. Bars, 
antielastase activity in units per fraction. The material from fraction 16 was used for 
NH2-terminal sequencing. V0, void volume; Ova, ovalbumin (43 kDa); Cyt-c, cytochrome 
с (12 kDa); Vp total volume. 
One subclone, pGSKAl, containing the desired insert was characterized 
by DNA sequence analysis. The predicted amino acid sequence of the 
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insert of clone pGSKAl corresponded to the region from amino acid 31 
to 107 in Fig. 2. 
5'-CC 002 
Met Arg Ala Ser Ser Phe Leu Ile Val Val Val Phe Leu Ile Ala 015 
ATG AGG GCC AGC AGC TTC TTG АТС GTG GTG GTG TTC CTC АТС GCT 047 
Gly Thr Leu Val Leu Glu Ala Ala Val Thr Gly Val Pro Val Lys 030 
GGG ACG CTG GTT СТА GAG GCA GCT GTC ACG GGA GTT CCT GTT AAA 092 
Gly Gin Asp Thr Val Lyg Gly Arg Val Pro Phe Asn Gly Gin Asp 045 
GGT CAA GAC ACT GTC AAA GGC CGT GTT CCA TTC AAT GGA CAA GAT 137 
Pro Val Lys Gly Gin Val Ser Val Lys Gly Gin Asp Lys Val Lys 060 
CCC GTT AAA GGA CAA GTT TCA GTT AAA GGT CAA GAT AAA GTC AAA 182 
Ala Gin Glu Pro Val Lys Gly Pro Val Ser Thr Lys Pro Gly Ser 075 
GCG CAA GAG CCA GTC AAA GGT CCA GTC TCC ACT AAG CCT GGC TCC 227 
Cys Pro Ile Ile Leu Ile Arg Cys Ala Met Leu Asn Pro Pro Asn 090 
TGC CCC ATT АТС TTG АТС CGG TGC GCC ATG TTG AAT CCC CCT AAC 272 
Arg Cys Leu LyB Asp Thr Asp Cys Pro Gly Ile Lys Lys Cys Cys 105 
CGC TGC TTG AAA GAT ACT GAC TGC CCA GGA АТС AAG AAG TGC TGT 317 
Glu Gly Ser Cys Gly Met Ala Cys Phe Val Pro Gin END 117 
GAA GGC TCT TGC GGG ATG GCC TGT TTC GTT CCC CAG TGA GAGGGAG 363 
CCGGTCCTTGCTGCACCTGTGCCGTCCCCAGAGCTACAGGCCCCATCTGGTCCTAAGTC 422 
CCTGCTGCCCTTCCCCTTCCCACACTGTCCATTCTTCCTCCCATTCAGGATGCCCA-3' 4 7Θ 
Fig. 2. Nucleotide sequence and amino acid sequence of preSKALP. The first 18 base 
pairs of the cDNA are not indicated in this figure (see "Results"). The deduced amino 
acid sequence reveals a protein of 117 amino acids. The numbering of the amino acids 
starts with the methionine. The cleavage site for the putative signal sequence (τ) is 
indicated. Amino acids 23 to 48 and amino acids 85 to 100 were confirmed by NH2-
terminal gas-phase sequencing of SKALP from cultured human keratinocytes (see 
"Results") and from psoriatic scales [13], respectively. Amino acids 61 to 117 and amino 
acids 42 to 60 (underlined) are identical to, respectively, the amino acid sequence of 
elafin [14] and an additional NH2-terminal amino acid sequence of elafin [28]. The sites 
to which the PCR primers were directed are double underlined. 
Subsequent screening of a human keratinocyte cDNA library (lxlO5 
clones) with pGSKAl as a probe yielded three positive clones with 
larger inserts. After plaque purification and rescreening, the largest, 
clone FlAc53, was selected for further analysis. An .EcoRI-fragment 
which strongly hybridized with the cDNA probe, was subsequently 
subcloned into pGEM-4. Sequence analysis of the resulting subclone, 
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designated pGESKA, revealed an insert comprising 496 base pairs, 
including an open reading frame coding for a 117-amino acid protein 
(Fig. 2) with a calculated molecular mass of 12.3 kDa, an isoelectric 
point of 8.84 and a putative signal sequence of 22 amino acids [29]. The 
first 18 base pairs of the 5'-untranslated region are scrambled with a 28 
S rRNA gene fragment. The 3'-untranslated region comprises 122 
nucleotides and does not contain a poly(A)-tail nor a polyadenylation 
signal since a random primed cDNA library was used. 
Cross-linking of SKALP 
The NH2-terminal part of the 9.9-kDa SKALP-protein (amino acid 23 to 
68 in Fig. 2) from cultured keratinocytes contains four repeats which 
match remarkably well with a consensus sequence for transglutaminase 
cross-linking, first described in seminal vesicle protein I from guinea pig 
[30,31]. Covalent clotting of this protein is catalyzed by a 
transglutaminase, involving the formation of y-glutamyl-6-lysine cross-
links. Three residues in these repeats, 2 lysines and 1 glutamine, are 
thought to participate in the cross-links. Fig. 3 shows the repeats in 
SKALP as compared to the supposed consensus sequence for 
transglutaminase-catalyzed cross-linking. 
Consensus: GQDxVKxxxxxK 
Repeat a: 31GQDTVKGRVPFN42 
Repeat b: 43GQDPVKGQVSVKS4 
Repeat c: 49GQVSVKGQDKVK60 
Repeat d: 55GQDKVKAQEPVK66 
Fig. 3. Comparison of four repeats in the putative transglutaminase substrate domain 
with the supposed consensus sequence for transglutaminase cross-linking [30,31]. 
Identical amino acids are marked. Numbering is according to Fig. 2. 
To investigate whether SKALP can act as a transglutaminase substrate, 
three strategies were followed. 
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First, we extracted proteins from psoriatic scales directly in SDS-
sample buffer and ran them on SDS-PAGE (16% gel). The proteins were 
blotted on PVDF membrane and stained with an antiserum against the 
low molecular weight (6 kDa) form of SKALP. As shown in Fig. 4a 
(lane 4) several forms of SKALP appear to be present in scale extract 
(including the 9.9- and the 6-kDa forms). It should be noted that the 
molecular mass determination of SKALP is not reliable on these gels (as 
indicated by the marker proteins) due to the cationic nature of the 
molecule as described before [13,14]. 
In addition to the expected SKALP forms, in lane 4, positive bands in 
the higher molecular weight range are visible, suggesting that SKALP is 
covalently attached to other proteins. No positive reaction of the antisera 
with high molecular weight proteins in extracts of normal skin was 
found. For comparison partially purified SKALP/elafin from psoriatic 
scales (lane 1), purified SKALP from cultured cells (lane 3) and 
recombinant elafin/SKALP (lane 2) were stained on the same blot as 
shown in Fig. 4a. 
Second, we used a biotinylated synthetic peptide comprising amino 
acids 23 to 36 of SKALP, as a substrate for transglutaminase. The 
peptide was derived from the NH2-terminal domain and contained a 
glutamine of a putative transglutaminase substrate motif as a potential 
amine acceptor. The biotinylated peptide was added to extracts of 
psoriatic scales, with or without exogenous transglutaminase. The 
presence of an excess EDTA was used as a control for the Ca2+-
dependent reaction. Fig. Ab shows that the biotinylated peptide is cross-
linked to many skin proteins in the absence of exogenous 
transglutaminase (lane 2), presumably by the action of endogenous 
epidermal transglutaminase which is known to be present in psoriatic 
scales [32]. Addition of liver transglutaminase (lane 3) clearly increases 
the amount of labeled proteins. EDTA almost completely blocks the 
formation of biotinylated skin proteins (lane 4), presumably by inhibiting 
transglutaminase activity. 
Third, highly purified SKALP from cultured keratinocytes (9.9-kDa 
form) was used as a substrate for guinea pig liver transglutaminase, 
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using [l4C]methylamine as an acyl-acceptor probe. Fig. Ac shows that 
SKALP can indeed act as a substrate in this reaction. 
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Fig. 4. A, immunoblots of SKALP preparations and scale extracts with anti-SKALP 
serum. Lane 2, recombinant elafin/SKALP (6 kDa); lane 3, purified SKALP from 
cultured keratinocytes (9.9 kDa); lane 1, partially purified SKALP/elafin from psoriatic 
scales, containing multiple forms of SKALP/elafin, including the 6- and 9.9-kDa forms; 
lane 4, total scale extract showing additional high molecular weight proteins, suggesting 
cross-linking of SKALP to proteins of the stratum corneum. B, autoradiograph from a 
Western blot of SDS-PAGE demonstrating linkage of a biotinylated peptide to stratum 
corneum proteins by transglutaminase. Lane I, scale extract without biotinylated peptide; 
lane 2, scale extract with biotinylated peptide; lane 3, scale extract with biotinylated 
peptide and exogenous transglutaminase; lane 4, scale extract with biotinylated peptide in 
the presence of EDTA. C, autoradiograph from a Western blot of SDS-PAGE showing 
purified SKALP (9.9-kDa form) as an amine acceptor with [l4C]-methylamine as a probe 
{lane 2). Radiolabeled markers are shown in lane 1. 
DISCUSSION 
From comparison of the predicted amino acid sequence of our cloned 
cDNA with the known amino acid sequence of elafin and our protein 
sequence data of SKALP (Fig. 2) we conclude that clone pGESKA 
encodes the complete preSKALP protein. 
When this manuscript was in preparation, the genomic organization 
and complete nucleotide sequence of the human elafin gene were 
reported [33]. Comparison of our cDNA with the predicted exon sequen-
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ces shows 100% homology, confirming that SKALP and elafin indeed 
are identical proteins. 
Three domains in preSKALP 
A signal peptide cleavage site in preSKALP is predicted [29] between 
amino acid residues 22 and 23. Based on the genomic DNA sequence 
[33] it was speculated that the signal peptide spans a region of 25 amino 
acids. However, this was not supported by sequence data at the protein 
level. Our results from the NH2-terminal gas-phase sequencing of 
SKALP purified from cultured keratinocytes clearly show that the 
protein starts at amino acid 23 from the cDNA-deduced amino acid 
sequence (Fig. 2). We therefore conclude that this protein indeed is the 
preSKALP polypeptide, and that the site of cleavage for the signal 
peptide as we predict it must be correct. 
The presence of a putative signal sequence suggests that translation of 
SKALP-coding mRNA takes place at the rough endoplasmic reticulum 
[34]. It is not yet clear through which intracellular routes the protein is 
finally secreted, and this is currently under investigation. 
The COOH-terminal part of SKALP contains 8 cysteine residues 
which are probably involved in disulfide bonds. Small proteins showing 
this characteristic have been called "four-disulfide core" proteins [35]. 
Several proteins have been shown to belong to this group, like whey 
acidic protein [36], the sodium potassium ATPase inhibitors 1, 2 and 3 
[37] and antileukoprotease/secretory leukocyte protease inhibitor 
(ALP/SLPI) [38,39]. The COOH-terminal part of ALP/SLPI shows 40% 
homology with the COOH-terminal part of SKALP (amino acid 68 to 
117 in Fig. 2) and especially the positions of the cysteine residues are 
highly conserved. The NH2-terminal parts of SKALP and ALP/SLPI 
show no significant homology. Based on the homology between the 
COOH-terminal parts of SKALP and ALP/SLPI, we denote the domain 
spanning amino acid 68 to 117 (Fig. 2) of SKALP as being the 
proteinase inhibiting domain. 
The NH2-terminal part of SKALP was shown to contain four repeats, 
highly homologous to a consensus sequence for transglutaminase cross-
linking, as we already mentioned (see "Results"). Based on this striking 
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homology, we surmised that this region can act as a putative substrate 
domain for epidermal transglutaminase. Our transglutaminase 
experiments clearly show that SKALP can indeed become cross-linked 
by transglutaminase to proteins extracted from psoriatic scales. It is 
therefore tempting to speculate that SKALP can exist as an immobilized 
9.9-kDa protein, covalently attached to the comified envelopes by 
transglutaminase cross-linking. Currently, experiments with the 9.9-kDa 
form of SKALP as a product of recombinant DNA technology, in 
combination with site-directed mutagenesis, are in progress in order to 
determine the exact sites used for cross-linking. 
Immunohistochemical staining of psoriatic epidermis suggests that at 
least part of the SKALP present in the epidermis is indeed closely 
associated to the comified envelopes [16]. However, extraction and 
purification of SKALP/elafin from psoriatic scales predominantly yields 
a low molecular weight form [13,14]. We therefore speculate that in 
psoriatic lesions a mechanism exists to cleave the proteinase inhibiting 
domain from the putative transglutaminase domain. Cross-linking to the 
comified envelopes might be a prerequisite for this mechanism since, in 
cultured keratinocytes, where comified envelopes are not present, we 
mainly find the complete 9.9-kDa protein. Further studies on in vitro and 
in vivo differentiation of keratinocytes should give us a more detailed 
insight into the pathways of SKALP processing. 
ACKNOWLEDGEMENTS 
We thank Dr. W. Hendriks for his helpful advise and D. Iles for critical reading of this 
manuscript. Dr. W. de Jong and P. Groenen are acknowledged for advise and 
participation in the transglutaminase experiments. We gratefully acknowledge the use of 
the services and facilities of the Dutch CAOS/CAMM Center. 
Purification and cloning of SKALP 35 
REFERENCES 
1. Weiss SJ: Tissue destruction by neutrophils. N Engl J Med 320:365-376, 1989 
2. Janoff A, Scherer J: Mediators of inflammation in leukocyte lysosomes. IX. 
Elastinolytic activity in granules of human polymorphonuclear leukocytes. J Exp 
Med 128:1137-1155, 1968 
3. Janoff A, Feinstein G, Malemud CJ, Elias JM: Degradation of cartilage 
proteoglycan by human leukocyte granule neutral proteases - A model of joint 
injury. Penetration of enzyme into rabbit articular cartilage and release of 
3SS04-labeled material from the tissue. J Clin Invest 57:615-624, 1976 
4. Mainardi CL, Dixit SN, Kang AH: Degradation of type IV (basement mebrane) 
collagen by a proteinase isolated from human polymorphonuclear leukocyte 
granules. J Biol Chem 255:5435-5441, 1980 
5. Mainardi CL, Hasty DL, Seyer JM, Kang AH: Specific cleavage of human type HI 
collagen by human polymorphonuclear leukocyte elastase. J Biol Chem 
255:12006-12010, 1980 
6. Travis J, Salvesen GS: Human plasma proteinase inhibitors. Ann Rev Biochem 
52:655-709, 1983 
7. Johnson D, Travis J: The oxidative inactivation of human alpha-1-proteinase 
inhibitor. Further evidence for methionine at the reactive center. J Biol Chem 
254:4022-4026, 1979 
8. Schalkwijk J, van den Berg WB, van de Putte LB, Joosten LA: Elastase secreted 
by activated polymorphonuclear leucocytes causes chondrocyte damage and matrix 
degradation in intact articular cartilage: escape from inactivation by 
alpha-1-proteinase inhibitor. Br J Exp Pathol 68:81-88, 1987 
9. Schrijver G, Schalkwijk J, Robben JCM, Assman KJM, Koene RAP: 
Antiglomerular basement membrane nephritis in beige mice. Deficiency of 
leukocytic neutral proteinases prevents the induction of albuminuria in the 
heterologous phase. J Exp Med 169:1435-1448, 1989 
10. Briggaman RA, Schechter NM, Fräki J, Lazarus GS: Degradation of the 
epidermal-dermal junction by proteolytic enzymes from human skin and human 
polymorphonuclear leukocytes. J Exp Med 160:1027-1042, 1984 
11. Takamori K, Yoshike T, Morioka S, Ogawa H: The role of proteases in the 
pathogenesis of bullous diseases. Int J Dermatol 27:533-539, 1988 
12. Schalkwijk J, Chang A, Janssen Ρ, de Jongh G J. Mier PD: Skin-derived 
antileucoproteinases (SKALPs): characterization of two new elastase inhibitors 
from psoriatic epidermis. Br J Dermatol 122:631-641, 1990 
13. Schalkwijk J, de Roo С, de Jongh GJ: Skin-derived antileukoproteinase (SKALP) 
an elastase inhibitor from human keratinocytes. Purification and biochemical 
properties. Biochim Biophys Acta 1096:148-154, 1991 
36 Chapter 2 
14. Wiedow О, Schröder J-M, Gregory H, Young JA, Christophers E: Elafin: an 
elastase specific inhibitor of human skin. Purification, characterization, and 
complete amino acid sequence. J Biol Chem 265:14791-14795, 1990 
15. Alkemade H, van de Kerkhof Ρ, Schalkwijk J: Demonstration of skin-derived 
antileukoproteinase (SKALP) in urine of psoriatic patients. J invest Dermatol 
99:3-7, 1992 
16. Schalkwijk J, van Vlijmen-Willems IMJJ, Alkemade JAC, de Jongh GJ: 
Immunohistochemical localization of SKALP/elafín in psoriatic epidermis. J Invest 
Dermatol 100:390-393, 1993 
17. Rheinwald JG, Green H: Serial cultivation of strains of human epidermal 
keratinocytes: the formation of keratinizing colonies from single cells. Cell 
6:331-344, 1975 
18. van Εφ PEJ, Brons PPT, Boezeman JBM, de Jongh GJ, Bauer FW: A rapid flow 
cytometric method for bivariate bromodeoxyuridine/DNA analysis using 
simultaneous proteolytic enzyme digestion and acid denaturation. Cytometry 
9:627-630, 1988 
19. Chomczynski P, Sacchi Ν: Single-step method of RNA isolation by acid 
guanidinium thiocyanalc-phenol-chloroform extraction. Anal Biochem 
162:156-159, 1987 
20. Lee CC, Wu XW, Gibbs RA, Cook RG, Muzny DM, Caskey CT: Generation of 
cDNA probes directed by amino acid sequence: cloning of urate oxidase. Science 
239:1288-1291, 1988 
21. Crowe JS, Cooper HJ, Smith MA, Sims MJ, Parker D, Gewert D: Improved 
cloning efficiency of polymerase chain reaction (PCR) products after proteinase К 
digestion. Nucleic Acids Res 19:184, 1991 
22. Sanger F, Nicklen S, Coulson AR: DNA sequencing with chain-terminating 
inhibitors. Proc Natl Acad Sci USA 74:5463-5467, 1977 
23. Sambrook J, Fritch EF, Maniatis T: Molecular cloning, a laboratory manual. 2nd 
ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY USA, 1989 
24. Schägger H, von Jagow G: Tricine-sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal 
Biochem 166:368-379, 1987 
25. Laemmli UK: Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature 227:680-685, 1970 
26. Groenen PJ, Bloemendal H, de Jong WW: The carboxy-terminal lysine of alpha 
B-crystallin is an amine-donor substrate for tissue transglutaminase. Eur J 
Biochem 205:671-674, 1992 
Purification and cloning of SKALP 37 
27. Berbers GA, Feenstra RW, van den Bos R, Hoekman WA, Bloemendal H, de 
Jong WW: Lens transglutaminase selects specific beta-crystallin sequences as 
substrate. Proc Natl Acad Sci USA 81:7017-7020, 1984 
28. Wiedow O, Young JA, Christophers E: Characterization of seven elastase specific 
inhibitors derived from psoriatic epidermis. Proceedings of the 18th world 
congress of dermatology, New York, 1992 
29. von Heijne G: A new method for predicting signal sequence cleavage sites. 
Nucleic Acids Res 14:4683-4690, 1986 
30. Moore JT, Hagstrom J, McCormick DJ, Harvey S, Madden B, Holicky E, Stanford 
DR, Wieben ED: The major clotting protein from guinea pig seminal vesicle 
contains eight repeats of a 24-amino acid domain. Proc Natl Acad Sci USA 
84:6712-6714, 1987 
31. Hagstrom JE, Harvey S, Madden B, McCormick D, Wieben ED: Androgens affect 
the processing of secretory protein precursors in the guinea pig seminal vesicle. II. 
Identification of conserved sites for protein processing. Mol Endocrinol 
3:1797-1806, 1989 
32. van Hooijdonk CA, Steijlen PM, Bergere M, Mier PD, Traupe H, Happle R: 
Epidermal transglutaminase in the ichthyoses. Acta Derm Venereol Stockh 
71:173-175, 1991 
33. Saheki T, Ito F, Hagiwara H, Saito Y, Kuroki J, Tachibana S, Hirose S: Primary 
structure of the human elafin precursor preproelafin deduced from the nucleotide 
sequence of its gene and the presence of unique repetitive sequences in the 
prosegment. Biochem Biophys Res Commun 185:240-245, 1992 
34. von Heijne G: Transcending the impenetrable: how proteins come to terms with 
membranes. Biochim Biophys Acta 947:307-333, 1988 
35. Drenth J, Low BW, Richardson JS, Wright CS: The toxin-agglutinin fold. A new 
group of small protein structures organized around a four-disulfide core. J Biol 
Chem 255:2652-2655, 1980 
36. Hennighausen LG, Sippel AE: Mouse whey acidic protein is a novel member of 
the family of'four-disulfide core' proteins. Nucleic Acids Res 10:2677-2684, 1982 
37. Araki K, Kuwada M, Ito О, Kuroki J, Tachibana S: Four disulfide bonds' 
allocation of Na+, K(+)-ATPase inhibitor (SPAI). Biochem Biophys Res Commun 
172:42-46, 1990 
38. Seemuller U, Amhold M, Fritz H, Wiedenmann K, Machleidt W, Heinzel R, 
Appelhans H, Gassen HG, Lottspcich F: The acid-stable proteinase inhibitor of 
human mucous secretions (HUSI-I, antilcukoprotease). Complete amino acid 
sequence as revealed by protein and cDNA sequencing and structural homology to 
whey proteins and Red Sea turtle proteinase inhibitor. FEBS Lett 199:43-48, 1986 
38 Chapter 2 
39. Thompson RC, Ohlsson K: Isolation, properties, and complete amino acid 
sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of 
leukocyte elastase. Proc Nati Acad Sci USA 83:6692-6696, 1986 
39 
Chapter 3 
SKALP/elafin is an inducible proteinase inhibitor 
in human epidermal keratinocytes 
J.A.C. Alkemade, H.O.F. Molhuizen, M. Ponec1, J.A. Kempenaar', 
Ρ.L.J.M. Zeeuwen, G.J. de Jongh, I.M.J.J, van Vlijmen-Willems, 
P.E.J, van Εφ, P.C.M, van de Kerkhof and J. Schalkwijk 
From the Department of Dermatology, 
University Hospital Nijmegen St Radboud, 
and the 'Department of Dermatology, University Hospital Leiden, 
the Netherlands 
J Cell Sci 107:2335-2342, 1994 
Reprinted with permission 
40 Chapter 3 
ABSTRACT 
Skin-derived antileukoproteinase (SKALP), otherwise known as elafin, is 
a recently discovered epidermal proteinase inhibitor with specificity for 
polymorphonuclear leukocyte (PMN)-derived elastase and proteinase-3; 
in addition to the proteinase-inhibiting domain, SKALP contains several 
transglutaminase substrate motifs. SKALP is virtually absent in normal 
human epidermis but is found in a number of inflammatory skin 
diseases, including psoriasis. Here we report the induction and 
processing of SKALP in vivo and in vitro. SKALP-expression in vivo 
could be demonstrated following injury in normal human epidermis, 
using histology, Western blotting, Northern blotting and a functional 
assay. In vitro, SKALP expression was studied in conventional 
submerged keratinocyte culture systems and in keratinocytes cultured in 
an air-liquid interface model. Induction of SKALP-activity in epidermis 
could be measured as early as 16 h after skin injury; immunohistological 
examination showed that SKALP expression was confined to the outer 
layers of the stratum spinosum and the stratum granulosum. Northern 
blot analysis revealed a 0.8 kb transcript, both in vivo (psoriatic skin, 
injured skin) and in vitro (cultured keratinocytes). Western blot analysis 
showed that the major SKALP form in vivo was a low molecular mass 
fragment, containing the antiproteinase domain. In all cultures that were 
positive for SKALP, larger (8-10 kDa) forms of SKALP, containing the 
N-terminal transglutaminase substrate motifs in addition to the 
antiproteinase domain, were found. SKALP expression in cultured cells 
was found to be dependent on the system used. In a submerged culture 
system, SKALP could be induced by fetal calf serum. 
These findings demonstrate that SKALP is an inducible proteinase 
inhibitor and support the concept that SKALP acts as a regulatory 
molecule in cutaneous homeostasis. 
INTRODUCTION 
Human epidermis is a stratified keratinizing epithelium that follows a 
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highly coordinated process of differentiation leading to a layer of dead 
cells, and forming the protective covering of the skin (for reviews, see 
[1,2]). Under pathological conditions (e.g. psoriasis) or during 
regenerative and adaptive processes (e.g. wound healing), human 
epidermis switches from the normal differentiation program to a 
'hyperproliferative' differentiation program. This includes the expression 
of different sets of cytokeratins [3], a premature expression of 
differentiation markers (involucrin, transglutaminase) in the spinous cell 
layers [4], and an increase of cycling cells, as measured by the 
expression of Ki-67 antigen [5]. A similar phenotype of keratin 16 
expression and a high percentage of cycling cells is found in 
exponentially growing keratinocyte monolayer cultures. In vivo, this 
hyperproliferative phenotype is usually associated with inflammatory 
changes in both the dermal and epidermal compartment. This was seen 
in diseased skin (e.g. psoriasis) as well as in experimental models [6]. 
Previously, we have described a new serine proteinase inhibitor (skin-
derived antileukoproteinase, which was given the acronym of SKALP) 
that is also part of the regenerative/hyperproliferative phenotype [7-9]. 
SKALP is found in lesionai psoriatic epidermis, but is virtually absent in 
normal epidermis. Initially, SKALP was shown to be a low molecular 
mass, cationic, heat-stable protein similar to elafin, an epidermal 
proteinase inhibitor that was subsequently described by others [10]. In 
addition, an elastase-specific inhibitor that is identical to SKALP has 
recently been reportedin bronchial secretions, although the exact cellular 
source in vivo remains obscure [11]. We cloned and sequenced the 
complementary deoxyribonucleic acid (cDNA) of SKALP [12], which 
proved that SKALP is identical to elafin [13]. We showed that SKALP, 
as expressed in cultured epidermal keratinocytes, is translated as a 12.3 
kDa protein. Cleavage of the signal peptide yields a 9.9 kDa protein that 
is the major form found in cultured cells, as was confirmed by 
purification and N-terminal amino acid sequencing [12]. Recently we 
have been able to assign the SKALP gene to chromosome 20, region 
ql2-ql3 [14]. The gene has been given the approved name of Protease 
Inhibitor, skin derived (SKALP), symbol: PI3, in the Genome Data Base 
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of the HUGO nomenclature committee. 
SKALP inhibits at least three serine proteinases, namely human 
leukocyte elastase, porcine pancreatic elastase and human leukocyte 
proteinase 3 [8,15]. The exact biological function of SKALP is not 
known at present, although the substrate specificity for PMN-derived, 
elastolytic proteinases suggests that SKALP is involved in regulation of 
cutaneous inflammation, or protection against PMN-dependent tissue 
damage. However, it is very possible that other target enzymes (e.g. 
from the keratinocytes or dermal fibroblasts) exist. Since we have found 
that the 9.9 kDa molecule, purified from cultured cells, contains multiple 
functional transglutaminase substrate motifs [12], functions other than 
controlling proteinase activity cannot be excluded. 
In previous studies SKALP was described biochemically [8,16] and 
characterized at the protein and DNA level [12]. We established the 
cellular source and localization in psoriatic epidermis [9], and recently 
we found that SKALP is differentially expressed in human epidermal 
tumors [17]. In the present study, we have investigated the expression of 
SKALP in dynamic models for keratinocyte growth and differentiation in 
vivo and in vitro. It is demonstrated that SKALP expression can be 
induced in normal human epidermis and in cultured keratinocytes. 
MATERIALS AND METHODS 
Chemicals 
Methoxysuccinyl-alanyI-alanyl-prolyl-valyl-7-amino-4-rnethyl coumarin 
was obtained from Bachern, Bubendorf, Switzerland. All reagents for 
sodium dodecylsulphate/polyacrylamide gel electrophoresis SDS-PAGE, 
including prestained markers, were obtained from Bio-Rad laboratories, 
Richmond, CA, USA. Polyvinylidenedifluoride (PVDF) membrane was 
from Millipore, Etten-Leur, The Netherlands. Low molecular mass 
markers used for SDS-gels, goat-anti-rabbit IgG biotin conjugate, avidin-
alkaline phosphatase, 5-bromo-4-chloro-3-indolyl phosphate, nitro blue 
tetrazolium, isoproterenol and iododeoxyuridine (IdUrd) were obtained 
from Sigma Chemicals, St. Louis, MO, USA. Swine-anti-rabbit 
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Peroxydase, fluorescein isothiocyanate-conjugated rabbit anti-mouse 
immunoglobulins (RAM-FITC) and mouse anti-IdUrd antibody were 
obtained from Dakopatts, Copenhagen, Denmark. Penicillin, 
streptomycin and trypsin were obtained from Gibco, Breda, The 
Netherlands. Epidermal growth factor (EGF) and hydrocortisone were 
from Collaborative Research Inc., Lexington, MA, USA. Dulbecco's 
minimal essential medium (DMEM) and F12 medium were obtained 
from Flow laboratories, Irvine, UK. Keratinocyte growth medium 
(KGM) and bovine pituitary extract were from Clonetics, San Diego, 
CA, USA. A synthetic peptide comprising amino acid 23 to 36 of 
SKALP was synthesized by Eurosequence, Groningen, The Netherlands; 
at the C-terminus a cysteine residue was added to enable coupling to a 
carrier protein. The sulfo-SMCC kit and Sulfolink gel were obtained 
from Pierce, IL, USA, and anti-involucrin (rabbit) from Biomedical 
Technologies Inc., Stoughton, MA, USA. RNA zol™ В was obtained 
from Cinna/Biotex Laboratories, Inc., Houston, TX, USA, and a32PdCTP 
from Amersham, UK. The 'Living Skin Equivalent' (LSE) culture 
system was purchased from Organogenesis, Cambridge, MA, USA. 
Recombinant SKALP/elafin was a kind gift from Dr Norman Russell, 
ICI Pharmaceuticals, UK. As a probe for ribosomal 28S RNA, a 2.1 kb 
EcoRl/Bgäl fragment was used (a kind gift from Dr Jan Bauman, TNO 
Rijswijk, The Netherlands). As a probe for glyceraldehyde phosphate 
dehydrogenase (GAPDH) a 1.1 kb Pstl fragment was used (a kind gift 
from Dr Wiljan Hendriks, Dept of Cell Biology and Histology, 
University of Nijmegen, The Netherlands). 
Skin biopsies and tape stripping 
Biopsies of normal, psoriatic and tape-stripped skin were taken under 
local anaesthesia with a keratotome. The skin samples were either fixed 
in buffered 4% formalin or stored at -20°C until use for extraction of 
SKALP. 
Tape stripping of human skin is the repeated application and removal 
of adhesive tape, which produces a standardized injury of the epidermis 
by removal of the stratum corneum [18]. Keratotome biopsies of the 
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stripped test sites and of normal skin were taken at several intervals and 
processed for SKALP measurement, Western blots, RNA extraction or 
histology. For functional assays, the biopsies were homogenized in a 
glass-glass grinder in distilled water, and centrifuged at 8,000 g for 15 
minutes. After measurement of SKALP activity (as described below), the 
supernatant was concentrated by vacuum evaporation, and subjected to 
SDS-PAGE and immunoblotting. 
Approval of the local medical ethical committee was obtained for all 
experiments. 
Functional measurement of SKALP activity. 
Inhibition of leukocyte elastase activity, using the fluorogenic substrate 
methoxysuccinyl-alanyl-alanyl-prolyl-valyl-7-amino-4-methyl coumarin 
[19], was used to assay SKALP. In this assay SKALP activity is 
calculated as the percentage inhibition of 1 ng elastase; the amount 
required to reduce the elastase activity in the assay by 50% is defined as 
one unit of inhibitory activity. 
Purification and N-terminal sequencing of SKALP 
SKALP was purified from psoriatic scales using chromatofocusing, 
reversed-phase chromatography and gel permeation chromatography, 
according to previously described methods [8,12]. N-terminal gas-phase 
sequencing of this material was performed by Eurosequence, Groningen, 
the Netherlands [8]. 
Antisera 
An antiserum against recombinant SKALP/elafin was obtained as 
described previously [9]. An antiserum against a synthetic peptide 
comprising amino acids 23 to 36 of SKALP was prepared by coupling 
the peptide to chicken ovalbumin via a C-terminal cystein residue, using 
the sulfo-SMCC procedure, according to the manufacturer's instructions. 
This conjugate was used for immunization of a rabbit, according to 
previously described methods [8]. The antiserum was affinity-purified 
using the synthetic peptide coupled to Sulfolink coupling gel, according 
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to the manufacturer's instructions. Preimmune serum was drawn as a 
control. The two antisera against recombinant SKALP/elafin and 
synthetic peptide gave identical staining patterns on histological sections. 
A monoclonal antibody against involucrin was obtained as previously 
described [20]. 
Immunohistology. 
Air-exposed cell cultures and biopsies of normal, psoriatic and tape-
stripped skin, were fixed in buffered 4% formalin for at least 24 hours 
and processed for embedding in paraffin. Sections (5 ц т ) were 
deparaffinized, rehydrated, preincubated with normal swine serum and 
incubated with anti-SKALP/elafin serum, raised either against 
recombinant SKALP/elafin or against the synthetic peptide. After 
incubation with peroxidase-conjugated swine-anti-rabbit Ig, the sections 
were developed with aminoethylcarbazole as the chromogenic substrate. 
Control staining was performed as indicated above, substituting anti-
SKALP/elafin serum with preimmune serum of the same animal. 
SDS-PAGE and Western blotting. 
Supematants of homogenates of cell cutures and skin biopsies were 
vacuum-evaporated to dryness, dissolved in non-reducing sample buffer 
and subjected to SDS-PAGE. Proteins were separated on a 16% 
Polyacrylamide gel, using tricine as a trailing ion instead of tris-glycine. 
Gels were blotted on PVDF membranes, and proteins were detected 
immunologically using biotinylated goat anti-rabbit IgG, avidin-
conjugated alkaline phosphatase, 5-bromo-4-chloro-3-indolyl phosphate, 
and nitro blue tetrazolium. A polyclonal rabbit antiserum raised against 
recombinant SKALP/elafin was used. 
RNA isolation and Northern blot analysis. 
Total RNA from cultured cells and samples of normal, psoriatic and 
tape-stripped skin were extracted with RNAzol B, as suggested by the 
supplier. For Northern blot analysis, 10 μg of total RNA was 
fractionated on a denaturing 1% agarose gel containing formaldehyde, 
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following standard procedures [21] and blotted by capillary transfer on a 
nylon membrane. After transfer, RNA was fixed to the membrane by 
ultraviolet irradiation (312 nm, 0.2 J/cm2). Hybridization was performed 
in phosphate buffer as previously described, using a 0.42 kbp 
PvuWEcoRl fragment of the SKALP cDNA clone pGESKA as a probe 
[12]. Control hybridizations for equal loading were performed using a 
human 28S ribosomal RNA probe and GAPDH probe. All probes were 
labelled with 3 2P by random priming, following standard procedures. 
Autoradiography was done for on X-Omat S film (Kodak, France) at -
80°C with an intensifying screen. 
Kcratinocyte culture in the Rheinwald-Green system. 
First passage human keratinocytes derived from the backs of healthy, 
adult volunteers were seeded on gamma-irradiated Swiss mouse 3T3 
fibroblasts [22]. Growth medium was DMEM/F12 3:1 supplemented 
with 0.4 ^g/ml hydrocortisone, 10"*Μ isoproterenol, 100 U/ml penicillin 
plus 100 ^g/ml streptomycin, 6% fetal calf serum and, starting at day 
three after seeding, 10 ng/ml EGF. The Ca2+-concentration in the 
medium was 2 mM. Keratinocytes were grown at 37°C, 95% relative 
humidity and 7.5% C0 2 . Cells were harvested by trypsinization, counted 
and used for SKALP measurement, Northern blot analysis or flow 
cytometry. Labelling with IdUrd was performed for 30 hours before 
harvesting the cells. Either exponentially growing cells, confluent cells 
or cells in suspension (see below) were used. 
Keratinocyte culture in suspension. 
Confluent keratinocyte cultures were trypsinized and resuspended in 
DMEM/F12 medium (without EGF), as described above. The cell sus­
pension was kept in a continuously rotating device for 48 hours, as 
described before [23], and analysed as described above. This procedure 
induces terminal differentiation, as measured by involucrin expression, 
and gives results similar to the systems previously used by others 
[24,25]. 
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Keratinocyte culture in KGM. 
Human keratinocytes from healthy volunteers were cultured in serum-
free KGM that was composed of keratinocyte basal medium (KBM) with 
0.15 mM Calcium, supplemented with 0.1 mM ethanolamine, 0.1 mM 
phosphoethanolamine, 0.4% bovine pituitary extract, 10 ng/ml EGF, 5 
μ§/πι1 insulin, 0.5 ^g/ml hydrocortisone, 100 U/ml penicillin and 100 
jug/ml streptomycin. For induction of SKALP expression, cultures were 
switched at 30% confluency to KGM plus 5% fetal calf serum or KGM 
with additional Ca2+ (either 0.35 mM or 2 mM). Cells were harvested 
after 48 h by trypsinization and extracted for measurement of SKALP 
activity and Northern blot analysis. 
Keratinocyte culture under air-exposed conditions. 
Human keratinocytes derived from healthy individuals were first cultured 
using the Rheinwald-Green feeder technique, and subsequently seeded 
on de-epidermized dermis (DED) and grown under air-exposed 
conditions according to the Régnier-Pruniéras method [26]. Growth 
medium at air-exposed conditions was Dulbecco-Vogt and Ham's F12 
3:1 supplemented with 0.4 μg/ml hydrocortisone, 10"6 M isoproterenol, 
5% fetal calf serum, 10 ng/ml EGF [27]. 
The LSE model for air-exposed culture, consisting of human 
keratinocytes seeded on a fibroblast populated collagen gel, was cultured 
according to the manufacturer's instructions. 
Immunocytochemical staining and flow cytometric analysis. 
A standard indirect immunocytochemical labelling technique was used 
with both anti-involucrin and anti-IdUrd antibodies on ethanol-fixed 
cells. DNA staining was performed with propidium iodide. Flow 
cytometric analysis was carried out using previously described methods 
[23,28]. 
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RESULTS 
Expression of SKALP in vivo. 
In previous studies we have shown that SKALP is expressed in the 
upper suprabasal layers of lesionai psoriatic skin but is virtually absent 
in normal human skin. Here, removal of stratum corneum by tape 
stripping was used as a model for standardized epidermal injury in 
normal human skin. Fig. 1 shows a time curve of SKALP-activity in 
biopsies, measured as anti-elastase activity using a fluorimetrie assay. At 
48 hours a peak was found, and this time point was used to characterize 
SKALP on Western blots and for detection by immunohistochemistry. 
SKALP activity (units/mg) 
Figure 1. Time course of SKALP 
induction by tape stripping of the 
skin of healthy volunteers (n=6). 
SKALP activity is given in units 
per mg skin homogenate. Maximal 
SKALP activity is seen after 48 
hours, standard error is represented 
by the vertical lines at each time of 
«me (h) sampling. 
In Fig. 2 it is demonstrated that, after tape stripping, one major low 
molecular mass form of SKALP is found, in contrast with findings in 
psoriatic epidermis and psoriatic scales, which contain multiple low 
molecular mass forms of SKALP. 
Figure 2. Western blot of extracts from 
psoriatic scales (lane 2), normal human skin 
(lanes 4, 6 and 8), and tape-stripped skin 
after 48 hours, taken from the same 
individuals (lanes 3, 5 and 7). Lanes 1 and 
9: molecular mass markers. Staining with 
polyclonal rabbit antiserum against 
recombinant SKALP/elaftn. Preimmune 
serum was negative with all samples (not 
4 » 8 — 
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In extracts of biopsies from normal skin only trace amounts of SKALP 
were detected, in accordance with previous findings [7]. N-terminal 
amino acid sequencing of SKALP purified from psoriatic scales gave 3 
sequences (KGPVSTP, AQEPVKGP and VxAQxxVK) which 
correspond with SKALP fragments starting at amino acid 66, 61 and 59, 
respectively (numbering based on the 12.3 kDa translation product). The 
SKALP forms found in tape-stripped skin and in psoriatic epidermis 
could not be purified in sufficient quantities for N-terminal amino acid 
sequencing. 
Immunohistological staining of skin after repeated tapestripping 
revealed 2-3 cell layers (mainly granular cells) with cytoplasmic staining 
positive for SKALP (Fig. 3a). This pattern is similar to that found in 
lesionai psoriatic skin (Fig. 3b) with respect to the absence of SKALP 
staining in the basal layers; a difference with psoriatic skin is the 
absence of staining in cells of the stratum spinosum. Normal epidermis 
was totally negative (Fig. 3c). 
Figure 3. Immunohistology of tape-stripped skin (after 48 hours), psoriatic lesionai skin, 
and normal epidermis, a. Tape-stripped skin. The staining is limited to the upper layers 
of the suprabasal compartment, which contains mainly granular cells, b. Psoriatic lesionai 
skin. Note that several layers of suprabasal spinous cells of the psoriatic lesion are 
positive. Basal cells are negative. Non-lesional skin was also negative (not shown), с 
Normal epidermis. No positive staining was seen in the epidermis. Staining with 
polyclonal rabbit antiserum against recombinant SKALP/elafin. Bar, 50 μιτι. 
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Fig. 4 shows the presence of a 0.8 kb messenger ribonucleic acid 
(mRNA) in biopsies taken from psoriatic skin and from normal skin 40 h 
after injury. Normal, uninjured skin is essentially negative for SKALP, 
even on an overloaded gel. 
Figure 4. Northern blot of SKALP mRNA in skin biopsies and cultured keratinocytes 
(upper panel). 10 μg of total RNA was loaded. In biopsies from normal skin at 40 hours 
after injury (lane 1), and in skin from psoriatic patients (lane 2) a 0.8 kb message was 
found. Normal human epidermis was essentially negative (lane 3) even on overloaded 
(50 μg RNA) gels. Keratinocytes cultured in KGM were essentially negative (lane 4). 
Addition of 1% and 5% fetal calf serum (lanes 5 and 6) induced SKALP mRNA, in a 
dose-dependent fashion. Keratinocytes cultured on a 3T3 feeder layer give a strong signal 
(lane 7) which is slightly increased when cells are cultured in suspension (lane 8). The 
lower panel shows control hybridizations to check for equal RNA loading. In lane 1-6 a 
probe for 28S ribosomal RNA was used; in lanes 7 and 8 a GAPDH probe was used. 
Expression of SKALP in submerged culture systems. 
We have previously shown that keratinocytes cultured in the Rheinwald-
Green system, using a feeder layer of irradiated 3T3 cells, produce 
SKALP in a high molecular mass form that contains both the 
transglutaminase substrate domain and the antiproteinase domain. To 
investigate modulation of SKALP expression, we studied exponentially 
growing cells, confluent cells and cells that were kept in suspension in 
order to induce differentiation. Fig. 5 shows the amounts of SKALP 
extracted from cells cultured under these conditions, as measured by 
functional anti-elastase activity. Under hyperproliferative conditions 
(high percentage of IdUrd-positive cells) a high amount of SKALP was 
found and a low degree of differentiation, as assessed by the percentage 
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involucrin-positive cells using flow cytometry. Keratinocytes in 
Suspension leave the cell cycle (low percentage of IdUrd-positive cells) 
and show a rapid induction of involucrin, whereas the total amount of 
soluble SKALP decreases. 
SKALP activity % Positive cells 
2000 
1S00 
1000 
500 
о 
Exponential Confluent Suspension 
%Ш SKALP ^Ш IdUrd I I Involucrin 
Figure 5. SKALP activity in cultured keratinocytes. Amounts of soluble SKALP 
extracted from exponentially growing cells, confluent cells or from cells that were kept in 
suspension are shown (left hand у axis). SKALP activity is expressed in units per 106 
keratinocytes. Markers of proliferation (IdUrd) and differentiation (involucrin) were 
measured using flow cytometry, and the percentage of positive keratinocytes for these 
markers are shown (right hand у axis). 
This is in contrast to Northern blot analysis, which showed a slight 
increase of SKALP mRNA in keratinocytes cultured in suspension (Fig. 
4). The pattern of SKALP expression in this culture system is distinct 
from that found in vivo where basal, proliferating keratinocytes are 
negative for SKALP and the upper suprabasal, differentiated cells show 
SKALP expression. 
Induction of SKALP expression in keratinocyte monolayers was 
studied in the KGM system, a serum-free, submerged culture system, 
using bovine pituitary extract as a source of growth factors. In KGM 
alone no significant SKALP expresssion was found either at the protein 
or at the mRNA level. However, addition of fetal calf serum could 
I U U 
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induce SKALP expression in a dose-dependent fashion, as shown in Fig. 
4, at the mRNA level. In a functional assay more than a 10-fold increase 
in SKALP activity was found 48 hours after the addition of 5% fetal calf 
serum (Fig. 6). 
SKALP activity 
1000, 
0.15 mM 0.35 mM 2.0 m M 5% FCS 
Ca-concentration 
Figure 6. Induction of SKALP activity in submerged keratinocyte cultures using KGM. 
In unsupplemented KGM (0.15 mM Ca2+) very little SKALP activity is found. Addition 
of 5% fetal calf serum induces SKALP, as measured after 48 hours, in a functional assay 
on cell extracts. Addition of CaCl2 up to 2 mM did not induce a significant increase. 
SKALP activity is expressed as units per IO6 keratinocytes. 
As 5% serum raises the Ca2+-concentration in KGM from 0.15 mM to 
approximately 0.35 mM, we tested the effect of additional Ca2+ in KGM. 
As shown in Fig. 6 no effect was noted up to 2 mM Ca2+. 
Expression of SKALP in air-exposed culture systems. 
In submerged culture systems, as described above, keratinocyte 
phenotype and functional properties are distinct from the in vivo 
situation in normal skin. This has been demonstrated for several proteins 
including keratins, involucrin and transglutaminase. The expression 
pattern of SKALP in these systems does not correlate with the in vivo 
patterns found in psoriasis and tape-stripped skin, where SKALP is 
found in the differentiated compartment. We therefore investigated the 
expression pattern and processing of SKALP in the 'reconstructed skin' 
model, which approaches the in vivo situation. Cultures of human 
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epidermal keratinocytes seeded on DED were extracted for Western 
blottings and processed for immunohistology. Fig. 7 shows that high 
molecular weight forms of SKALP are present, with a predominance of 
the 9.9 kDa form also found in keratinocytes in the Rheinwald-Green 
system. 
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Figure 7. Western blot of cultures of human epidermal keratinocytes seeded on DED. 
Lanes 2-6, extracts of five different culture conditions: 10 days submerged; 3 days 
submerged and 7 days air-exposure; 3 days submerged and 5 days air-exposure; 3 days 
submerged and 2 days air-exposure; 3 days submerged, respectively. Lane 8, an extract 
from exponentially growing keratinocytes in the Rheinwald-Green system. Lane 9, 
recombinant SKALP/elafin. Lanes 1 and 7, prestained molecular mass markers. Cultured 
keratinocytes (lanes 2-6 and 8) contain high molecular mass forms of SKALP (including 
the 9.9 kDa processed form), whereas the 6 kDa form found in psoriatic scales (identical 
to recombinant SKALP/elafin) is absent. Note that the molecular masses given in the text 
are obtained from amino acid sequencing data. These values significantly deviate from 
the values obtained on SDS-PAGE, probably because of the cationic nature of SKALP. 
The 6 kDa form, which is the major form in psoriatic skin, is absent in 
these cultures. No change in the pattern of SKALP processing is seen 
with time. Immunohistology shows that SKALP is barely detectable in 
submerged keratinocytes cultured on DED (Fig. 8a), but is moderately 
expressed in granular cells shortly after air exposure (Fig. 8b). In 
addition to the 'reconstructed skin' model, we examined SKALP 
expression in the commercially available LSE model, which uses a 
fibroblast-populated collagen gel as a matrix for keratinocytes. 
·:·;, · 
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Figure 8. Immunohistology of cultures of human keratinocytes seeded on DED, and 
keratinocytes cultured on a fibroblast-populated collagen gel (LSE model), a. Culture of 
human keratinocytes seeded on DED, 10 days submerged. No significant SKALP 
expression was found, b.. Culture of human keratinocytes seeded on DED, 3 days 
submerged followed by 3 days air-exposure. Scattered keratinocytes with a flattened, 
granular cell morphology were positive for SKALP (arrows), с LSE model. SKALP is 
highly expressed in the upper suprabasal layers, similar to the in vivo expression in 
psoriatic and tape-stripped skin; see also Fig. 3 a. and b. Bar, 50 μιη. 
Fig. 8c shows that in this system SKALP is highly expressed in the 
upper suprabasal layers, similar to the in vivo expression of SKALP in 
psoriatic and tape-stripped skin. 
DISCUSSION 
We have examined the expression of SKALP by human epidermal 
keratinocytes using in vitro and in vivo models. It is shown that a 
transient wave of SKALP expression can be induced in normal human 
skin by epidermal injury. One major, low molecular mass form is found 
on Western blots. Positive immunohistological staining is found in cells 
of the granular layer. In vitro, the pattern and amount of SKALP 
expression depends on the culture system used. SKALP expression in the 
KGM sytem is inducible by fetal calf serum. In all in vitro systems 
tested, it is mainly the high molecular mass forms of SKALP that are 
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found. 
Because of its specificity for the PMN-derived proteinases, elastase 
and proteinase-3, SKALP/elafin has been assigned a putative role in the 
control of epidermal inflammation [7,10]. Using cDNA cloning and N-
terminal sequencing of SKALP purified from cultured keratinocytes, we 
have shown that the molecule contains a hydrofobic signal peptide and 
an additional functional domain with multiple transglutaminase substrate 
motifs [12]. Removal of the signal peptide results in a mature 9.9 kDa 
protein, which is the major form in cultured keratinocytes. However, in 
psoriatic skin, tape-stripped skin and in urine of psoriatic patients [16], 
low molecular mass forms predominate. Whether these forms result from 
interaction with PMN-derived proteinases, or from intracellular 
processing by keratinocyte-derived proteinases, remains to be 
investigated. The molecular masses, as indicated in the text, refer to 
calculated molecular masses obtained from amino acid and DNA 
sequence analysis, while apparent molecular masses on SDS-PAGE and 
Western blots are much higher (see Figs 2 and 7). This anomalous 
behaviour on SDS-gels is probably due to the highly cationic nature of 
the molecule. 
At present it is not known which factors in vivo are responsible for 
SKALP induction. In psoriatic skin and in tape-stripped skin the 
expression pattern follows that of other differentiation-related markers 
such as involucrin and transglutaminase; a difference with these markers 
is the absence of SKALP in normal epidermis (at least epidermis of the 
trunk and the extremities). The expression pattern of SKALP more 
closely resembles that of cytokeratin 16, which is absent in normal 
epidermis but is induced under hyperproliferative conditions such as 
psoriasis, regeneration after injury, and in cell culture in the Rheinwald-
Green system. SKALP expression in cell culture systems was found to 
be strongly dependent on the model used. High amounts of soluble 
SKALP could be found in exponentially growing keratinocytes in the 
Rheinwald-Green system, whereas exponentially growing cells in KGM 
produced very low quantities of SKALP. Addition of fetal calf serum to 
KGM was shown to induce SKALP expression, both at the protein level 
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and at the mRNA level. Obviously this Finding does not rule out the 
contribution of extracellular matrix molecules from 3T3 fibroblasts, 
soluble 3T3 fibroblast factors or negatively regulating factors in KGM. 
When cells cultured in the Rheinwald-Green system were kept in 
suspension (which induces terminal differentiation), the amount of 
soluble SKALP decreased, but no significant change was found at the 
mRNA level. Low SKALP activity in differentiated cells was not due to 
crosslinking of SKALP to the insoluble fraction, since the amounts of 
both soluble and particulate SKALP activity decreased in terminally 
differentiating keratinocytes (not shown). The discrepancy between 
Northern blot results and the SKALP content of the cells could be 
explained by secretion of SKALP in the medium of the suspension 
cultures. However, due to interference by serum proteins we have so far 
been unable to obtain accurate SKALP measurements in the culture 
media. 
Using immunohistology, in the air-exposed culture systems, a moderate 
induction of expression was found in the 'reconstructed skin' model, 
shortly after air exposure. This induction was not found in Western blots 
of culture extracts, as shown in Fig. 7. However, the Western blots were 
primarily performed for qualitative analysis with respect to SKALP 
processing, and not for quantification of SKALP in the culture extracts. 
Histologically the expression pattern resembled that of tape-stripped skin, 
where positive SKALP staining was found mainly in flattened, granular 
cells. Using immunohistochemistry, a strong expression was observed in 
the LSE model. Possible explanation could be differences in the growth 
state of the cells, or stimulation of SKALP expression by fibroblast-
derived factors (such as interleukin-6). Extrapolating the in vitro data to 
the in vivo situation, we speculate that induction of SKALP after tape 
stripping or inflammation in general, could be due to plasma derived 
factors. This notion is supported by a recent report showing that during 
inflammation, plasma protein levels are strongly increased in epidermis, 
which is otherwise devoid of plasma proteins [29]. 
The in vivo and in vitro models described here will be used to further 
identify the factors that induce SKALP expression. This will provide 
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relevant data on the cell biology of cutaneous inflammation as seen in 
pathological conditions (e.g. psoriasis) and the pathophysiology of 
wound healing. 
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ABSTRACT 
Skin-derived antileukoproteinase (SKALP), also known as elafin, is a 
serine proteinase inhibitor that was first discovered in psoriatic 
epidermis. SKALP was absent in normal skin but later shown to be 
induced in other inflammatory skin disorders and in several epidermal 
tumors. SKALP inhibits leukocytic elastase and proteinase 3, both 
derived from polymorphonuclear neutrophils (PMN), which suggests that 
it plays a role in the regulation of the inflammatory response. Until now 
immunohistochemical localization studies have been restricted to normal 
and pathological human skin from various origins. Here we have studied 
the distribution of SKALP in a number of normal tissues. 
Immunohistologically, SKALP appeared to be present in the following 
epithelial tissues: tongue, palate/lingual tonsil, gingiva, epiglottis, 
pharynx, esophagus, uterine cervix, vagina, and hair follicle. No SKALP 
could be observed in brain, comea, larynx, bronchus, lung, duodenum, 
colon, liver, kidney, urethra, and normal epidermis of various locations. 
In general, stratified squamous epithelia are positive, in contrast to the 
pseudostratified epithelia, simple epithelia (glandular epithelia) and 
normal epidermis. The tissues that are positively stained are in direct 
contact with the environment subjected to a constant load of 
inflammatory stimuli. Low-grade PMN infiltration in some of these 
tissues is almost physiological, and was observed in many sections. The 
histological findings were largely confirmed by Northern blot analysis. 
In view of the fact that SKALP inhibits PMN-derived proteinases, 
these results suggest that this molecule plays a role in the control of 
epithelial tissue homeostasis and integrity. 
INTRODUCTION 
In previous studies we have shown that the proteinase inhibitor skin-
derived antileukoproteinase (SKALP), also termed elafin, is present in 
human epidermal keratinocytes under pathological conditions such as 
cutaneous inflammation or epidermal injury, but is virtually absent from 
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normal skin [1-3]. Cultured keratinocytes and some epidermal tumors 
also produce SKALP [4,5], and in bronchial secretions SKALP has been 
described by others as 'elastase-specific inhibitor' (ESI) [6]. SKALP has 
been characterized in biochemical and cell biological studies [4,7-9]. The 
cDNA and gene of SKALP have recently been cloned and sequenced, 
and the chromosomal localization has been assigned to chromosome 
region 20ql2-ql3 [9-11]. Although inhibition of the proteinases human 
leukocyte elastase and proteinase 3 points at an involvement in the 
regulation of cutaneous inflammation [1,12], the exact biological 
function is not known at present. Apart from a region with proteinase 
inhibiting properties, the SKALP molecule also contains a domain with 
transglutaminase substrate motifs [9]. Immunohistologically, a 
colocalization of SKALP expression and expression of transglutaminase 
is observed in hyperproliferative epidermis. Previous studies in 
epidermis, cultured keratinocytes, and human epidermal tumors showed 
that SKALP expression patterns appear to be similar to that of 
cytokeratin 16, which is known to be indicative for hyperprol iferation 
[5,7,13,14]. However, since previous studies were restricted to inflamed 
epidermis and epidermal tumors, little is known about presence and 
localization in other human epithelial tissues. 
The aim of this investigation was to study the expression of SKALP in 
normal human epithelia. The presence of SKALP in several but not all 
epithelial tissues is demonstrated and the differential expression is 
discussed. 
MATERIALS AND METHODS 
Chemicals 
Goat-anti-rabbit IgG biotin conjugate, avidin-alkaline phosphatase, and 
the chromogenic substrates 5-bromo-4-chloro-3-indolyl phosphate, 
nitroblue tetrazolium, and aminoethyl carbazole were obtained from 
Sigma Chemicals, St. Louis, MO, USA. Swine-anti-rabbit Ig conjugated 
with horseradish peroxidase (SWARPO) was obtained from Dakopatts, 
Glostrup, Denmark. A synthetic peptide comprising amino acid 23 to 36 
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of SKALP was synthesized by Eurosequence, Groningen, the 
Netherlands; at the C-terminus a cysteine residue was added for coupling 
to a carrier protein. The sulfo-SMCC kit and Sulfolink gel were obtained 
from Pierce, Rockford, IL, USA. RNA zol™ В was obtained from 
Cinna/Biotex Laboratories, Inc., Houston, TX, USA, and a32PdCTP from 
Amersham, UK. 
Recombinant SKALP was a kind gift from Dr. Norman Russell, ICI 
Pharmaceuticals, UK. As a probe for ribosomal 28S RNA, a 2.1 kb 
EcoRl/Bglll fragment was used (a kind gift of Dr Jan Bauman, TNO 
Rijswijk, the Netherlands). 
Histology 
Archival biopsy material as well as autopsie material were selected. The 
following epithelial tissues were studied with respect to SKALP 
expression: brain; cornea; tongue; palate/lingual tonsil; gingiva; pharynx; 
larynx; epiglottis; vocal fold; lung; bronchus; esophagus; duodenum; 
colon; liver; kidney; urethra; uterine cervix; vagina; skin from various 
regions including head, ear, breast, axillar region, mamilla, inguinal 
region, pubic area, scrotum, finger, and foot sole; and hair follicle. The 
specimens were fixed in buffered 4% formalin for at least 24 h, 
dehydrated in ethanol, and embedded in paraffin. 
Antisera 
An antiserum against recombinant SKALP was obtained as described 
previously [3]. An antiserum against a synthetic peptide comprising 
amino acids 23 to 36 of SKALP was prepared by coupling the peptide 
via a C-terminal cystein residue to chicken ovalbumin, using the sulfo-
SMCC procedure according to the manufacturer's instructions. This 
conjugate was used for immunization of a rabbit according to previously 
described protocols [7]. Control serum (pre-immune serum) was drawn 
before the immunization procedure. The antiserum against the synthetic 
peptide was affinity purified using the synthetic peptide coupled to 
Sulfolink coupling gel according to the manufacturer's instructions. The 
specificity of the antiserum was validated on Western blots as previously 
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described [7]. The two antisera against recombinant SKALP and against 
the synthetic peptide gave identical staining patterns in histological 
sections. 
A rabbit polyclonal antiserum against secretory leukocyte proteinase 
inhibitor (SLPI) was a kind gift of Dr. Hans Kramps, C.D.I., Lelystad, 
the Netherlands. 
Immunohistological staining for SKALP 
Before staining, sections were deparaffinized, and pre-incubated with 
20% normal swine serum in PBS for 15 min, followed by an incubation 
for 60 min with the polyclonal anti-SKALP serum (at a dilution of 
1:500) in PBS with 1% bovine serum albumine (BSA). After rinsing in 
PBS, sections were incubated for 30 min with SWARPO (at a dilution of 
1:50) in PBS with 1% BSA and 5% human AB serum. Subsequently, 
sections were rinsed in PBS and Na-acetate buffer, and developed using 
aminoethyl carbazole as chromogenic substrate. Counterstaining with 
hematoxylin was performed, and sections were dried and embedded in 
glycerol-gelatin solution. 
Control staining was performed as indicated above, the polyclonal 
rabbit anti-SKALP serum being replaced with pre-immune serum of the 
same animal. Staining with anti-SLPI serum (at a dilution of 1:50) was 
carried out following the procedure described above. 
RNA isolation and Northern blot analysis 
Total RNA from different tissues obtained from autopsy was extracted 
with RNAzol В as suggested by the supplier. The following epithelial 
tissues were studied: tongue, pharynx, larynx, epiglottis, vocal fold, lung, 
duodenum, colon, liver, kidney, urethra, and inguinal skin. For Northern 
blot analysis, 10 μg total RNA was fractionated on a denaturing 1% 
agarose gel containing formaldehyde following standard procedures [15] 
and blotted by capillary transfer on nylon membrane. After transfer, 
RNA was fixed to the membrane by ultraviolet irradiation (312 nm, 0.2 
J/cm2). Hybridization was performed in phosphate buffer as previously 
described, using a 0.42 kbp Pvull/EcoRl fragment of the SKALP cDNA 
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Figure 1. Immunohistology of various normal epithelial tissues. Staining with polyclonal rab­
bit anti-SKALP antiserum, a. meninges/gray matter (brain), b. stratified squamous epithelium 
(cornea), с stratified squamous epithelium (dorsal part of the tongue), d. parakeratotic 
squamous epithelium (gingiva), e. stratified squamous epithelium (pharynx), f. pseudostrati-
fied ciliated epithelium (larynx), g. stratified squamous epithelium (epiglottis), h. stratified 
squamous epithelium (true vocal fold), i. alveoli (lung), j . pseudostratified epithelium (bron­
chus), k. stratified squamous epithelium (esophagus), 1. crypt (duodenum), m. crypt (colon) n. 
mesothelium/parenchym (liver), o. cortex (kidney), p. urethelium (urethra), q. stratified 
squamous epithelium (uterine cervix), r. stratified squamous epithelium (vagina). Bar 50 μηι. 
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Figure 2. Immunohistology of various normal epithelial tissues. Staining with polyclonal rab­
bit anti-SKALP antiserum, a.-i. epidermis (skin), a. head, the infundibuli of the hair follicles 
are stained, the epidermis is negative, b. ear, с breast, d. orifice of the hair follicle, axilla. 
Compare with e. where staining is absent, e. axilla without hair, f. mamilla, g. inguinal region, 
h. mons pubis, i. scrotum, j . finger tip, k. foot sole. Note that the excretory duct of an eccrine 
sweat gland is positive for SKALP staining, 1. Transition of stratified squamous epithelium, 
positively stained, to pseudostratification with ciliated cells that are negative for SKALP 
expression (epiglottis). Bar 50 μηι. 
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clone pGESKA as a probe [9]. Control hybridizations for equal loading 
were performed using a human 28S ribosomal RNA probe. All probes 
were labeled with 32P by random priming following standard procedures. 
Autoradiography was performed on X-Omat S film (Kodak, France) at -
80°C with an intensifying screen. 
RESULTS 
Immunohistology 
We studied SKALP expression in the epithelial lining of 21 normal 
human tissues (see table 1). Epithelial tissues that were positive with 
respect to SKALP expression were tongue, palate/lingual tonsil, gingiva, 
pharynx, epiglottis, vocal fold, esophagus, uterine cervix, vagina and the 
hair follicle. The expression varied considerably from one weakly stained 
cell layer to an increasing number of intensely stained layers (up to 10). 
Similar to the SKALP expression already described in pathological 
epidermis [3,5,16], staining was never seen in the basal cells. When 
multiple layers were stained, the density of the cytoplasmatic staining 
increased in the direction of the differentiated cells, often in a distinct 
apical localization in the cytoplasm (polarized appearance), whereas in 
other cases staining appeared to be localized close to the cell membrane. 
The tongue dorsum was strongly positive: up to ten cell layers were 
intensively stained (Fig. 1 .c). By contrast, the ventral part of the tongue 
was negative (not shown). The furrows surrounding the vallate papillae 
of the tongue stained intensively, but the taste buds were negative (Fig. 
3.a). In palate/lingual tonsil a distinct SKALP expression was observed 
in destroyed epithelial lining, whereas staining was absent in the intact 
cover of the tonsil (Fig. 4). Keratinizing gingiva was moderately positive 
for three or four of the most differentiated cell layers (Fig. l.d). The 
pharyngeal part showed a more or less patchy positive pattern, with 
SKALP expression in the epithelium overlying foci with inflammatory 
cells. Many layers with a varying staining intensity were observed in the 
positive areas (Fig. l.e). The lining of the epiglottis was positively 
stained in multiple layers (Fig. l.g). In between, areas of pseudostratified 
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columnar cells, with ciliated cells common to respiratory epithelia, were 
negative with respect to expression of SKALP (Fig. 2.1). True vocal fold 
was slightly positive (Fig. l.h). Esophageal lining showed many positive 
cell layers, especially the superficial layers, intensively stained in a 
polarized pattern as already described (Fig. l.k). The uterine cervix and 
vagina were positive for multiple cell layers, with varying intensity. The 
staining appeared to be more cell membrane associated than 
cytoplasmatic (Fig l.q and r). The infundibular part of the hair follicles 
demonstrated a distinct SKALP expression (Figs. 2.a and 3.b). 
Epithelial and non-epithelial tissues negative for SKALP expression 
included brain, cornea, larynx, lung, bronchus, duodenum, colon, liver, 
kidney, urethra, and skin from various body regions (see Material and 
Methods section) (Figs. 1 and 2). 
SKALP shows considerable functional similarity and sequence 
homology to SLPI, a proteinase inhibitor in glandular tissues [6,7,17]. In 
order to ascertain whether a topographical overlap exists between 
SKALP and SLPI, we performed immunohistochemical staining for 
SLPI in a limited number of tissues. In psoriasis both anti-SKALP and 
anti-SLPI sera resulted in a positive signal, similar in pattern but 
different in intensity (Fig. 5.a and 5.b). As demonstrated in Fig 6, 
staining patterns were completely different for the two antisera in the 
tongue dorsum. The antiserum against SKALP gave a clear signal in the 
upper cell layers of the epithelial lining of the tongue (Fig. 6.a), whereas 
staining using the anti-SLPI serum was negative (Fig. 6.b). The minor 
salivary glands of the tongue, however, were positively stained with the 
antiserum against SLPI (Fig. 6.d), but were negatively stained with the 
antiserum against SKALP (Fig. 6.c). 
These findings indicate that the polyclonal antisera against SKALP and 
SLPI are not mutually cross reactive. This was further checked on 
Western blots using recombinant SKALP and SLPI (data not shown). In 
addition to the antiserum raised against recombinant SKALP we used an 
antiserum against a synthetic peptide (12 N-terminal amino acids) from a 
region of SKALP that has no sequence homology to SLPI. The SKALP 
distribution patterns in immunohistology were identical for both antisera. 
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Figure 3. Immunohistology of a. part of furrow, surrounding lateral surface of vallate papilla 
(*), with negative taste buds (arrows), b. infundibulum of hair follicle. Staining with polyclon­
al rabbit anti-SKALP antiserum. Bar 50 μπι. 
Figure 4. Immunohistology of the epithelial lining of the lingual tonsil. Staining with poly­
clonal rabbit anti-SKALP antiserum, a. Intact epithelial lining, negative, b. and с The epithe­
lial lining of the tonsillar crypt is positive. Lympho-diapedese causes desolution of the epithe­
lial integrity, probably inducing SKALP expression. Bar 50 μπι. 
••AAV 
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Figure 5. Immunohistology of psoriatic skin. a. Staining with a polyclonal rabbit anti-SKALP 
antiserum raised against a synthetic peptide comprising amino acids 23 to 36 of the SKALP 
molecule, b. Staining with rabbit polyclonal anti-SLPI antiserum. The staining pattern using 
the different antisera is similar, but the intensity is different. Bar 50 μτη. 
Figure 6. Immunohistology of the epithelial lining of normal human tongue, a and с Staining 
with a polyclonal rabbit anti-SKALP antiserum, b and d. Staining with rabbit polyclonal anti-
SLPI antiserum. Epithelial cover of the tongue (a and b) is positive for SKALP but negative for 
SLPI, whereas salivary glands (c and d) are positive for SLPI and virtually negative for SKALP. 
Bar 50 μιη. 
72 Chapter 4 
Northern blot analysis 
Fresh autopsy material was obtained, stored at -80 °C, and used for 
Northern blot analysis. A strong expression of SKALP could be 
demonstrated in tongue and pharynx, and moderate levels were present 
in epiglottis and vocal fold (Fig. 7). No SKALP mRNA was found in 
larynx, lung, duodenum, colon, liver, kidney, urethra and inguinal skin. 
1 2 3 4 5 6 7 8 9 10 11 12 13 
Figure 7. Northern blot of SKALP mRNA in autopsy material of various epithelial 
tissues. Lower panel. In tongue (lane 1), epiglottis (lane 2), pharynx (lane 3) and vocal 
fold (lane 9) and in lesionai psoriatic skin which was used as the positive control (lane 
13) a 0.8 kb message is found. Larynx, lung, kidney, urethra, skin of the inguinal region, 
and liver (lanes 4, 5, 6, 7, 8 and 11 respectively) are negative. Esophagus and bronchus 
mRNA (lane 10 and 12) could not be properly analyzed. In addition, colon and 
duodenum were analyzed and found to be negative (data not shown). In the upper panel 
a probe for 28S ribosomal RNA was used for control hybridizations to check for equal 
RNA loading. 
DISCUSSION 
The proteinase inhibitor SKALP is not present in normal skin, but is 
expressed by keratinocytes under hyperproliferative conditions, including 
psoriasis, epidermal injury, several skin tumors, and cell culture 
[1,4,9,13]. Under hyperproliferative or regenerative conditions, an 
alternative epidermal differentiation pathway is followed, and several 
proteins are expressed that are not normally present, such as the 
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cytokeratins 6, 16 and 17 [18,19]. In skin, the expression of these 
hyperproliferation-associated cytokeratins 6 and 16 is restricted to the 
suprabasal cells in lesions of psoriasis, actinic keratosis, the well-
differentiated cells of squamous cell carcinoma, and epidermis adjacent 
to the tumor; basal epidermal cells do not show this K6/16 expression at 
the protein level [20]. In epidermis and epidermal tumors, SKALP is co-
expressed with cytokeratin 16 [3,5,21], and is possibly subject to similar 
regulatory mechanisms. Some of the molecules that are expressed in 
epidermis during the regenerative differentiation program such as the 
cytokeratins 6 and 16 are also present in a number of normal tissues 
such as foot sole epidermis, hair follicle, and the lining epithelia of the 
tongue, esophagus and epiglottis [22]. Up to now, no data were available 
on the expression of SKALP in other tissues than skin. 
Here we provide an immunohistological demonstration of the presence 
of SKALP in human tongue, tonsil (palate/lingual), gingiva, pharynx, 
epiglottis, esophagus, uterine cervix, vagina and the infundibular part of 
the hair follicle. When we compare these data with literature findings, it 
is clear that there is no absolute correlation between cytokeratin 16 and 
SKALP expression patterns, which suggests that they are differentially 
regulated at the tissue level. 
It is shown that the distribution of SKALP is distinct from SLPI, 
which is a proteinase inhibitor with functional and structural similarities. 
Interestingly, SKALP and SLPI localization are mutually exclusive in 
tongue (Fig. 6). In psoriatic skin, however, SKALP and SLPI colocalize 
(Fig.5), which is in accordance with previous biochemical data on 
SKALP and SLPI present in psoriatic scales [1,2,23,24]. 
In contrast to the previous reports that dealt with SKALP present either 
in pathology or in cell culture, here we demonstrate that SKALP is 
expressed in 'normal' squamous epithelia. For a number of tissues the 
presence of SKALP is confirmed at the mRNA level. In general, a good 
correlation was found between SKALP expression or absence 
demonstrated by immunohistology and Northern blot analysis (see table 
I). The adjective 'normal' in this respect should be used with caution. 
Several 'normal' tissues are subjected to continuous mechanical stress or 
74 Chapter 4 
inflammatory stimuli, which may influence the structure and 
organization of the lining epithelium. In normal epiglottis, squamous 
metaplasia can be observed that is partly functional or due to mechanical 
stress. Pathogens may be present in the pharynx of healthy individuals, 
and PMN infiltration is not considered to be pathological in normal 
pharynx and esophagus. Also in the infundibular part of the hair follicle 
the presence of bacteria that may induce an inflammatory response is 
common. SKALP expression was demonstrated in the tonsillar crypts 
where destruction of the epithelial lining by lymphocytes was observed 
(Fig. 4). Lymphocytes transmigrate the tonsillar epithelium into the 
crypts that also contain the desquamated cells of the stratified squamous 
epithelium. This passage is accompanied by desolution of the epithelium, 
which may trigger SKALP induction as part of the ongoing 
inflammatory response. 
On the basis of the pattern of SKALP expression, one would surmise 
that SKALP expression is induced by inflammatory cells such as PMN. 
Interestingly, Sallenave et al. demonstrated induction of SKALP 
expression in tumor cell lines by the cytokines interleukin 1 (IL-1) and 
tumor necrosis factor (TNF), but also by the PMN-derived proteinases 
human leukocyte elastase and cathepsin G [25]. This finding is in line 
with that of Perlmutter et al, who reported that neutrophil elastase 
regulates the synthesis of its inhibitor αϊ-PI in human monocytes and 
bronchoalveolar macrophages [26]. The cytokines IL-1 and TNF are 
considered to be initiating cytokines in inflammatory processes in 
cutaneous tissues [27]. As a result SKALP could be synthesized by the 
keratinocytes, and may hence be termed a local 'acute phase reactant' 
[1,25,28]. A single triggering signal for both PMN invasion and 
production of SKALP, which functionally counteracts PMN activity, is 
plausible since an unbalanced presence of elastase/proteinase-3 might 
cause unwanted tissue damage. In normal tissues where transient PMN 
presence is desired for reasons of host defense, this control mechanism 
might explain SKALP presence in epithelia such as esophagus, pharynx, 
tongue and vagina. The difference in SKALP expression in the various 
epithelia can be related to differences in mechanical forces and 
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inflammatory stimuli to which the tissues are subjected. Future studies 
are aimed at elucidating the mechanisms of SKALP induction in vivo 
and the functional significance of the molecule. 
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Table I. SKALP expression on immunohistology and expression of SKALP mRNA on 
Northern blots of various normal epithelial tissues. +. positive for SKALP expression. - : 
negative for SKALP expression, η d.: not done. : positive in most of the infundibuli of 
the the hair follicles if present in the sections. 
Tissue 
Brain 
Cornea 
Tongue dorsal 
ventral 
Palate/lingual tonsil 
Gingiva 
Pharynx 
Larynx 
Epiglottis 
Vocal fold 
Lung 
Bronchus 
Esophagus 
Duodenum 
Colon 
Liver 
Kidney 
Urethra 
Uterine cervix 
Vagina 
Skin head 
ear 
breast 
back 
axilla 
marmila 
inguinal -egio 
mons pubis 
scrotum 
fìnger tip 
foot sole 
Hair follicle (lnfundibulum) 
Immunohistology 
-
-
+ 
-
+ 
+ 
+ 
-
+ 
+ 
-
-
+ 
-
-
-
-
-
+ 
+ 
_· 
_· 
-" 
-" 
- ' 
-
-" 
- ' 
- ' 
-
-
+ 
Northern blot j 
nd 
nd 
+ 
nd 
nd 
nd 
+ 
nd 
+ 
+ 
-
nd 
nd 
_ 
-
-
-
nd 
nd 
nd 
nd 
nd 
nd 
nd 
— 
nd 
nd 
nd 
nd 
nd 
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ABSTRACT 
Recently we have reported the purification and biochemical 
characterization of a new, inducible elastase inhibitor [skin-derived 
antileukoproteinase (SKALP)], which could be extracted in high amounts 
from psoriatic skin but not from normal human skin. Here we 
demonstrate the immunohistochemical localization of SKALP in 
psoriatic epidermis. SKALP was found exclusively in the upper layers of 
the suprabasal compartment and stratum comeum of lesionai psoriatic 
epidermis. Basal keratinocytes were always negative. No immunoreactive 
SKALP was found in normal epidermis and non-lesional psoriatic 
epidermis, in accordance with findings in functional assays. Western 
blots of skin extracts from psoriatic and normal skin confirmed the 
immunohistochemical findings and revealed two major bands with 
apparent molecular weights of 10.5 and 11.5 kDa. 
We would hypothesize that SKALP could act as a modulator of 
epidermal inflammation by interfering with polymorphonuclear leukocyte 
trafficking, and that it could protect structural proteins against elastase-
mediated damage. 
INTRODUCTION 
Neutral proteinases derived from polymorphonuclear leukocytes (PMNs) 
such as elastase, cathepsin G, and proteinase-3 have been implicated in a 
number of pathological processes [1], including lung emphysema [2], 
glomerulonephritis [3], arthritis [4,5] and inflammatory skin diseases [6]. 
Under non-pathological conditions, elastase and cathepsin G are 
controlled by specific high-affinity proteinase inhibitors such as alpha-1-
proteinase inhibitor and alpha-1-antichymotrypsin in plasma, and 
secretory leukocyte proteinase inhibitor/antileukoproteinase (SLPI/ALP), 
which is produced locally in mucous tissues. Recently we have described 
a new, specific elastase-inhibitor in human epidermis that does not 
inhibit cathepsin G [7-9]. Using scales collected from patients with 
psoriasis, we purified and characterized this high-affinity inhibitor, which 
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was shown to be a cationic protein with an apparent molecular weight of 
9 to 11 kDa. There is evidence that this molecule is derived from an 18-
kDa protein, which is found in cultured keratinocytes and in variable 
amounts in psoriatic scales. Partial amino acid sequencing of SKALP [8] 
showed homology to SLPI/ALP [10]. SKALP is identical to elafin, a 
proteinase inhibitor which was recently described by others [11], on the 
basis of amino acid composition and amino acid sequence data. 
Until now, only biochemical data were available on SKALP/elafin, and 
the exact source in human skin was not clear. In this article we studied 
the cellular localization of SKALP in psoriatic epidermis using 
immunohistochemistry; and it is shown that only a distinct subpopulation 
of the keratinocytes expresses this molecule. 
METHODS 
Chemicals 
All reagents for sodium dodecylsulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) were obtained from Biorad laboratories, 
Richmond, CA. Aminoethylcarbazole, tricine, low-molecular-weight 
markers for SDS-PAGE, biotinylated swine-anti-rabbit immunoglobulin 
(Ig), avidin-peroxidase and avidin-conjugated alkaline phosphatase were 
from Sigma Chemicals, St Louis, MO. Swine-anti-rabbit Ig conjugated 
with horseradish peroxidase was obtained from Dakopatts, Glostrup, 
Denmark. Columns and materials for chromatographic purification of 
SKALP or anti-SKALP serum were from Pharmacia, Uppsala, Sweden. 
This included polybuffer exchanger 94, cyanogen activated sepharose 
4B, protein A sepharose, a Superdex 75 FPLC-column, and a reverse-
phase цЯРС C2/C18 column. 
Skin biopsies 
Biopsies from psoriatic patients (n=9) and normal healthy volunteers 
(n=7) were taken with a keratotome or a razor blade, under local 
anaesthesia, and were either fixed in buffered formalin or stored at -20°C 
until used for extraction of SKALP. Permission from the local medical-
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ethical committee had been obtained. 
Extraction of SKALP from keratotome slices 
Keratotome biopsies (5 to 10 mg) of psoriatic patients and healthy 
volunteers were homogenized in a glass-glass grinder in distilled water. 
After centrifugation (15 min at 12000 χ g) the supernatant was boiled 
and again centrifuged. The supernatant was concentrated by vacuum 
evaporation, and subjected to SDS-PAGE and immunoblotting as 
described below. In addition, skin extracts were used for functional 
measurement of SKALP activity (anti-elastase activity) as described 
before [7-9]. For measurement of SKALP in the margin zone of the 
lesion, the keratotome biopsies of 7 patients were cut in 2-mm slices, 
which were extracted separately and assayed for anti-elastase activity. 
We checked whether the total anti-elastase activity of these crude 
extracts could be attributed to SKALP, to exclude the possible 
interference by other elastase inhibitors such as alpha-1-proteinase 
inhibitor and SLPI/ALP. All elastase-inhibiting activity could be 
absorbed by sepharose 4B-conjugated immunoglobulins purified from 
anti-SKALP serum by protein-Α chromatography. In addition, the assay 
conditions exclude the possible interference by alpha-1-proteinase 
inhibitor, and the amount of SLPI/ALP we found in psoriatic skin is far 
lower than SKALP (less than 5%). 
Antiserum 
The antiserum was raised against SKALP purified from psoriatic scales 
using chromatofocusing, affinity chromatography on immobilized 
pancreatic elastase, and finally Superdex-75 gel permeation fast protein 
liquid chromatography as described previously [8]. SKALP-preparations 
obtained by this procedure or alternatively via reverse-phase 
chromatography on a SMART цЯРС-соІитп as a final step appear to be 
homogeneous on chromatograms. However on SDS-PAGE multiple 
bands between 11 and 9 kDa (apparent molecular weight) can be seen, 
which probably represent truncated and extended forms of SKALP/lafin 
that were recently reported by Wiedow et al [12]. We could confirm 
Localization of SKALP/elafin 85 
these findings by N-terminal sequencing, which showed that our 
preparation contains at least three elafin forms of different length (data 
not shown). N-terminal sequencing of a fragment generated by cleavage 
with pancreatic elastase from PVDF-blots [8] revealed substantial 
homology of SKALP with SLPI/ALP. However, the anti-SKALP serum 
did not crossreact with recombinant SLPI/ALP as shown before [9]. 
The antiserum was prepared in a rabbit which was selected to be 
devoid of reactivity to normal human skin. This was a necessary 
precaution since five of six rabbits had low titers of reactivity against the 
cytoplasm of normal epidermal kertinocytes (presumably keratins) or 
against basal membranes. Purified SKALP (50 μg) was crosslinked with 
glutaraldehyde, dialysed against distilled water, and emulsified with 
Freund's complete adjuvant. Rabbits were immunized intracutaneously in 
the back, followed by two subcutaneous boosters at weeks 2 and 4. Pre-
immune serum was drawn before the experiments and immune serum 
was collected after 6 weeks. Titers in enzyme-linked immunosorbent 
assay were 1/20,000. For histology, dilutions between 1/100 and 1/1,000 
were used. The antiserum was negative with extracts of normal human 
skin and human plasma proteins, on Western blots. 
SDS-PAGE and Western blotting 
Proteins were separated on a 16 % Polyacrylamide gel, using tricine as a 
trailing ion instead of tris-glycine [8]. Low-molecular-weight markers 
from Sigma were used: Myoglobin (16950 Da), myoglobin fragment I+II 
(14440 Da), myoglobin fragment I+III (10600), myoglobin fragment I 
(8160), and myoglobin II (6210 Da). Gels were blotted on PVDF 
membranes and protein staining was performed with amido black 
according to standard procedures. Immunologic detection of proteins was 
performed using the antiserum described above, followed by biotinylated 
swine-anti-rabbit Ig and avidin-conjugated alkaline phosphatase. Pre­
immune serum was used as a control. 
Histology 
Shave biopsies of human skin were fixed in buffered 4% formalin for at 
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least 24 h and processed for routine histology. Paraffin sections were 
made (5 μπι) that were used for immunostaining according to standard 
protocols. Sections were deparaffinized, rehydrated, pre-incubated with 
normal swine serum, and incubated with anti-SKALP serum at a dilution 
of 1:100. After incubation with peroxidase-conjugated swine-anti-rabbbit 
Ig, the sections were developed with aminoethylcarbazole as the 
chromogenic substrate. Pre-immune serum from the immunized rabbit 
was used as a control. 
RESULTS 
Immunohistochemical localization of SKALP 
Immunohistochemical staining of all normal skin specimens (n=7) was 
negative (Fig 1). 
Figure 1. Immunoperoxidase 
staining of normal human skin 
with polyclonal anti-SKALP. 
Counterstained with hematoxylin 
and eosin. Bar, 50 μ. No positive 
staining was found. The darker 
cells are melanin contaning basal 
cells (arrows) and cells of the 
granular layer that pick up the 
counterstaining more intensely 
t h a n t h e o t h e r c e l l s 
(arrowheads). 
The same was found for the non-lesional skin (n=7) of psoriatic patients 
(Fig 2). However, lesionai psoriatic skin (n=9) revealed a subpopulation 
of the epidermal keratinocytes that was strongly positive for SKALP 
(Fig 3). The upper layers of the suprabasal compartment showed a strong 
cytoplasmic staining in all specimens studied, with minor interpatient 
variation. Staining of the upper parakeratotic layers and the stratum 
corneum varied from mild to strong. The wall of the cornified envelope 
was often found to be strongly positive, suggesting that SKALP is to 
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some extent crossi inked to the envelope proteins. No staining of basal 
cells or dendritic cells was observed in the epidermis. Also the dermal 
tissue was completely negative. 
ψ 
Figure 2. Uninvolved skin of a psoriatic patient. Staining as indicated in Fig 1. No 
positive staining was seen. The apparent staining of the basal cell layer is caused by 
melanin (arrows). Bar, 50 μ. 
Figure 3. Lesionai psoriatic skin, stained with polyclonal anti-SKALP serum. Note the 
strong, positive staining of the suprabasal keratinocytcs. Also the cornified envelopes in 
the stratum corneum are stained. Hematoxylin and eosin counterstaining. Bar, 50 μ. 
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The control (pre-immune) serum was negative with all tissue samples 
studied (not shown). These immunohistochemical findings correlate with 
previous findings on the presence of SKALP in normal and psoriatic 
skin as determined with a functional biochemical assay [7]. 
The margin zone of the spreading psoriatic lesion is of particular 
interest since early pathogenetic events can be detected in this area. 
Previous studies [13] have shown that the pronounced changes in the 
lesionai epidermis (such as parakeratosis, cytokeratin 16 expression, Ki-
67 binding) show a clear transition to clinically uninvolved skin. It was 
found that SKALP expression declined when the morphology of the 
epidermis became normal (no acanthosis, no parakeratosis, and a well-
developed granular layer). The transition, however, is not sharp. In Fig 
4, a biopsy taken from the margin zone is shown. 
Figure 4. Biopsy from the margin zone of a psoriatic lesion, stained with anti-SKALP 
serum. On the left hand side a typical psoriatic morphology is seen with positive staining 
for SKALP in the upper spinous layers (arrows). On the right hand side the morphology 
resembles that of normal skin with little acanthosis and a well-developed graular layer 
(arrowheads). No positive staining for SKALP in the spinous layer is found. 
Hematoxylin and eosin counterstaining. Bar, 50 μ. 
Positive staining for SKALP is seen in the suprabasal cells of the 
lesionai part of the biopsy where acanthosis and scaling are visible and a 
granular layer is absent. At the other end of the biopsy no positive 
staining for SKALP is present; here the epidermal thickness is nearly 
normal and a well-developed granular layer is present. The 
immunohistochemical distribution correlated with previous findings in 
biochemical assays. SKALP activity in the lesion was 302 + 182 units 
per mg, in the margin zone 52 + 37 units per mg and just outside the 
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lesion in the clinically uninvolved skin 4 + 4 units per mg tissue (mean 
of seven keratotome biopsies + SD). 
Western blots of skin extracts 
The presence of SKALP ¡n lesionai psoriatic skin could also be 
demonstrated on Western blots. Extracts of keratotome biopsies were 
subjected to SDS-PAGE and blotted on PVDF membrane. Staining with 
anti-SKALP revealed two major bands of approximately 10.5 and 11.5 
kDa, using the Sigma low-molecular-weight standards (Fig 5). 
1 
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Figure 5. Western blot of 
proteins extracted from 
psoriatic lesionai skin. 
Lane 1, staining with 
polyclonal anti-SKALP; 
lane 2, preimmune 
(control) serum; lane 3, 
Amido black staining of 
blotted proteins; lane 4, 
m a r k e r p r o t e i n s . 
Molecular weights in 
kDa. 
The staining pattern matches the pattern found for SKALP found in 
urine [9]. In SKALP preparations from psoriatic scales usually more 
heterogeneity in molecular weight is found. Normal human skin and 
non-lesional psoriatic skin were negative for SKALP (not shown). The 
preimmune serum was negative with all tissues studied. 
DISCUSSION 
In this article we demonstrate that SKALP/elafin, a new epidermal 
elastase inhibitor that was recently described by two groups at the 
biochemical level [7,11], is localized in the epidermal keratinocyte of 
psoriatic skin. In accordance with previous functional assays [7], no 
SKALP could be demonstrated in normal human epidermis. Surprisingly, 
90 Chapter 5 
SKALP is only expressed in the suprabasal cells; basal cells are 
completely negative. The pattern of expression resembles the pattern 
found for differentiation-related proteins in psoriatic skin such as 
involucrin and transglutaminase [14]. A difference with these molecules 
is the fact that SKALP is lacking in normal skin, whereas involucrin and 
transglutaminase are expressed in the granular layer of normal skin but 
are prematurely expressed in the spinous layers of psoriatic skin. 
Originally, SKALP/elafin was purified from psoriatic scales, and 
Wiedow et al (11) initially reported a molecular weight of 7017 for a 
57-amino-acid molecule, as determined by N-terminal gas-phase 
sequencing. Recently Wiedow et al reported that at least five forms of 
elafin existed due to N-terminal deletions and extensions of the original 
57-amino-acid molecule [12]. We have also consistently found 
heterogeneity in scale preparations; even SKALP preparations that 
appear pure on reverse-phase chromatography were found to contain 
mixtures of at least three SKALP peptides (not shown). As shown in this 
paper, in extracts of psoriatic epidermis (with only a minimal amount of 
scale present) two major bands of approximately 10.5 and 11.5 kDa are 
present. A similar finding was previously reported for urine from 
psoriatic patients [9]. In previous papers we reported the presence of 
SKALP in cultured human keratinocytes, with an apparent molecular 
weight of 18 kDa. We have recently completed the purification and N-
terminal sequencing of this protein, which is indeed identical to 
SKALP/elafin but contains an additional 38 amino acids at the N-
terminal side compared to the original 57-amino-acid molecule. These 
findings were confirmed at the cDNA level (Molhuizen et al, manuscript 
in preparation). Interestingly the elongated form of SKALP/elafin 
contains multiple motifs that are a consensus sequence for 
transglutaminase crosslinking. This might explain the 
immunohistochemical observation that SKALP is associated with the 
cornified envelope (see Fig 3). 
Although there is now firm evidence for a role of the keratinocyte in 
the initiation of inflammation [15], little is know about the mechanisms 
that control inflammation. In this paper we demonstrate that epidermal 
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keratinocytes can produce a proteinase inhibitor that could act as an off-
switch mechanism for the acute (PMN-dependent) phase of cutaneous 
inflammation. We have shown that SKALP is a molecule not present in 
normal skin. However, SKALP can be induced in normal skin following 
injury, and it is found in the lesionai skin of psoriasis and other 
inflammatory dermatoses [7,16]. Speculatively, SKALP could function 
as in inhibitor of PMN migration and provide protection against elastase-
mediated damage. SKALP could control the proteolysis of structural 
proteins in the epidermis (e.g., desmosomes) thereby preventing 
intraepidermal blister formation. It is very likely that SKALP also 
reaches the dermal compartment, because we have recently demonstrated 
SKALP in urine of psoriatic patients that is presumably derived from the 
epidermis [9]. Therefore, SKALP could also protect the dermal elastin 
fibers against proteolytic attack. 
These findings suggest a novel and intriguing contribution of 
keratinocytes in the regulation of cutaneous inflammatory processes. 
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ABSTRACT 
Recently we described a new elastase inhibitor (Skin-derived 
antileukoproteinase, SKALP) that is expressed in psoriatic epidermis and 
cultured keratinocytes, but is virtually absent in normal skin. In this 
study we investigated whether SKALP activity could be measured in 
urine of psoriatic patients and healthy controls. We found that urine of 
psoriatic patients contained considerable amounts of anti-elastase 
activity, whereas this activity in urine from normals was significantly 
lower. The properties of the urinary anti-elastase activity in psoriatic 
patients were indistinguishable from that of epidermal SKALP. It was 
found to be a cationic, heat-stable protein with an apparent molecular 
weight of 11 kDa on sodium dodecylsulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE), and a K, of approximately 2 χ 10'" M. In 
addition, in Western blotting partially purified inhibitor from urine was 
found to react with a polyclonal anti-SKALP serum. SKALP in urine 
was either present in a free form or in a latent form, most likely 
complexed with elastase. We speculate that SKALP in urine of psoriatic 
patients is derived from the epidermis, and that it might serve as a 
marker for disease activity. 
INTRODUCTION 
Polymorphonuclear leukocyte (PMN)-derived proteinases, including 
elastase, cathepsin G, proteinase III and collagenase, are known to cause 
tissue damage by attacking a variety of macromolecular substrates [1]. 
Proteinase inhibitors, either systemically present (e.g., al-proteinase 
inhibitor, a2-macroglobulin) or locally synthesized (e.g., 
antileukoprotease (ALP) or secretory leukocyte proteinase inhibitor 
(SLPI)), are able to limit this proteinase action [2-4]. Disturbance of the 
local proteinase-antiproteinase balance is associated with several 
diseases, including pulmonary emphysema [5,6], arthritis [7,8], 
glomerulonephritis [9], cutaneous vasculitis [10] and several bullous 
dermatoses [11]. Recently we have described a new elastase-specific 
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proteinase inhibitor (SKALP) that is found in psoriatic epidermis and in 
cultured keratinocytes [12,13]. SKALP is very similar if not identical to 
Elafin, a skin-derived elastase inhibitor described by others [14,15], and 
to an elastase-specific inhibitor from sputum [16]. We have previously 
shown that anti-elastase activity can be found in scales from various 
dermatoses [17]. Normal skin, however, was found to contain very little, 
if any, anti-elastase activity [12]. Because anti-elastase is found to be 
inducable in normal skin following tape-stripping [12,18], it was 
concluded that it acts as a regulatory mechanism to control elastase-
mediated epidermal tissue damage. 
In this study we show that urine of psoriatic patients contains 
appreciable amounts of anti-elastase activity, either free or in a latent 
form. This anti-elastase activity was indistinguishable from SKALP, 
using biochemical and immunological criteria. 
MATERIALS AND METHODS 
Chemicals 
Methoxysuccinyl-alanyl-alanyl-prolyl-valyl-7-amino-4-methylcoumarin, 
was obtained from Bachern, Bubendorf, Switzerland. Cetyltrimethyl 
ammoniumbromide (СТАВ) was obtained from ICI, UK. All reagents 
for sodium dodecylsulphate Polyacrylamide gelelectrophoresis (SDS-
PAGE) including prestained markers, were obtained from Biorad 
laboratories, Richmond, CA. Polybuffer exchanger 94 (РВЕ 94) was 
obtained from Pharmacia fine Chemicals, Uppsala, Sweden, and 
polyvinylidenedifluoride (PVDF) membrane from Millipore, Etten-Leur, 
The Netherlands. Swine-anti-rabbit peroxidase was obtained from 
Dakopatts, Copenhagen, Denmark. Low molecular weight markers used 
for SDS-gels and diaminobenzidine were obtained from Sigma 
Chemicals, St. Louis, MO. 
Sample collection and preparation 
Urine was collected from patients with severe psoriasis and volunteers 
without skin diseases, and stored at -20° С The patient group consisted 
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of 16 men and 17 women, mean age 45 + 20 years. The control group 
consisted of 7 men and 3 women, mean age 3 8 + 1 2 years. 
Urine samples were assayed for anti-elastase activity as described below. 
Elastase activity was measured both in untreated urine and urine that had 
been boiled for 2 min. 
For preparative purposes, 40 ml urine was concentrated by vacuum 
evaporation, dialyzed against distilled water, and used for 
chromatographic purification. 
Assay of elastase and anti-elastase activity 
Elastase was measured according to previously described methods using 
the fluorogenic substrate methoxysuccinyl-alanyl-alanyl-prolyl-valyl-7-
amino-4-methylcoumarin [9]. Inhibition of elastase activity was 
measured as the percentage inhibition of a standard amount of elastase. 
A sensitive microassay was used to enable measurement of small 
amounts of inhibitory activity. Briefly, 10 μΐ of 4 nM leukocyte elastase 
was mixed with urine sample (10 μΐ) and incubated at 37°C for 15 
minutes to allow complexing of enzyme and the inhibiting component in 
the urine. Thereafter, 20 μΐ of 250 μΜ substrate solution was added and 
the reaction was allowed to proceed for 15 min at 37° C. All components 
were dissolved in 1 M NaCl, 0.4% СТАВ, 0.1 M Tris pH 8.5. The 
incubation was terminated by the addition of 1 ml buffer (100 mM 
Na 2C0 3, pH 10.5) and fluorescence was measured at 375 nm (excitation) 
and 440 nm (emission) in a Perkin-Elmer LS-5 fluorimeter. Inhibition of 
elastase activity in this assay was calculated as the percentage inhibition 
of the activity of 40 fmol elastase (quantity in the assay). The unit of 
inhibitory activity was defined as the amount required to reduce the 
elastase activity in the assay by 50%. Elastase activity was linear during 
the assay (final substrate concentration 125 μΜ, of which less than 10% 
is consumed during the 15 min incubation). For all urine samples a 
dilution curve was made starting from a 1:2 dilution in assaybuffer (see 
also Fig 1). The amount of anti-elastase activity was expressed in units. 
When maximal inhibition was less than 50%, anti-elastase activity was 
considered to be undetectable. Thus the actual detection limit is 2 units 
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per 10 μΐ of urine. 
Chromatographic procedures 
A РВЕ 94 chromatofocusing column (6 χ 1.4 cm) was equilibrated with 
0.025 M ethanolamine buffer pH 9.4 (starting buffer), and 1-ml sample 
of concentrated, dialysed urine was applied in starting buffer. After 
sample application the column was washed with 35 ml of starting buffer. 
As previously described, this column can be used as a convenient and 
efficient purification step without the need to generate a pH gradient 
over the column [13]. SKALP is extremely cationic and elutes in the 
void volume of the column, whereas most other proteins are bound. The 
column was regenerated by 1 M NaCI. 
The eluent was monitored at 280 nm, 2.5-ml fractions were collected 
and anti-elastase activity in the eluted fractions was measured as 
described above, expressed in units inhibitory activity per fraction. The 
fractions with elastase inhibiting activity were further concentrated by 
vacuum evaporation and used for kinetic studies, gel permeation 
chromatography, and SDS-gel electrophoresis. 
Determination of dissociation constant K¡ 
Kinetic parameters were determined according to the criteria posed by 
Bieth [19], using active-site titrated leukocyte elastase, which was also 
used for determination of urinary SKALP concentrations. The 
dissociation constant K, was determined by an Easson-Stedman plot 
based on the equation 1/(1-a) = K/a + E°, where a is the fractional 
activity (ratio of enzyme activity in the presence and absence of 
inhibitor), E° is the initial enzyme concentration, and 1 is the inhibitor 
concentration. The plot of 1/(1-a) vs. 1/a yields a straight line whose 
slope is K,. 
Determinations were made in 0.1 M Tris, IM NaCI, and 0.4% 
cetyltrimethylammonium bromide, pH 8.5, as described before. The use 
of detergent and high salt is a conditio sine qua non, in order to prevent 
nonspecific absorption of inhibitor or enzyme, because extremely low 
concentrations of purified protein are used. 
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SDS-PAGE and Western blotting 
Fractions with elastase inhibiting activity obtained after 
chromatofocusing were pooled, concentrated by vacuum evaporation, and 
subjected to SDS-PAGE (non-reducing conditions). Proteins were 
separated on a 16% Polyacrylamide gel, using tricine as a trailing ion 
instead of tris-glycine [20]. This system has an improved resolution for 
low molecular weight molecules. Gels were blotted on PVDF 
membranes or sliced in order to elute SKALP from the gel. To this end, 
2-mm slices of SDS-gel were extracted for 30 min in buffer and assayed 
as described above. Protein staining on PVDF membranes was 
performed with amido black according to standard procedures. Using a 
rabbit antiserum raised against highly purified SKALP from psoriatic 
scales, immunological detection of proteins was performed as described 
before [13]. A polyclonal antiserum against ALP/SLPI was a kind gift of 
Dr. J.A. Kramps, Department of Pulmonology, Academic Hospital 
Leiden, The Netherlands. 
RESULTS 
Measurement of anti-elastase activity in urine 
In preliminary experiments we noticed that in urine from psoriatic 
patients variable amounts of anti-elastase activity could be demonstrated, 
and even small amounts of free elastase activity were occasionally 
found. Due to the complex situation of both elastase and inhibitor being 
present, a direct quantification of the amount of biologically active 
inhibitor was not possible. Therefore we developed a protocol for 
measurement of the total (latent plus free) anti-elastase activity in urine, 
by making use of the differential heat stability of elastase and inhibitor. 
By boiling the urine for a short period, elastase is denatured and heat-
stable inhibitors are released from the enzyme-inhibitor complex. Figure 
1 shows an example of urine from a psoriatic patient that contained a 
small amount of free elastase activity. When the urine was boiled and 
samples were drawn at various time intervals, it was found that the 
elastase activity disappeared (within 1 min) and that anti-elastase activity 
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was released. The inhibition curves of urine samples taken at t = 0,1,2,4 
and 8 min as depicted in Fig 1, show that 2 min boiling gives an optimal 
recovery of heat-stable anti-elastase activity. 
elastase activity (%) 
urine (ul) 
Figure 1. Dilution curves showing the effect of boiling on elastase and anti-elastase 
activity in urine from a psoriatic patient. When untreated urine was added to a standard 
amount of human leukocyte elastase (100% value), additional elastase activity was 
measured (diamonds). Boiling the urine samples abolished all elastase activity and 
released inhibitory activity in a time-dependent manner. Boiling was done for 1, 2 and 8 
min, represented by stars, triangles and circles, respectively. Prolonged boiling resulted 
in a gradual decrease of inhibitory activity. 
Using this protocol, heat-stable anti-elastase activity in the urine of 33 
psoriatic patients and 10 healthy controls was measured as described in 
the Materials and Methods section. Table 1 shows the values of all 
patients and controls. Most of the psoriatic patients showed urinary anti-
elastase activity. In urine of healthy controls anti-elastase activity was 
undetectable in all but one cases. 
Characterization of urinary anti-elastase activity 
In order to investigate its possible identity to SKALP, the urinary anti-
elastase activity was further characterized by its behavior on a РВЕ 94 
chromatofocusing column. 
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Figure 2 shows that most of the activity elutes in the void volume, 
indicating that it is a cationic molecule, very much like SKALP [13]. 
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Figure 2. Chromatofocusing of concentrated urine. РВЕ 94 was used, eluated with 0.025 
M ethanolamine (pH 9.4). One milliliter of sample was applied (open arrow), after which 
the column was regenerated with 1 M NaCl (solid arrow). Anti-elastase activity was 
measured in all fractions and expressed as units per fraction (bars). As can be seen from 
the elution profile (solid line; absorbance 280 nm; arbitrary scale) most of this anti-
elastase activity elutes in the void volume, containing the material that does not bind to 
the column. 
In the fractions collected after regeneration of the column with 1 M 
NaCI, only a small amount (less than 5%) of inhibitor was eluted. 
Determination of the dissociation constant K¡ was carried out with the 
pooled fractions of the void volume of the chromatofocusing experiment, 
in which the highest anti-elastase activity was measured. Figure 3 shows 
an Easson-Stedman plot. The slope of the lines obtained for SKALP 
from urine and scales yields a similar K¡ of approximately 2-10 M, 
which is in accordance with previous findings [12,13]. 
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Figure 3. K, determination of SKALP. Easson-Stedman plot of 1/a (a = fractional 
activity) against I/( 1 -a) (I = inhibitor concentration). See also Materials and Methods 
section. The slope of the line yields the apparent K,. Open triangles: partially purified 
SKALP from urine, open squares: SKALP purified from scales. 
SDS-PAGE and Western Blotting 
The partially purified inhibitor preparation was subjected to SDS-PAGE. 
The gel was cut in 2-mm slices and assayed for anti-elastase activity as 
can be seen in Fig 4. Only one peak of activity was found, 
corresponding with a molecular weight of about 11 kDa, a value that 
was previously found for SKALP purified from psoriatic scales. In 
addition, gels were blotted on PVDF-membranes, which were used for 
protein staining and for immunostaining. As shown in Fig 5, the partially 
purified preparation obtained by chromatofocusing contains several low 
molecular weight bands, one of which coincides with the band of anti-
elastase activity found in gel slices (see Fig 4). Using a polyclonal 
antiserum raised against highly purified SKALP from psoriatic scales, 
two bands were stained. The high molecular weight band coincides with 
the 11-kDa band of anti-elastase activity, the low molecular weight band 
probably represents an inactive breakdown product. A polyclonal 
antiserum against ALP/SLPI that is a related proteinase inhibitor with 
similar properties was tested in parallel. Both the anti-ALP/SLPI 
antiserum and preimmune rabbit serum (control for anti-SKALP) were 
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units 
0 ^ 
1 
49.6 32.6 17 
i i i i i 
Úlh 
11 16 21 
slice number 
Figure 4. Anti-elastase activity 
eluted from an SDS gel. Partially 
purified urinary elastase inhibitor 
was electrophoresed under non-
reducing conditions. The SDS 
gel was cut in 2 mm-slices and 
extracted in СТАВ. The amount 
of anti-elastase activity recovered 
from the gel slices is given in 
units. The positions of marker 
proteins are indicated with 
arrows (kDa). 
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Figure 5. Western blotting of partially 
purified urinary elastase inhibitor. In 
lane 2 distinct bands were stained with a 
polyclonal rabbit antiserum raised 
against SKALP from psoriatic scales. 
Preimmune serum (lane 3) and a rabbit 
polyclonal antiserum against ALP/SLPI 
(lane 4) were used as a control, the latter 
to exclude ALP/SLPI as the cause of the 
anti-elastase properties of the urine; both 
lane 3 and 4 were negative. A positive 
control (10 ng recombinant ALP/SLPI) 
for the rabbit polyclonal antiserum 
against ALP/SLPI is shown in lane 5. 
Total protein staining of the urinary 
SKALP sample with amidoblack is 
shown in lane 6, and molecular weight 
markers (kDa) in lanes I and 7. 
DISCUSSION 
The structural integrity of human skin is at risk during acute 
inflammatory reactions when activated phagocytes (PMN, monocytes, 
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macrophages) invade the papillary dermis and epidermis, e.g., in 
psoriasis [21]. These inflammatory cells are known to secrete large 
amounts of proteinases that can damage extracellular matrix proteins, 
basement membranes, and desmosomal structures [1,9,22]. Normal 
human epidermis contains very little inhibiting activity against elastase, 
one of the major PMN-derived proteinases. However, we have recently 
shown that in a number of inflammatory skin diseases large amounts of 
epidermal anti-elastase activity can be found, in particular in psoriasis 
[12]. The major source of the anti-elastase activity could be ascribed to a 
cation ¡c, low molecular weight protein that was given the acronym 
SKALP [13]. In view of its physico-chemical properties, SKALP will 
easily cross the basal lamina, penetrate the connective tissue, and reach 
the circulation. Because small cationic proteins are readily excreted in 
the urine, we investigated whether SKALP could be found in urine from 
psoriatic patients. In this paper we show that considerable amounts of 
anti-elastase activity can be found in urine from most of the psoriatic 
patients, whereas urine from healthy controls is usually negative. The 
anti-elastase activity could be ascribed to SKALP, based on biochemical 
and immunological criteria. The urinary anti-elastase activity as 
measured in our assay was not due to αϊ-proteinase inhibitor (data not 
shown). In addition we could exclude that the activity was due to 
ALP/SLPI, which is a proteinase inhibitor that shows structural and 
functional similarity to SKALP. 
Interestingly, in some of the patients we found low levels of free 
elastase activity in the urine, whereas SKALP activity was undetectable. 
SKALP activity could be unmasked by boiling the urine, which destroys 
elastase activity, as shown in Fig 1. This finding emphasizes the 
importance of SKALP as a physiologically relevant elastase inhibitor. 
The presence of SKALP in urine strongly suggests (but does not 
prove) that it is from epidermal origin. Immunohistological and 
functional studies indicate that the keratinocytes are the source of 
epidermnal SKALP; inflammatory cells were found to be negative (data 
not shown). Unfortunately we have no assay at the moment that allows 
quantification of immunoreactive SKALP. Once a SKALP-specific 
106 Chapter 6 
enzyme-linked immunosorbent assay is available, the presence in plasma 
could be established, to link the presence in epidermis and urine. This 
would, in addition, allow a more sensitive measurement of SKALP and 
its breakdown products in urine. Preliminary results of measurement of 
biologically active SKALP in urine suggest a relationship between 
disease severity and urinary SKALP levels. 
Future research will be aimed at developing sensitive, discriminative 
assays for detection of urinary SKALP (active and inactive fragments). 
This might yield an useful, noninvasive, quantitative measure for disease 
activity. 
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TABLE I 
Anti-elastase activity in urine of psoriatic patients ( n - 3 3 ) and controls (n = 10) in units SKALP 
per ml. Inhibitory activity was measured as described in the Materials and Methods section. 
Values below the detection limit of 200 units per ml urine are marked with nd (non detectable). 
A statistically significant difference in inhibitory activity between psoriatics and controls was 
found (p < 0.002, Mann-Whitney U-test). 
Psoriatica 
Sex 
1. f 
2. f 
3. m 
4. m 
S. m 
6. œ 
7. о 
8. m 
9. α 
10. f 
11. η 
12. m 
13. f 
14. f 
15. f 
16. m 
17. f 
Ag· 
бб 
26 
49 
40 
42 
66 
35> 
38 
50 
86 
49 
23 
68 
23 
24 
18 
32 
SKALP 
880 
1568 
6656 
816 
nd 
456 
416 
nd 
352 
668 
nd 
704 
424 
nd 
416 
288 
204 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
28. 
29. 
30. 
31. 
32. 
33. 
. . 
Sex 
f 
m 
η 
f 
o 
f 
f 
f 
f 
m 
m 
f 
f 
f 
£ 
m 
Age 
34 
60 
29 
47 
65 
67 
31 
77 
80 
67 
76 
36 
27 
24 
18 
27 
SKALP 
1408 
nd 
212 
752 
768 
232 
312 
nd 
376 
nd 
424 
232 
1856 
1376 
456 
400 
Controle 
Sex 
1. m 
2. m 
3. m 
4. m 
5. m 
6. f 
7. m 
8. m 
9. £ 
10. f 
Age 
31 
28 
36 
28 
58 
25 
44 
33 
36 
57 
SKALP 
nd 
nd 
nd 
nd 
nd 
432 
nd 
nd 
nd 
nd 
108 Chapter 6 
REFERENCES 
1. Weiss SJ: Tissue destruction by neutrophils. N Engl J Med 320:365-376, 1989 
2. Travis J, Salvesen GS: Human plasma proteinase inhibitors. Ann Rev Biochem 
52:655-709, 1983 
3. Feinstein G: Physiological roles of protein inhibitors. J Protein Chem 3:131-141, 
1984 
4. Thompson RC, Ohlsson K: Isolation, properties, and complete amino acid 
sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of 
leukocyte elastase. Proc Natl Acad Sci USA 83:6692-6696, 1986 
5. Janoff A: Elastases and emphysema. Current assessment of the 
protease-antiprotease hypothesis. Am Rev Respir Dis 132:417-433, 1985 
6. Kramps JA, te Boekhorst АНТ, Fransen JAM, Ginsel LA, Dijkman JH: 
Antileukoprotease is associated with elastin fibers in the extracellular matrix of the 
human lung. An immunoelectron microscopic study. Am Rev Respir Dis 
140:471-476, 1989 
7. Janoff A, Feinstein G, Malemud CJ, Elias JM: Degradation of cartilage 
proteoglycan by human leukocyte granule neutral proteases - A model of joint 
injury. Penetration of enzyme into rabbit articular cartilage and release of 
"S04-labeled material from the tissue. J Clin Invest 57:615-624, 1976 
8. Schalkwijk J, van den Berg WB, van de Putte LB, Joosten LA: Elastase secreted 
by activated polymorphonuclear leucocytes causes chondrocyte damage and matrix 
degradation in intact articular cartilage: escape from inactivation by 
alpha-1-proteinase inhibitor. Br J Exp Pathol 68:81-88, 1987 
9. Schrijver G, Schalkwijk J, Robben JC, Assmann KJ, Koene RA: Antiglomerular 
basement membrane nephritis in beige mice. Deficiency of leukocytic neutral 
proteinases prevents the induction of albuminuria in the heterologous phase. J Exp 
Med 169:1435-1448, 1989 
10. Bandrup F, Ostergaard PA: a.-antitiypsin deficiency associated with persistent 
cutaneous vasculitis. Occurrence in a child with liver disease. Arch Dermatol 
114:921-924, 1978 
11. Takamori K, Yoshike T, Morioka S, Ogawa H: The role of proteases in the 
pathogenesis of bullous diseases. Int J Dermatol 27:533-539, 1988 
12. Schalkwijk J, Chang A, Janssen Ρ, de Jongh GJ, Mier PD: Skin-derived 
antileucoproteinascs (SKALPs): characterization of two new elastase inhibitors 
from psoriatic epidermis. Br J Dermatol 122:631-641, 1990 
13. Schalkwijk J, de Roo С, de Jongh GJ: Skin-derived antileukoproteinase (SKALP) 
an elastase inhibitor from human keratinocytes. Purification and biochemical 
properties. Biochim Biophys Acta 1096:148-154, 1991 
SKALP in urine of psoriatic patients 109 
14 Wiedow O, Schroder J-M, Gregory H, Young JA, Christophers E Elafin an 
elastase specific inhibitor of human skin Purification, characterization, and 
complete amino acid sequence J Biol Chem 265 14791-14795, 1990 
15 Wiedow O, Ludemann J, Utecht В Elafin is a potent inhibitor of proteinase 3 
Biochem Biophys Res Commun 174 6-10, 1991 
16 Sallenave J-M, Ryle AP Purification and characterization of elastase-specific 
inhibitor Sequence homology with mucus proteinase inhibitor Biol Chem 
Hoppe-Seyler 372 13-21, 1991 
17 Chang A, Schalkwijk J, Happle R, van de Kerkhof PCM Elastase-inhibiting 
activity in scaling skin disorders Acta Derm Venereol (Stockh ) 70 147-151, 1990 
18 Chang A, de Jongh G, Mier PD, van de Kerkhof PCM Enzymatic quantification 
of polymorphonuclear leukocytes in normal and psoriatic skin following 
standardized injury Clin Exp Dermatol 13 62-66, 1988 
19 Bieth JG Pathophysiological interpretation of kinetic constants of protease 
inhibitors Bull Europ Physiopath Resp 16 183-195, 1980 
20 Schagger H, von Jagow G Тпсіпе-sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis for the separation of proteins in the range from 1 to 100 kDa Anal 
Biochem 166 368-379, 1987 
21 Stadler R, Schaumberg-Lever G, Orfanos I E Histology In Mier PD, van de 
Kerkhof PCM (eds ) Textbook of psoriasis, 1st ed Churchill Livingstone, 
Edinburgh, 1986, pp 40-54 
22 Bnggaman RA, Schechter NM, Fraki J, Lazarus GS Degradation of the 
epidermal-dermal junction by proteolytic enzymes from human skin and human 
polymorphonuclear leukocytes J Exp Med 160 1027-1042, 1984 
по 
I l l 
Chapter 7 
Levels of skin-derived antileukoproteinase 
(SKALP)/eIafin in serum correlate with disease activity 
during treatment of severe psoriasis with cyclosporin A 
J.A.C. Alkemade, G.J. de Jongh, W.P. Arnold, 
P.C.M. van de Kerkhof and J. Schalkwijk 
Department of Dermatology, 
University Hospital Nijmegen St Radboud, 
the Netherlands 
J Invest Dermatol 104:1-5, 1995 
Reprinted with permission 
112 Chapter 7 
ABSTRACT 
The epidermal serine proteinase inhibitor SKALP (also known as elafin), 
directed against human leukocyte elastase and proteinase 3, is strongly 
induced in suprabasal keratinocytes during inflammation. The presence 
of SKALP/elafin in urine has been demonstrated for several 
inflammatory skin disorders, such as psoriasis, erythroderma and 
erysipelas. In this study we investigated whether SKALP/elafin levels in 
serum and urine of psoriatic patients can be used as a marker for disease 
activity during treatment. Patients with severe chronic disabling psoriasis 
were treated for 16 weeks with cyclosporin A, which resulted in a 
marked clinical improvement as measured with the PASI score. 
SKALP/elafin levels both in serum and urine were determined with an 
enzyme-linked immunosorbent assay (ELISA). Measurements were 
performed at the start of the cyclosporin A treatment, and after regular 
intervals up to 16 weeks. The results indicate that: 
1. SKALP/elafin determination in serum rather than in urine is the 
prefered method, because the decrease in serum SKALP levels 
during therapy is more pronounced and correlated better with the 
clinical course of the patients. 
2. SKALP/elafin levels in serum decreased during cyclosporin A 
treatment (p<0.05). 
3. SKALP/elafin levels in serum correlate with the PASI score 
(p<0.01). 
We conclude that SKALP/elafin measurement in serum of patients with 
severe psoriasis provides a tool for monitoring disease activity. 
INTRODUCTION 
We have recently shown that skin-derived antileukoproteinase (SKALP), 
a serine proteinase inhibitor which is virtually absent in normal 
epidermis, is induced in lesionai psoriatic skin [1]. We found that 
SKALP, also known as elafin [2,3], is not specific for psoriasis, but can 
be considered as one of the markers of the regenerative differentiation 
SKALP/elafm levels in serum 113 
program that is also found in other conditions such as wound healing 
[4,5] and several inflammatory skin diseases [6]. SKALP/elafm is a 
strong inhibitor of the leukocytic enzymes elastase [1] and proteinase-3 
[7] and is putatively involved in the regulation of cutaneous 
inflammation. In previous studies SKALP/elafm was described 
biochemically [8] and characterized at the protein and DNA level [9]. 
We established the cellular source and localization in psoriatic epidermis 
[10], and we found that SKALP/elafin is differentially expressed in 
human epidermal tumors [11]. Recently we have been able to assign the 
SKALP/elafin gene to chromosome region 20ql2-ql3 [12]. The gene has 
been given the approved name of Protease Inhibitor, skin derived 
(SKALP), symbol: PI3, in the Genome Data Base of the HUGO 
nomenclature committee. 
In psoriasis, SKALP/elafin is expressed in the upper spinous layers of 
lesionai skin [10]. We showed that SKALP/elafin as expressed in 
cultured epidermal keratinocytes is translated as a 12.3 kDa protein. 
Cleavage of the signal peptide yields a 9.9 kDa protein that is the major 
form found in cultured cells, as was confirmed by purification and N-
terminal amino acid sequencing [9]. The presence of a signal peptide, 
suggests that SKALP/elafin is a secreted protein. We indeed found that 
significant amounts of biologically active SKALP/elafin can be found in 
the urine of psoriatic patients [13], a finding that was recently confirmed 
by others [14]. In urine of healthy individuals SKALP/elafin was not 
detectable. Apparently, once secreted in the epidermis, SKALP/elafin is 
able to reach the circulation, and is subsequently cleared via the kidney. 
Although we were then not able to measure SKALP/elafin in serum, this 
was a likely route, since SKALP/elafin is a low molecular weight 
cationic protein which will easily cross basal membranes. 
In the present study there were two objectives: first, we wanted to 
develop an assay for SKALP/elafin assessment in serum of psoriatic 
patients, and second, we wanted to investigate if measurement of 
SKALP/elafin in urine and serum could be used as a marker for disease 
activity during therapy. In our previous study, we used a functional 
biochemical assay to measure SKALP/elafin in urine [13]. However, in 
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serum this is not possible due to interfering factors. We therefore 
developed an enzyme-linked immunosorbent assay (ELISA) which 
allows measurement of SKALP/elafin both in serum and in urine. Using 
this ELISA we found that patients with severe psoriasis during therapy 
with cyclosporin A (CyA) showed a decrease of SKALP/elafin activity 
in serum which correlated with a decrease in clinical scores (Psoriasis 
Area and Severity Index (PASI) score). These findings suggest that 
SKALP/elafin can be used as a marker for disease activity and can be 
used as a quantitative measure to monitor therapeutic effects. 
MATERIALS AND METHODS 
Chemicals 
Tween-20 was obtained from Merck, Schuchardt, Hohenbrunn bei 
Munich, Germany, and bovine serum albumin (BSA) from Organon 
Teknika, Boxtel, The Netherlands. Swine-anti-rabbit peroxidase was 
obtained from Dako, Copenhagen, Denmark, and o-phenylene 
diamine.2HCl (OPD) from Pierce, Rockford, IL, USA. Microtiter plates 
(96 wells) for ELISA were obtained from Greiner, Alphen a/d Rijn, The 
Netherlands. Recombinant SKALP/elafin was a kind gift from Dr. 
Norman Russell, ICI Pharmaceuticals, UK. 
Subjects, sample collection and preparation 
Fifteen healthy volunteers (5 males, 10 females, age 2-79 years) took 
part in the experiments to study age or sex differencess in SKALP/elafin 
serum levels. For determination of circadian variation blood was drawn 
every 4 hours during 24 hours in a psoriatic patient and a healthy 
control. Six male patients (age 36-64 years, mean age 48 years) with 
severe chronic disabling psoriasis participated. Patients had not used any 
systemic treatment for at least 4 weeks or local treatment for at least 1 
week prior to the start of CyA therapy. In all patients, initial dosage of 
CyA was 3 mg/kg body weight; in 2 patients this dosage was increased 
up to 4 mg/kg body weight after 8 weeks of treatment. Before treatment 
disease activity was evaluated and expressed using the PASI score. This 
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scoring system estimates disease activity depending on erythema, 
infiltration, desquamation, and the area of the psoriatic skin that is 
affected [15]. At the start of CyA therapy, and after 2, 4, 8, 12, and 16 
weeks, samples of blood and urine were taken, and a PASI score as 
measure of disease activity. Samples of blood and urine were frozen, and 
stored at -20 °C until measurement of SKALP/elafin. 
Anti-SKALP/elafin serum 
Recombinant SKALP/elafin was used for immunization procedures as 
described before [8]. In short, a rabbit was immunized intracutaneously 
with recombinant SKALP/elafin that was crosslinked with glutaraldehyde 
and emulsified in Freunds complete adjuvant. A booster with the same 
preparation was given after 2 weeks, and 4 weeks later serum was 
collected via standard methods. Control (preimmune) serum was drawn 
before the immunization procedure. The specificity of the antiserum was 
validated as described before [8]. 
Enzyme-linked immunosorbent assay (ELISA) 
To measure SKALP/elafin concentrations in serum and urine of psoriatic 
patients, we used a competitive-type ELISA. 
Blood samples were taken, coagulated for 60 min at room temperature, 
and centrifuged at 450 g for 10 min. Serum was acidified to a final 
concentration of 0.05 N HCl, boiled for 2 min, and centrifuged for 60 
min (2,000 g, 4 °C). Urine was boiled for 2 min, cooled on ice for 30 
min, and centrifuged for 15 min (2,000 g, 4 °C). Creatinine measurement 
was done before by an alkaline picrate determination with kinetic 
endpoint detection, carried out with reagents from Boehringer Mannheim 
using a Hitachi 747 analyzer. Supematants were taken for quantification 
of SKALP/elafin. 
The supematants were mixed to contain 80% supernatant, 0.1 M Tris, 
0.1% Tween-20, 1% BSA, and rabbit anti-SKALP/elafin antiserum 
(1:9500 diluted), and incubated overnight. Microtiter plates (96 flat 
bottom wells) were coated overnight with 50 ng/ml recombinant 
SKALP/elafin in phosphate-buffered saline (PBS). After washing of the 
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plates with PBS/0.05% BSA, microtiter plates were blocked, probed with 
the test samples, and developed during 60 min with swine-anti-rabbit 
peroxidase using OPD as chromogenic substrate for 30 min. Human 
recombinant SKALP/elafin in PBS with 0.1% BSA was used as a 
standard: a calibration curve was made, using recombinant SKALP/elafin 
in the range of 0.6-80 ng/ml. The SKALP/elafin concentrations in serum 
or urine samples were read from this curve. AU ELISA steps were 
performed at 4 °C, except development with OPD, which was done at 
room temperature. Data were read with a Biorad™ ELISA-reader, and 
evaluated using the Excell™ spread sheet program. 
Statistical analysis 
Regression analysis was performed to correlate SKALP/elafin levels in 
serum and urine with each other, with time of CyA treatment, and with 
the disease activity as expressed in the PASI score. Mean г (Pearson 
moment product correlation) was obtained after Fisher-z transformation. 
RESULTS 
PASI score and CyA treatment 
All patients showed good clinical improvement during 16 weeks of 
treatment with CyA, and apart from slight gastrointestinal discomfort no 
complaints were reported. Mean PASI score was 20.0 (10.6-36.0) at the 
start of the treatment, and decreased to 3.4 (2.0-5.4) at week 16. In 2 
patients dosage of CyA were increased at week 8 due to lack of clinical 
progress. Using routine blood tests for liver and kidney functions no side 
effects on these organs could be demonstrated; one patient showed 
hypertrichosis. Urine and blood samples of one of the patients could not 
be taken until 2 weeks after the start of the CyA treatment. 
Sensitivity and accuracy of the ELISA 
The ELISA we developed is of the competitive type, based on the 
displacement of a defined amount of recombinant SKALP/elafin by 
SKALP/elafin in the urine or serum samples. A calibration curve from 
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which the sample values are read in the interval between 3-40 ng per ml, 
is given in figure 1. The detection limit is 3 ng/ml. 
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Figure 1. Calibration curve of recombinant SKALP/elafin. A sigmoid relationship 
between the ELISA signal and the SKALP/elafin concentration of the samples is found. 
The useful range for measurement of SKALP/elafin concentrations is between 3-40 
ng/ml. 
Experiments to check the recovery of recombinant SKALP/elafin added 
to normal human serum revealed that recovery is temperature dependent 
(not shown). When the ELISA was performed at 4 °C a recovery of 
100% was found (figure 2). 
0 10 20 30 40 
Added raconMwK SKALP (ngftiH) 
Figure 2. Mean values ± 2 standard deviations of measurements in quadruplicate of 3 
concentrations of recombinant SKALP/elafin in normal human serum. Standard deviation 
is 10%. The intercept with the Y-axis indicates that in humans a background serum level 
of SKALP/elafin appears to be present. This background level is about 9 ng/ml. 
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Figure 2 also shows that a pool of normal human serum has a 
background level of SKALP/elafin per ml, which appeared to be about 9 
ng/ml (intercept of the Y-axis). The standard deviation of measurements 
in quadruplicate was within 10%. 
SKALP/elafin measurement in urine 
SKALP/elafin levels were expressed in ng/ml urine, and corrections for 
creatinine concentrations were made. SKALP/elafin levels in urine 
varied from 3 ng/ml up to more than 120 ng/ml (Figure 3). Five out of 
six patients showed a clear decrease in urinary SKALP/elafin levels. One 
patient showed extremely low values of creatinine concentration, which 
had an enormous impact on correction for creatinine (Figure 3c); note 
that his serum level of SKALP/elafin decreased during treatment (Figure 
4c). Decrease of SKALP/elafin levels in urine during treatment was 
statistically significant (Fisher-z, p<0.05). 
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Figure 3. SKALP/elafin levels in urine of 6 psoriatic patients (a-f) during treatment with 
CyA. SKALP/elafin levels (ng/ml) are shown before (open squares) and after correction 
for creatinine concentration (solid squares). Decrease of SKALP/elafin levels in urine is 
statistically significant (Fisher-z, p<0.05). 
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Urinary SKALP/elafin levels decreased, but were not found below 3 
ng/ml. Healthy controls do show a similar amount of SKALP/elafin in 
urine (data not shown), and 3-10 ng/ml may be regarded as a normal 
background level of SKALP/elafin in human urine. 
SKALP/elafin measurement in serum 
Serum levels for SKALP/elafin were measured in 15 healthy volunteers. 
No effect of age on SKALP/elafin levels was found (not shown). A 
small difference in SKALP/elafin serum levels (ng/ml) was found 
between males (14.6±2.6) and females (8.5±6.1). No circadian rhythm 
was observed (not shown). SKALP/elafin levels psoriatic patients varied 
from 11 ng/ml up to more than 300 ng/ml (Figure 4). 
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Figure 4. SKALP/elafin levels in serum of 6 psoriatic patients (a-f) during treatment with 
CyA. Amount of SKALP/elafin in serum is given in ng/ml (solid squares). Decrease of 
SKALP/elafin levels in serum is statistically significant (Fisher-z, p<0 05). PASI scores 
at time of sampling are given (open squares). 
These levels significantly decreased during treatment with CyA (Fisher-
z, p<0.05) and correlated well with clinical improvement as expressed in 
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the PASI score (Fisher-z, p<0.01). This decrease in SKALP/elafin level 
was found in the serum of all six patients. SKALP/elafin levels in serum 
were about sixfold higher than in urine, and levels in serum were 
positively correlated with levels in urine (Fisher-z, p<0.01). 
DISCUSSION 
Increased amounts of SKALP/elafin have been demonstrated in urine of 
patients with psoriasis [13] and several other inflammatory skin diseases 
[14]. Since SKALP/elafin is barely detectable in normal skin and is 
strongly expressed in inflamed skin, we hypothesized that the increase in 
urinary SKALP/elafin in psoriatics is derived from local production in 
skin. This would be in line with the fact that SKALP/elafin is a secreted 
molecule [16] and the notion that epidermis acts as a secretory organ as 
recently described [17,18]. However, no definitive proof could be given 
for the epidermal origin of urinary SKALP/elafin in psoriatic patients, 
because SKALP/elafin could not be demonstrated in the intermediate 
compartments between epidermis and urine (i.e. dermis and blood). In 
our initial study we used a functional assay to measure SKALP/elafin, 
that could not be applied to serum, due to interference by the 
overwhelming amount of other plasma-derived proteinase inhibitors. 
Intraepidermal accumulation of PMN is an early event in the 
pathogenesis of the psoriatic lesion [19], and PMN derived proteinases 
were shown to degrade the dermo-epidermal junction in vitro [20]. This 
suggests that elastase may be involved in PMN migration and PMN 
dependent tissue damage and may promote the inflammatory response. 
Several antipsoriatic therapies are known to interfere with this PMN 
migration, suggesting that they are involved in the downregulation of 
inflammation [21]. In addition to proteinases from inflammatory cells, 
keratinocyte derived proteinases such as plasminogen activator may act 
as a proinflammatory mediator in psoriatic skin [22]. Synthesis of 
proteinase inhibitors that counteract proteinases by forming inactive 
complexes is one of the in vivo mechanisms to protect tissue against 
unwanted proteolysis [23]. These proteinase inhibitors may be present in 
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plasma, or can be produced locally at the site of action [8,24,25]. 
Complexes between elastase and elastase inhibitors in serum, sputum, 
bronchoalveolar lavage, and urine, have been described, the inhibitors 
being al-PI [26-28], antileukoproteinase [29] or SKALP/elafin [13]. 
Levels of these complexes may be related to disease activity, and 
measurement may provide a tool for monitoring therapeutic result. 
Increased levels of complexes between elastase and inhibitors, but also 
of free elastase or free inhibitor have been reported in lung cancer [30], 
neonatal systemic infection [31,32], adult respiratory distress syndrome 
[27,32], cervical cancer [33,34], psoriasis, eczema and other cutaneous 
disorders [35-37], and these levels can be used as parameters for 
monotoring disease activity. 
In normal epidermis anti-elastase activity is hardly detectable [1], 
although the presence of al-PI, and a2-macroglobulin in normal skin 
has been described [38,39]. Teleologically, it is plausible that after a 
disturbance of the proteinase-antiproteinase balance in skin, resulting in 
an excess of elastase, SKALP/elafin is produced to limit proteolytic 
action of this leukocytic proteinase. After a period of proteolysis by 
elastase a rebalancing takes place, and SKALP/elafin molecules may 
temporarily outnumber elastase molecules. Complexes are secreted in 
urine [13], but epidermic clearance via loss of scales that contain 
complexes may take place as well. Finally, restoration of normal 
homeostasis is followed by an off-switch of SKALP/elafin production by 
the epidermal cells. 
Using a competitive-type ELISA, we were able to demonstrate the 
presence of SKALP/elafin in serum of normal individuals and psoriatic 
patients. The assay was found to be reproducable and reasonably 
sensitive (detection limit 3 ng/ml). We found a background level of 
SKALP/elafin in serum of healthy controls and symptom-free psoriatic 
patients which is probably derived from the turnover in tissues where 
SKALP/elafin is constitutively expressed. We have recently completed a 
survey of SKALP/elafin in normal human epithelia (Alkemade et al., 
manuscript in preparation) and found that the molecule is expressed in a 
limited number of normal tissues. This background level of 
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SKALP/elafin in serum negatively influences the sensitivity of the assay 
for detecting an increase in inflammatory skin diseases. 
In severe psoriatic patients with a large area of involved skin, serum 
levels are significantly higher than in healthy controls and symptom-free 
psoriatic patients. It is shown that during therapy with CyA, which is a 
potent antipsoriatic drug, serum levels gradually decrease and stabilize to 
a level which is still higher than in normal controls. This decrease in 
SKALP/elafin levels correlate with the decrease in PASI scores, and we 
assume that the decrease in serum SKALP/elafin levels during therapy 
reflects the rate of normalization of the epidermis. The SKALP/elafin 
concentrations in serum were about sixfold higher than in urine, and the 
decrease in serum during treatment was more impressive and correlated 
better with the clinical course. Therefore, determination of SKALP/elafin 
in serum rather than in urine was considered to be the method of 
preference. Because SKALP/elafin levels correlated well with the 
clinical state as represented by the PASI score, we conclude that 
SKALP/elafin measurement in serum of patients with severe psoriasis 
provides a tool for monitoring disease activity. 
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ABSTRACT 
Recently we described a new epidermal serine proteinase inhibitor, skin-
derived antileukoproteinase (SKALP), also known as elafin. 
SKALP/Elafin was found to be absent in normal human epidermis, but 
can be induced in vitro and in vivo under hyperproliferative conditions. 
Here we studied the expression of SKALP/elafin in several types of 
epidermal tumors (basal cell carcinoma, squamous cell carcinoma, 
Bowen's disease, actinic keratosis, and keratoacanthoma). Using 
immunohistochemical staining SKALP/elafin appeared to be 
differentially expressed in these tumors. Functional measurements of 
antiproteinase activity, and Western blotting of tumor extracts confirmed 
our findings at the histological level. In well-differentiated squamous cell 
carcinoma, SKALP/elafin messenger RNA was demonstrated by non-
radioactive in situ hybridization. We conclude that SKALP/elafin is a 
marker for abnormal or disturbed squamous differentiation. A possible 
role of SKALP/elafin in the control of tumor cell invasion is discussed. 
INTRODUCTION 
Deregulation of gene expression may cause transcription of oncogenes or 
loss of action of growth suppressor genes, leading to abnormal growth of 
tumor cells. However, in addition to disturbed growth control, also 
invasion and metastasis are features of malignant behavior. Several 
proteinases such as plasminogen activators, cathepsins and 
metalloproteinases, as well as the inhibitors of these enzymes have been 
reported to be associated with tumor invasion and metastasis [1-9]. 
Expression of proteinases is thought to promote the migrational capacity 
of cells; specific inhibitors of these proteinases counteract this process. 
Hence, the term metastasis suppressor proteins has been coined for these 
inhibitors [10,11]. 
Recently we described a new serine proteinase inhibitor (skin-derived 
antileukoproteinase, SKALP) which is expressed in lesionai psoriatic 
epidermis and in epidermis after injury, but is absent in normal 
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epidermis [12,13]. Initially, SKALP was shown to be a low molecular 
weight, cationic, heat-stable protein, that was similar to elafin, an 
epidermal proteinase inhibitor described by others [14]. We have 
recently cloned and sequenced the cDNA of SKALP, which proved 
SKALP and elafm to be identical, and which showed that SKALP/elafin 
as expressed in cultured epidermal keratinocytes is translated as a 12.3-
kd protein [15]. Cleavage of the signal peptide yields a 9.9-kd protein 
that is the major form found in cultured cells, as was confirmed by 
purification and N-terminal amino acid sequencing [15]. Elastase-specific 
inhibitors from bronchial secretions with molecular weights of 10 kd, 5 
kd, and 2.5 kd as reported by Hochstrasser, Kramps and Sallenave 
respectively [16-18], are biological active fragments of the same larger 
precursor molecule [19]. SKALP/Elafin inhibits at least three serine 
proteinases derived from polymorphonuclear leukocytes (PMN), namely 
human leukocyte elastase, porcine pancreatic elastase, and human 
leukocyte proteinase 3 [12,13,20]. 
Recently we could assign the chromosomal localization of the SKALP 
gene to chromosome 20, band ql2-13 [21]. The gene has been given the 
approved name of Proteinase Inhibitor, skin derived (SKALP), symbol: 
PI3, in the Genome Data Base of the HUGO nomenclature committee. 
The exact biological function of SKALP/elafin is not known at present, 
although the substrate specificity for polymorphonuclear cell-derived, 
elastolytic proteinases suggests that SKALP/elafin is involved in 
regulation of cutaneous inflammation, or protection against 
polymorphonuclear cell-dependent tissue damage. However, it is very 
likely that other target enzymes (eg, from the keratinocytes or dermal 
fibroblasts) exist; hence other functions cannot be excluded. 
Because the expression of SKALP/elafin appears not to be associated 
with the differentiation program of normal epidermis but is found in 
differentiating cells in the context of the hyperproliferative differentiation 
program (eg, psoriasis and wound healing), we investigated its 
expression in a number of epidermal tumors that are characterized by 
abnormal differentiation. The data clearly show that SKALP/elafin is 
differentially expressed in these tumors. 
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MATERIALS AND METHODS 
Chemicals 
Methoxysuccinyl-alanyl-alanyl-prolyl-valyl-7-amino-4-methyl coumarin, 
was obtained from Bachern, Bubendorf, Switzerland. Cetyltrimethyl 
ammoniumbromide was obtained from ICI, UK. All reagents for sodium 
dodecyl sulfate Polyacrylamide gel electrophoresis (SDS-PAGE) 
including prestained markers were obtained from Bio-Rad Laboratories, 
Richmond, CA. Polybuffer exchanger 118, a Superdex 75 fast protein 
liquid chromatography column, a Superdex 75 PC 3.2/30 column, and a 
SMART chromatography system were obtained from Pharmacia, 
Uppsala, Sweden. Polyvinylidenedifluoride membrane was from 
Millipore, Etten-Leur, the Netherlands. Low molecular weight markers 
used for SDS gels, goat anti-rabbit IgG biotin conjugate, avidin-alkaline 
phosphatase, 5-bromo-4-chloro-3-indoIyl phosphate, and nitroblue 
tetrazolium were obtained from Sigma Chemicals, St. Louis, MO. 
Calibration proteins used in chromatography were obtained from 
Boehringer Mannheim GmbH, Mannheim, Germany. Recombinant elafin 
was a gift from Dr. Norman Russell, ICI Pharmaceuticals, United 
Kingdom. 
Tumors 
Material used for histology was selected from archive biopsy material 
sent for routine analysis. The specimens had been fixed in buffered 4% 
formalin for at least 24 hours, and had been embedded in paraffin. Seven 
basal cell carcinomas, seven squamous cell carcinomas, three Bowen's 
diseases, seven actinic keratoses, and seven keratoacanthomas were 
selected. The tissue was cut in 5-μ sections, using a Reichert Jung 
rotation microtome (Leica, Rijswijk, The Netherlands), and mounted on 
slides, which were coated with 3-aminopropyltriethoxysilane. Sections 
were dried 48 hours at 37 °C. Some of the sections were used for in situ 
hybridization experiments as well. 
A limited amount of fresh tumor material was available for extraction 
and was used for functional measurements and Western blotting (two 
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basal cell carcinomas, two keratoacanthomas and one squamous cell 
carcinoma). 
Construction of plasmid and synthesis of RNA probes 
A 0.42-kb PvuiVEcoRl fragment of pGESKA [15], containing almost 
complete SKALP/elafin complementary DNA was cloned into the 
plasmid pGEM4 (Promega, Madison, WI). Sense and anti-sense 
complementary RNA probes were prepared. Briefly, after linearizing the 
construct with either BamHl or Kpnl, the anti-sense and sense cRNAs 
were transcribed in vitro using digoxigenin-labelled UTP, T7 and SP6 
RNA polymerase, respectively, according to the manufacturer's 
instructions (Boehringer). The cRNAs were fragmented with limited 
alkaline hydrolysis to reduce the size of the synthesized RNAs to 
approximately 0.2 kb [22]. 
In situ hybridization 
Nonradioactive in situ hybridization was, with some modifications, 
performed as described by Yokouchi et al [23]. Sections were 
deparaffinized with xylene, rehydrated using solutions of diminishing 
ethanol concentrations (99.8 to 50%), and finally rinsed in phosphate-
buffered saline (PBS). Sections were then treated with 0.01% Triton Χ­
Ι 00 for 1.5 minutes, rinsed with PBS, incubated with pepsin 1 mg/ml in 
0.2 N HCl for 15 minutes at 37 °C, and again rinsed with PBS. 
Thereafter postfixation with 4% paraformaldehyde in distilled water was 
performed. After acetylation with 0.1 M triethylamine, pH 8.0, and 
0.25% acetic anhydride for 10 minutes, sections were rinsed with PBS 
and dehydrated with increasing concentrations of ethanol (50 to 99.8%). 
The hybridization mixture consisted of 50% formamide, 2X standard 
sodium citrate (SSC), 10% dextransulfate, 5X Denhard's solution (0.1% 
bovine serum albumin, 0.1% polyvinylpyrrolidone, 0.1% Ficoll 400), 10 
mM dithiothreitol, 1 mg/ml Escherigia coli transfer RNA. and 4 μg/ml 
probe. After overnight hybridization at 37 °C, the sections were washed 
twice for 45 minutes at 37 °C in 2X SSC and IX SSC, respectively, 
incubated for 20 minutes at room temperature with 20 μg/ml DNase free 
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RNase A, (Boehringer) and 50 mM NaCI in Tris EDTA. A second wash 
step with IX SSC was carried out for 30 minutes at room temperature. 
Hybridization signals were detected by an enzyme-linked immunoassay 
using a nucleic acid detection kit as suggested by the manufacturer 
(Boehringer). 
Isolation and purification of SKALP/elafin 
Skin-derived antileukoproteinase/elafin was isolated both from psoriatic 
scales and from cultured human keratinocytes as described before 
[12,13]. In short, psoriatic scales were homogenized in distilled water, 
yielding a suspension that was boiled and centrifuged, followed by 
chloroform extraction and centrifugation. After concentration, the 
preparation was further purified by chromatofocusing (РВЕ 118 column, 
triethylamine buffer) and affinity chromatography (porcine pancreatic 
elastase coupled to cyanogen bromide-activated Sepharose 4B, 
phosphate-buffered saline (PBS) washing buffer, 0.1 M acetic acid 
eluting buffer). Final purification was by gel permeation chromatography 
on a Superdex-75 fast protein liquid chromatography column. Extracts of 
cultured keratinocytes were prepared by sonication of the cells in 
distilled water and subjected to the SMART chromatography system 
(Superdex 75 PC 3.2/30 column). Anti-elastase activity in obtained 
fractions was measured; relevant fractions were pooled and vacuum 
evaporated to dryness, dissolved in nonreducing SDS-sample buffer and 
used for SDS-PAGE. 
Anti-SKALP/elafin serum 
Skin-derived antileukoproteinase/elafin purified from psoriatic scales or 
recombinant elafin was used for immunization procedures as described 
before (13). In short, a rabbit was immunized intracutaneously with 
highly purified SKALP/elafin that was partially crosslinked with 
glutaraldehyde and emulsified in Freunds complete adjuvant. A booster 
with the same preparation was given after 2 weeks, and 4 weeks later 
serum was collected via standard methods. Control (preimmune) serum 
was drawn before the immunization procedure. The specificity of the 
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antiserum was validated on Western blots and in functional assays which 
showed 1) that the elastase-inhibiting activity could be absorbed by the 
antiserum and 2) that the band stained on a Western blot corresponded 
with a band of anti-elastase activity eluted from the SDS-PAGE gel as 
shown before [13]. The two antisera yielded identical staining patterns 
both in immunohistology and Western blotting. 
Immunohistology 
Before staining, sections were deparaffinized with xylene, rehydrated 
using solutions of diminishing ethanol concentrations (99.8 to 50%) and 
finally rinsed in PBS. Thereupon, sections were preincubated with 
normal swine serum 20% for 15 minutes, and incubated with a 
polyclonal rabbit antiserum against SKALP at a dilution of 1/100 in PBS 
with 1% bovine serum albumin for 60 minutes. After washing in PBS, 
sections were incubated with peroxidase conjugated swine anti-rabbit 
immunoglobulin at a dilution of 1/50 in PBS with 1% bovine serum 
albumin and 5% human AB serum. Subsequently, sections were washed 
in PBS and Na-acetate buffer and developed with aminoethylcarbazole 
as the chromogenic substrate (incubation period, 10 minutes). Finally, 
sections were washed in distilled water, counterstained with hematoxylin 
and eosin, washed again, dried and embedded in glycerol-gelatin 
solution. 
Control staining was performed as indicated above, with polyclonal 
rabbit anti-SKALP/elafin serum substituted by preimmune serum of the 
same animal. 
SDS-PAGE and Western blotting. 
Three types of tumors were studied (basal cell carcinoma, squamous cell 
carcinoma, and keratoacanthoma). Tumor tissue (average weight 
approximately 110 mg) was homogenized in distilled water with the help 
of a glass-glass grinder, whereafter the homogenate was centrifuged for 
10 minutes at 12,000 revolutions per minute. Anti-elastase activity of the 
supernatant was assayed as described before [12,24]. The clear 
supernatant was vacuum evaporated to dryness, and subsequently 
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dissolved in 500 μΐ nonreducing SDS-sample buffer; 5μ1 of this 
preparation was subjected to SDS-PAGE. As a reference, samples of 
recombinant elafin, psoriatic scale extract, and partially purified 
SKALP/elafin of cultured keratinocytes were used in the same run of 
electrophoresis. Proteins were separated on a 16% Polyacrylamide gel, 
using tricine as a trailing ion instead of tris(hydroxymethyl) 
aminomethane-glycine [25]. Gels were blotted on polyvinylidene 
difluoride membranes, and immunologic detection of proteins was 
performed using biotinylated goat anti-rabbit immunoglobulin G, avidin-
conjugated alkaline phosphatase, 5-bromo-4-chloro-3-indolyl phosphate, 
and nitroblue tetrazolium. Both a polyclonal rabbit antiserum raised 
against highly purified SKALP/elafin from psoriatic scales and a rabbit 
antiserum against recombinant elafin were used. 
Microphotography 
Microphotographs were taken with a Leitz photomicroscope and a Zeiss 
Axiophot, Wetzlar and Oberkochen/Württemberg, Germany, respectively, 
using black-and-white negative film Agfapan APX 25 from Agfa-
Gevaert AG, Leverkusen, Germany. 
RESULTS 
Immunohistology 
In basal cell carcinoma, all tumor cells with a typical basaloid phenotype 
were negative with respect to SKALP/elafin expression. Cells of the 
granular layer in epidermis overlying the tumor were positive in some 
cases. The epidermis of distant normal skin did not show any 
SKALP/elafin expression at all (not shown). 
In squamous cell carcinoma, SKALP/elafin expression varied both 
between tumors and within the individual tumors. However, most tumors 
and tumor cell nests that had a clear squamous phenotype were strongly 
positive as shown in Figure 1. In all specimens basal cells were negative. 
SKALP/elafin expression was seen from the suprabasal cells upward, 
with the strongest staining in the cells just underneath the layer of the 
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cornified envelopes, namely, in the stratum granulosum and the most 
superficial layers of the stratum spinosum. 
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Figure 1. Immunohistology of squamous cell carcinoma, staining was performed with 
anti-SKALP/elafin antibody, (a) Cell nests with a clear squamous phenotype are strongly 
positive. Overlying epidermis is negative. Magnification: χ 125. (b) Detail. SKALP/elafin 
staining is most distinct in cells with a granular cell morphology. Magnification: x313. 
Figure 2. Immunohistology of 
actinic keratosis. Variation in 
intensity of SKALP/elafin 
staining and in the number of 
stained cell layers as well, was 
observed. Here SKALP/elafin 
staining is limited to one or two 
layers of granular cells, just 
beneath ridges of thickened 
stratum corneum. Magnification: 
xl25. 
In Bowen's disease we found that the tumor cells showed a weak 
cytoplasmic staining, which was less pronounced than in the well 
differentiated squamous cell carcinomas (not shown). 
All biopsies from actinic keratoses were positive, with a variation both 
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in intensity of SKALP/elafin expression and in the number of cell layers 
that were stained (two to eight layers, basal cells were negative; an 
example of an actinic keratosis with only one to two positive layers of 
keratinocytes is shown in Figure 2). 
Keratoacanthomas were strongly positive for SKALP/elafin as shown 
in Figure 3. 
Figure 3. Immunohistology of keratoacanthoma. (a) Strong SKALP/elafin staining is seen 
in multiple layers of well differentiated suprabasal cells. Magnification: xl25. (b) Detail. 
Note the polarized distribution of SKALP/elafin-staining pattern close to the upper cell 
membrane, in the direction of increasing differentiation, possibly because of cross-linking 
to the cornified envelope by transglutaminase. Magnification: x313. 
The staining pattern was comparable to that of the other tumors, i.e., the 
suprabasal layers were stained, and staining was most pronounced in the 
cell layer just below cornified envelope formation. 
Staining of the stratum corneum in all positive tumors was 
inconsistent, varying both in intensity and distribution pattern from 
strong to nearly absent, and from continuous to patchy. 
In situ hybridization 
Using cRNA probes, sections of a well differentiated squamous cell 
carcinoma, which showed high expression of SKALP/elafin using 
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immunohistochemistry, were studied for the presence of SKALP/elafin 
messenger RNA. In general, mRNA expression colocalized with 
expression of SKALP/elafin at the protein level as shown on serial 
sections (Figure 4). 
Figure 4. In situ hybridization and immunohistology on serial sections of a well 
differentiated squamous cell carcinoma. Using antisense cRNA probes, SKALP/elafin 
messenger RNA is shown (a), and immunostaining demonstrates presence of 
SKALP/elafin protein (b). Note that the expression at the mRNA level roughly coincides 
with the expression at the protein level; eg, see the region indicated by the arrows. 
Magnification: χ 100. 
Sense cRNA probes, used as controls, were completely negative. 
Functional measurements and Western blotting. 
Using a sensitive microassay [12,24], both squamous cell carcinoma 
and keratoacanthoma showed inhibitory activity against human leukocyte 
elastase, whereas basal cell carcinoma was negative. Squamous cell 
carcinoma contained an anti-elastase activity of 2.3 U/mg tissue, anti-
elastase activity of keratoacanthoma was 167 U/mg tissue, and in basal 
cell carcinoma no inhibitory activity was measured. Western blotting 
showed SKALP/elafin expression both in squamous cell carcinoma and 
in keratoacanthoma, but not in basal cell carcinoma (Figure 5). 
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Figure 5. Western blot of human skin tumor extracts stained with a polyclonal anti-
SKALP/elafin serum. In lane 5 distinct bands were stained in a squamous cell carcinoma 
extract. In lane 6, only a single band is seen in an extract from keratoacanthoma. Lane 7 
shows the absence of SKALP/elafin staining in a basal cell carcinoma extract. Partially 
purified SKALP/elafin of cultured keratinocytes, recombinant elafin, and psoriatic scale 
extract have been used as reference samples, and staining is shown in lanes I, 2, and 4, 
respectively. Molecular weight markers (kDa) are shown in lanes 3 and 8. 
Interestingly, there were clear differences in staining patterns between 
the tumors. Keratoacanthoma showed one clear band with an apparent 
molecular weight of 13.6 kd. In contrast, squamous cell carcinoma 
showed four different bands with apparent molecular weights of 15.7 kd, 
15.0 kd, 13.8 kd and 12.4 kd. Basal carcinoma was negative. 
SKALP/Elafin from cultured keratinocytes (apparent molecular weight 
about 16 kd), recombinant elafin (apparent approximate molecular 
weight 11 kd) and psoriatic scale extract were used as positive controls 
and as a reference range for the various forms of SKALP/elafin that are 
known to exist [12,13]. 
DISCUSSION 
In this study we have demonstrated that the recently discovered serine 
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proteinase inhibitor SKALP/elafin is differentially expressed in human 
epidermal tumors. On immunohistology, the cytoplasmatic staining was 
mostly limited to the upper differentiating layers of the tumors. Basal 
layers were completely negative, which is in accordance with previous 
findings in psoriatic epidermis and in a model for wound healing 
[26,27]. Basal cell carcinomas were negative as well. In situ 
hybridization of well differentiated squamous cell carcinoma showed 
presence of messenger RNA in the same regions where SKALP/elafin 
protein is demonstrated by immunostaining. 
Previous studies showed that SKALP/elafin exists in multiple forms 
[12-14]. In material from psoriatic patients a consistent pattern of two 
major bands emerges. As shown in Figure 5, in squamous cell carcinoma 
and keratoacanthoma different forms of SKALP/elafin are found. 
Because only a limited number of fresh tumors was available to us, it is 
not clear whether these patterns are specific for a type of tumor. The 
antisera used in this study were polyclonal rabbit antisera against 
recombinant elafin or SKALP/elafin purified from psoriatic scales. These 
sera yielded identical staining patterns on Western blots and in 
immunohistology. Both sera were raised against SKALP/elafin fragments 
that contained the anti-proteinase activity, which is located in the ex-
terminai half of the mature SKALP/elafin molecule. Because the 
different forms of SKALP/elafin are generated by various N-terminal 
deletions, all these cleavage products are recognized by these antisera. 
As can be seen in Figure 5, the apparent molecular weights of 
SKALP/elafin obtained on SDS-PAGE significantly deviate from the 
calculated molecular weights (as mentioned above). This is probably 
caused by the strong cationic nature of the molecule (isoelectric point = 
9.6) which causes a slower migration in this electrophoresis system. 
At present there are no conclusive data on the biological significance 
of SKALP/elafin in human skin. However, previous studies suggest that 
the expression of SKALP/elafin in vivo is linked to inflammatory 
processes. We have shown that SKALP/elafin-activity is found in 
epidermis from inflammatory skin diseases and that it is absent in 
normal skin and in non-inflammatory skin diseases [28]. Recently we 
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have found that SKALP/elafin is secreted in urine of psoriatic patients 
and that the levels found roughly correlate with the severity of the 
disease [29]. In addition we have found that SKALP/elafin can be 
induced in normal human skin as a result of standardized injury by tape 
stripping [12,27]. These findings show that SKALP/elafin is induced in 
human skin under inflammatory conditions, which suggests (but not 
proves) that SKALP/elafin could act as a negative feedback on the 
inflammatory response. Whether this would be at the level of 
interference with migration of polymorphonuclear cells/monocytes or as 
a protective mechanism against tissue damage remains to be investigated. 
Apart from this teleological interpretation, SKALP/elafin expression 
can also be regarded as part of the regenerative/hyperproliferative 
differentiation program of human epidermis as seen in psoriasis and 
wound healing. The normal differentiation program includes the 
expression of keratin 1 and 10, the absence of keratin 6 and 16 in the 
suprabasal layers, and expression of differentiation-related proteins (eg, 
filaggrin, involucrin, transglutaminase) exclusively in the stratum 
granulosum [30]. The differentiation program of the regenerative/ 
hyperproliferative type is characterized by the induction of keratin 6 and 
16, down-regulation of keratin 10, premature expression of 
differentiation-related proteins and, as we have shown, the induction of 
SKALP/elafin. Within the context of this differentiation program, 
SKALP/elafin could function as an inhibitor of proteinases from 
inflammatory cells or could, speculatively, be directed to keratinocyte-
derived proteinases to control other, hitherto unknown processes. 
Evidence that SKALP/elafin expression is coupled to the 
regenerative/hyperproliferative phenotype is further supported by the 
notion that cultured keratinocytes, which are also negative for keratins 
1/10 and positive for keratins 6/16, produce large amounts of 
SKALP/elafin [12,15]. 
In this study we demonstrate that SKALP/elafin expression is high in 
tumors with a clear squamous phenotype, and is absent in poorly 
differentiated squamous cell carcinomas and in basal cell carcinomas. 
Tumor cells display disturbed differentiation programs that are distinct 
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from the differentiation programs mentioned above. Speculatively, loss 
of expression of anti-proteinase activity could promote tumor cell 
migration, invasive growth, or induce detachment of tumor cells. This 
could be caused either by proteinase activity from the tumor cells or by 
proteinases derived from neighbouring cells (stroma, inflammatory cells). 
The finding in the present study that SKALP/elafin expression is low or 
absent in the tumors that are able to invade the dermal connective tissue 
is in line with this hypothesis. 
In general, little is known with respect to the role of other proteinases 
and proteinase inhibitors in normal human skin. It has been suggested 
that cathepsin D is involved in transglutaminase processing [31]. Both 
urokinase-type plasminogen activator and its inhibitor, plasminogen 
activator inhibitor were demonstrated in human epidermis [32-34], and 
are supposed to be involved in keratinocyte migration [35,36]. 
Expression levels of proteinases and proteinase inhibitors have been 
reported to correlate with tumor proliferation, tissue invasion and tissue 
destruction. The resulting tissue destruction would be caused by a local 
imbalance between proteinases and their inhibitors [7,37-42]. Recently 
the presence of urokinase-type plasminogen activator in squamous cell 
carcinoma and the absence in basal cell carcinoma was described, with 
the interesting finding that those squamous cell carcinomas that were 
lacking urokinase-type plasminogen activator were histologically well 
differentiated tumors [34,43]. 
Because not a single factor but cascades and combinations of different 
events is important in carcinogenesis, it is interesting to speculate on a 
possible role of SKALP/elafin in this process. SKALP/Elafin may 
interfere with elastolytic activity that tumor cells need to penetrate the 
dermal tissue either directly by inhibiting elastase [44,45] or indirectly 
through interference with an elastase-dependent pathway of plasminogen 
activation [46]. In addition, SKALP/elafin might inhibit unknown 
proteinases and interfere with proteolysis in an elastase-independent way. 
Therefore, within the spectrum of keratoacanthoma, actinic keratoses and 
squamous cell carcinomas with varying degrees of differentiation, a 
progressive loss of SKALP/elafin expression could facilitate invasive 
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growth. To date, a correlation between tumor aggressiveness and the 
expression of lytic enzymes such as heparanases, plasminogen activators, 
cathepsins, and metalloproteinases has been described (for review see 
references [7] and [47]). Furthermore, it has been shown that inhibitors 
of metalloproteinases or inhibitors of serineproteinases can block tumor 
cell invasion [1,48,49]. Most likely a panel of different enzymes and 
inhibitors will determine the migrational behavior of tumor cells, and 
SKALP/elafin might be part of this panel. 
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ABSTRACT 
Skin-derived antileukoproteinase (SKALP), also known as elafin, is a 
strong and specific inhibitor of elastase and proteinase 3. SKALP is not 
present in normal epidermis, but is expressed by epidermal keratinocytes 
under hyperproliferative conditions such as psoriasis, wound healing, and 
in cell culture. In human epidermal tumours, SKALP is differentially 
expressed and restricted to tumours with distinct squamous 
differentiation. We have studied the presence of both SKALP and one 
of its known target enzymes, leukocyte elastase, in 41 squamous cell 
carcinomas of the skin. SKALP expression correlated with the degree of 
differentiation: strong expression was seen in well-differentiated cells 
and expression was absent in poorly differentiated tumour cells. Most of 
the squamous cell carcinomas showed elastase-positive cells in the 
tumour stroma and also within the tumour cell nests. SKALP may 
interfere with the proteolytic activity of infiltrating inflammatory cells or 
with hitherto unknown proteinases from the tumour cells. We 
hypothesize that in squamous cell carcinomas progressive loss of 
SKALP expression could facilitate tumour spread. 
INTRODUCTION 
Elastase, a major proteinase in humans, is predominantly present in 
neutrophils, although elastolytic activity has also been reported in 
monocytes, macrophages, smooth muscle cells, fibroblasts, and blood 
platelets [1]. Neutrophils contain 3 pg of elastase per cell, which results 
in a daily turnover of at least 250 mg elastase [2]. Human leukocyte 
elastase (EC 3.4.21.37) has a broad range of extracellular matrix 
substrates, such as elastin, proteoglycans, collagen, and fibronectin [1]. A 
significant role has been suggested for elastase in the pathophysiology of 
several diseases including lung emphysema, arthritis, nephritis, bullous 
dermatoses, sepsis, and the allergic late-phase asthmatic response [1,3]. 
Elastase can be very destructive if not controlled and the presence of 
enzyme inhibitors is one of the physiological mechanisms which protect 
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tissue against unwanted proteolysis [4]. Derangement of homeostasis 
between enzyme and inhibitor leading to tissue damage was first 
recognized by Laurell and Eriksson and assimilated in the concept of 
their protease-antiprotease imbalance hypothesis in emphysema [5]. This 
hypothesis is now generally accepted not only in emphysema, but also in 
cancer. Tissue destruction preceding invasion and metastasis is 
considered to be the result of a local imbalance in favour of the 
proteinase, and many proteinases and their inhibitors are associated with 
features of malignant behaviour [6,7]. 
Skin-derived antileukoproteinase (SKALP) is a low molecular weight, 
cationic, heat- and pH-stable serine proteinase inhibitor that specifically 
inhibits human leukocyte elastase and proteinase 3 [8-10]. Cloning and 
sequencing of the cDNA proved SKALP to be identical to elafin and 
elastase-specific inhibitor (ESI), as described by others [11-13]. SKALP 
is locally produced by epidermal keratinocytes under hyperproliferative 
conditions such as psoriasis, wound healing and keratinocyte culture 
[8,9,14]. Furthermore, SKALP is differentially expressed in human 
epidermal tumours [15]. 
The aims of this study were two-fold. First, we wished to determine 
whether SKALP expression is related to the degree of differentiation of 
tumour cells in squamous cell carcinoma (SCC). Second, because of the 
specific inhibiting properties of SKALP against human leukocyte 
elastase, we wished to study the presence of elastase-positive cells in 
SCC. 
MATERIALS AND METHODS 
Chemicals 
Goat-anti-rabbit IgG biotin conjugate, avidin-alkaline phosphatase, and 
the chromogenic substrates 5-bromo-4-chloro-3-indolyl phosphate, 
nitroblue tetrazolium, and aminoethyl carbazole were obtained from 
Sigma Chemicals, St. Louis, MO, U.S.A. Swine-anti-rabbit Ig conjugated 
with horseradish peroxidase (SWARPO) was obtained from Dakopatts, 
Glostrup, Denmark. Goat-anti-mouse Ig conjugated with alkaline 
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phosphatase (GAMAP) was obtained from TAGO, Burlingame, CA, 
U.S.A. Recombinant SKALP/elafin was a kind gift from Dr. Norman 
Russell, ICI Pharmaceuticals, U.K. 
Tumours 
Archival biopsy material used for routine histology was selected. The 
specimens had been fixed in buffered 4 per cent formalin for at least 24 
h and had been embedded in paraffin. SCCs of various degrees of 
differentiation were selected, and 17 well-differentiated SCCs, 17 
moderately differentiated, and seven poorly differentiated SCCs were 
used. Serial sections were employed for histopathological grading and 
for immunohistology. 
Well-differentiated tumours were characterized by a high degree of 
differentiation, with polygonal squamous cells having abundant 
cytoplasm, well-developed intercellular bridges, and a large number of 
horn pearls, some with nearly complete central keratinization. Poorly 
differentiated SCCs showed tumour fields with completely atypical or 
anaplastic cells, with nuclear pleomorphism and hyperchromasia. 
Keratinization was almost completely absent and the tumour cells were 
devoid of clear intercellular bridges. Atypical forms of mitosis were 
seen. Tumours that showed some focal differentiation in addition of 
these features were classified as poorly differentiated. Those tumours 
that did not fulfil the criteria for the well- or poorly differentiated groups 
were classified as moderately differentiated SCCs. 
Antibodies 
A polyclonal rabbit antiserum against recombinant SKALP/elafin was 
raised as described before [9]. Control serum (preimmune serum) was 
drawn before the immunization procedure. The specificity of the 
antiserum was validated on Western blots and in functional assays as 
previously described [9]. 
A monoclonal mouse antibody to human neutrophil elastase was 
obtained from Dakopatts, Glostrup, Denmark. 
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Immunohistochemical double staining for SKALP and elastase 
Before staining, sections were deparaffinized and preincubated with 10 
per cent normal swine serum and 10 per cent normal goat serum in 
phosphate-buffered saline (PBS) for 15 min. This was followed by an 
incubation for 60 min with the polyclonal anti-SKALP serum and the 
monoclonal anti-elastase (at a dilution of 1:500 and 1:250, respectively) 
in PBS with 1 per cent bovine serum albumine (BSA). After washing in 
PBS, sections were incubated for 30 min with SWARPO and GAMAP 
(at a dilution of 1:50 and 1:20, respectively) in PBS with 1 per cent BSA 
and 5 per cent human AB serum. Subsequently, sections were washed in 
100 mM NaCL, 5 mM MgCl2 and 10 mM Tris in distilled water (AP 
buffer) and developed using a mixture of 0.33 per cent 5-bromo-4-
chloro-3-indolyl-phosphate-toluidine and 0.66 per cent nitro-blue-
tetrazolium in AP buffer. Thereafter, sections were washed in PBS and 
sodium acetate buffer and developed using aminoethyl carbazole as 
chromogenic substrate. Because of the purple precipitate due to the 
alkaline phosphatase in the double staining method, no haematoxylin 
counterstaining was performed. Finally, sections were washed in distilled 
water, dried, and embedded in glycerol-gelatin solution. In total, 36 of 
the 41 tumours were double-stained with antibodies against SKALP and 
elastase; the remaining five tumours were only stained with anti-SKALP 
antiserum. Haematoxylin and eosin (H&E) staining was carried out on 
all tumours. 
Control staining was performed as indicated above, with the omission 
of monoclonal anti-elastase and the replacement of polyclonal rabbit 
anti-SKALP/elafin serum with preimmune serum of the same animal. 
RESULTS 
SKALP expression 
Well-differentiated SCCs 
The cells of all but one tumour showed SKALP expression, although the 
number of stained cells and the intensity of the staining varied. In 
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general, the staining intensity was most distinct in tumour fields with 
mature squamous epithelial cells that showed only slight atypia. Where 
horn pearls were present, SKALP expression was maximal in the region 
adjoining the keratinized center (Figs la and lb). 
Figure 1. Serial sections of a well-differentiated SCC. (a). H&E staining. Tumour cell 
nests show a high degree of differentiation with nearly complete keratinization of the 
center. In the tumour cell nests PMN are visible (arrows), (b). Immunostaining with 
antibody against SKALP. Intensity of staining is maximal around the keratinized center. 
Note that SKALP staining is polarized and is present in the cytoplasm just beneath the 
cell membrane (arrows), in the direction of increasing differentiation, resulting in a rose-
like appearance of the tumour cell nest. (c). Double staining with antibodies against 
SKALP and elastase. Elastase-positive cells are seen around and within the tumour cell 
nests (arrows), in close apposition to SKALP-positive cells (arrow heads). 
Moderately differentiated SCCs 
All but one tumour showed SKALP expression, which was maximal near 
areas of keratinization. Four tumours showed both positively and 
negatively stained tumour fields. 
Poorly-differentiated SCCs 
All the tumours containing fields with undifferentiated cells were 
negative for SKALP (Fig. 2). Some of the poorly-differentiated tumours 
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also showed cells with a higher degree of differentiation, resulting in 
SKALP-positive and SKALP-negative areas within the same tumour. 
Figure 2. Serial sections of a poorly-differentiated SCC. (a). H&E staining. Atypical and 
anaplastic cells with basophilic cytoplasm are seen. Cells vary in shape, size and number 
of nuclei, some show abnormal mitotic figures, (b). Staining with anti-SKALP serum. No 
positive cells could be detected in this tumour area with poorly-differentiated cells. 
Four of the seven tumours that were graded as poorly differentiated SCC 
showed SKALP expression in tumour areas with distinct squamous 
differentiation (Fig. 3). 
In all grades of SCC, SKALP staining in positive tumour cells was 
cytoplasmatic, with a predominance towards the side of the cell in the 
direction of keratinization (Fig. 1), as has been previously reported in 
other types of tumours, in psoriasis and in wound healing. 
Elastase-positive cells 
In SCC, mixed infiltrates of mononuclear cells and polymorphonuclear 
cells (PMN) are often seen. In 32 of the 36 tumours that were double 
stained, elastase-positive cells could be demonstrated in all subgroups. 
The number of positive cells varied considerably between the tumours 
and within each tumour. 
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Figure 3. Serial sections of a poorly-differentiated SCC. (a). H&E staining. Tumour 
fields of basaloid cells are visible (arrows) together with tumour areas that show distinct 
squamous differentiation and keratinization (arrow heads), (b). Double staining with 
antibodies against SKALP and elastase. SKALP-positive cells are seen in the tumour 
fields that show keratinization. Elastase-positive cells (visible as the dark condensed 
spots) are seen around and within tumour fields (arrows), some in close apposition with 
SKALP-positive cells (visible as the more diffusely-stained cells, arrow heads). Note that 
basaloid cells are completely negative. 
In 19 tumours, the elastase-positive cells were seen between and around 
SKALP-positive cells, being in close apposition (see Figs lc and 3b). In 
Fig. 4, destruction of tumour fields by infiltrating cells is seen. The 
majority of infiltrating cells can be identified as PMN on H&E-stained 
sections (Fig. 4a). Double staining with anti-SKALP and anti-elastase 
antibodies shows that elastase-positive cells penetrate the tumour cell 
nests and appear to be in contact with the tumour cells (Fig. 4b). Groups 
of tumour cells appear isolated and individual cells are detached from 
the tumour mass. The infiltrating PMN are seen in both well-
differentiated and poorly differentiated parts of the tumour (Fig. 5). 
Bearing in mind the functional relationship between SKALP and 
elastase, an interaction between SKALP and human leukocyte elastase in 
tumour cell nests is suggested. 
SKALP and elastase in squamous cell carcinoma 155 
Figure 4. Serial sections of a poorly-differentiated SCC. (a). H&E staining. PMN are 
seen in close apposition to detached and lysed tumour cells in the center of the tumour 
nests. Note the great number of infiltrating PMN (arrows), (b). Double staining with 
antibodies against SKALP and elastase. Elastase-positive cells (visible as dark condensed 
spots) are seen adjacent and attached to isolated (groups of) tumour cells. SKALP 
presence is scarce, and restricted to one or two suprabasal, squamous cell layers at the 
edge of the tumour nest (arrow head). 
In two of the 36 sections that were double stained, elastase-positive cells 
were present without any SKALP expression (6 per cent) and SKALP 
expression without the presence of elastase-positive cells was seen in 
three of the 36 doublestained sections (8 per cent). 
DISCUSSION 
In this study of SCC in human skin, we have demonstrated that the 
presence of the serine proteinase inhibitor SKALP correlates with the 
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degree of differentiation of the tumour cells. SKALP is exclusively 
expressed by well-differentiated cells in tumour areas that show distinct 
squamous differentiation. 
Figure 5. Serial sections of a poorly-differentiated SCC. (a). H&E staining. Tumour 
fields of basaloid cells are visible, and only scarce keratinization can be seen (arrow), 
(b). Immunostaining with antibody against SKALP. SKALP-positive cells are restricted 
to the well-differentiated part of the tumour (arrows), (c). Double staining with antibodies 
against SKALP and elastase. An enormous number of elastase-positive cells (visible as 
the dark condensed spots) can be seen in the tumour. Note that ΡΜΝ are present in all 
parts of the tumour, irrespective of the differentiation grade of the cells. 
In general, different degrees of malignancy may be present in different 
fields of the same tumour [16] and grading of the tumour is carried out 
according to the least differentiated area [17]. A relationship between 
histological differentiation and metastasis has been described, with 
poorly differentiated SCC of skin having a higher metastatic rate [18]. 
When SKALP expression was seen, irrespective of the degree of 
differentiation of the tumour, it was restricted to the well-differentiated 
cells. Cells positive for elastase, which is one of the target proteinases of 
SKALP, were found in 89 per cent of the tumours. 
Inflammatory cells often accumulate at sites of tumour invasion, but 
reports about their relationship with tumour cells and tumour behaviour 
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are conflicting. Elastase-positive granulocytes were identified close to 
tumour cells and stroma of breast cancer tissue, where they might have a 
cytotoxic effect on the tumour cells and could play a protective role 
against tumour invasion and metastatic spread [19]. In contrast, an 
association between infiltrating cells and an increase of invasive growth 
of the tumour has also been described. In cutaneous tumours, infiltration 
of PMN that contain type IV collagenase, and extracellular deposition of 
the enzyme in the basement membrane zone resulted in more aggressive 
tumour behaviour [20]. Mast cells at sites of tumour invasion contributed 
to the connective tissue breakdown commonly associated with tumour 
invasiveness and metastatic spread [6]. PMN-induced detachment of 
cultured epidermal carcinoma cells from the substratum has been 
interpreted as a contribution of PMN to tumour cell killing, although the 
majority of the detached cells were alive [21]. In contrast, Sloane et al. 
suggested that the release of cathepsin B, which degrades pericellular 
protein, may contribute to detachment of the cells from the primary 
tumour and hence to metastasis [22]. 
The expression levels of proteinases have been implicated in tumour 
proliferation, tissue invasion and metastasis [6,7]. Because elastase is one 
of the target enzymes of the proteinase inhibitor SKALP, its expression 
in tumours was of particular interest to us. In cell culture, tumour cells 
of rat, mice, and humans have been proven to produce elastase or 
elastase activity [23-26]. Elastase might be used as an indicator of 
metastatic ability of Dunning R-3327 rat prostatic adenocarcinoma [27]; 
pharmacological interference reduces elastase activity and inhibits the 
metastatic spread of tumours in the lungs of mice [28]. Elastase may 
also facilitate tumour invasion in an indirect way, by activating 
plasminogen [29]. Finally, enhanced elastin degradation in patients with 
lung cancer [30], and breast cancer [31] has been reported, the elastin 
degradation being possibly due to proteolysis at the site of the tumour, 
mediated by elastase-like enzymes from tumour cells or infiltrating cells. 
The balance between proteinases and proteinase inhibitors is 
considered to be of major importance in tumour invasion and metastasis, 
and many proteinase inhibitors are known to counteract the process of 
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tumour spread [6,7,32]. In vivo, a local increase of antiprotease and 
neutrophil elastase-a,-proteinase inhibitor complexes in lung cancer has 
been reported [33]. SKALP is known to be produced by tumour cells, 
both in vivo and in vitro [15,34]. In normal skin, SKALP is not 
expressed; under hyperproliferative conditions, however, such as 
psoriasis, wound healing, and tumours, SKALP is found in suprabasal 
keratinocytes. In other words, SKALP is part of the 
regenerative/hyperproliferative differentiation programme, which also 
includes the expression of keratin 6 and 16 [35]. Teleologically, 
expression of SKALP could be interpreted as a mechanism to prevent 
the migration and invasive growth of (normal) keratinocytes under 
hyperproliferative conditions and during disturbance of the normal tissue 
integrity. According to this view, SCC cells that express SKALP would 
still be able to counteract invasive growth or detachment of tumour cells, 
by inactivation of elastase activity from infiltrating cells, stroma, or the 
tumour cells themselves. It remains to be investigated whether 
infiltrating elastase-positive cells promote or suppress tumour cell 
invasion and spread. In Fig. 4, a beneficial role of PMN is suggested 
because lysis of cells adjacent to PMN is seen. This putative cytotoxic 
effect of elastase-positive cells is in accordance with the findings of 
Schmitt et al. and Katayama et al. [19,21], but in contrast with effects of 
infiltrating PMN as described by Karelina et al. [20]. If elastase has a 
beneficial role with respect to tumour cell killing, then why is there a 
potent inhibitor simultaneously present? It is very unlikely that a 
proteinase inhibitor enhances tumour spread, since until now only anti-
tumour effects have been described [6,7,32]. Speculatively, a 
physiological function of SKALP may be to control excessive elastase 
activity and to prevent damage to normal tissue. Moreover, SKALP in 
association with elastase, or fragments of SKALP after interaction with 
elastase, may be chemotactic for PMN, as has been described for a l -
proteinase inhibitor [36]. Another possibility is that SKALP counteracts 
other proteinases present in tumour cells. 
We would hypothesize that SKALP is one of the many factors that 
contribute to the maintenance of tissue homeostasis and the control of 
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tumour spread. Loss of SKALP expression during tumour progression 
from the well-differentiated SCCs to the more aggressive poorly-
differentiated types, as observed in our study, could contribute to the 
altered migrational behaviour of the tumour. However, SKALP 
expression in itself may be insufficient, since cell-induced proteolysis 
has been described even in the presence of inhibitors [37,38]. Several 
mechanisms of inactivation of proteinase inhibitors have been reported, 
including oxidation by reactive oxygen metabolites and enzymatic 
degradation [39,40]. Cell-surface elastases may provide local proteolytic 
activity that is difficult to counteract [23,26]. For inhibition of its target 
enzyme, the proteinase inhibitor should be able to reach the active site of 
the proteolytic enzyme, since binding of the degrading enzyme to its 
substrate appears to be a very effective way of escaping inhibition [41]. 
Limited extracellular proteolysis at sites of contact may result in 
directional cell migration [42,43], and a balanced action of both 
proteinases and proteinase inhibitors might be involved in tumour cell 
invasion. 
In conclusion, we have found a correlation between expression of a 
proteinase inhibitor and the degree of differentiation of tumour cells. 
Although this finding does not necessarily imply a causal relationship, it 
fits within a conceptual framework of tumour invasion and metastasis. 
At present, it is not clear whether SKALP only inhibits elastase released 
by infiltrating inflammatory cells or whether it also inhibits other still 
unidentified proteinases produced by tumour cells or stroma. The close 
apposition of SKALP and human leukocyte elastase in more than 50 per 
cent of the SCCs studied suggests a possible in vivo interference with the 
process of tumour spread. We do not know whether the lack of an 
absolute correlation in well-differentiated and moderately differentiated 
SCCs arises from the dynamics of PMN infiltration or from the ability 
of SKALP to counteract PMN migration. Future studies will be directed 
at elucidating the role of SKALP and its target proteinases in functional 
assays and in experimental models of tumour cell migration. 
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SUMMARY, DISCUSSION AND FUTURE PROSPECTS 
The aim of this thesis as defined in the introduction was to characterize 
the SKALP molecule in greater detail, and to elucidate the 
(patho)physiological role of this proteinase inhibitor. Although after four 
years of research many questions with respect to the exact biological 
function of SKALP still need to be answered, the present thesis provides 
new data on its molecular aspects and relevance to the pathogenesis of 
various skin disorders. 
In chapter 2 SKALP is characterized at the molecular level. It could be 
shown that SKALP is encoded for as a 117 amino acids protein, with a 
calculated molecular weight of 12.3 kDa, and consists of two functional 
domains, and a signal peptide of 22 amino acids. Cleavage of the signal 
peptide results in the 95 amino acids molecule, comprising the first 
domain with transglutaminase substrate motifs and a second domain with 
proteinase-inhibiting properties. Isolation of SKALP from cultured 
keratinocytes predominantly yielded this two-domain form, while in 
psoriatic scales the main form is the 6 kDa 57 amino acids form. The 
signal peptide points at the rough endoplasmic reticulum as the site for 
SKALP mRNA translation. In the near future a survey on subcellular 
SKALP localization will be performed. In the first domain, 
transglutaminase substrate motifs are found, which may point at another 
yet unknown function of SKALP. It was shown that SKALP can act as a 
transglutaminase substrate, although the exact cross-linking sites remain 
to be demonstrated. Both at the protein level [1,2], and at the mRNA 
level [3,4] SKALP and transglutaminase type 1 are present in the 
suprabasal compartment of the psoriatic epidermis. The co-expression of 
SKALP and transglutaminase in the tissue suggests but does not prove a 
functional interaction. The second domain with the proteinase-inhibiting 
property is not completely needed to inhibit human leukocyte elastase. 
The 9.9 kDa form (both the first domain with the transglutaminase 
substrate motifs and the second proteinase-inhibiting domain), the 6 kDa 
form (only the proteinase-inhibiting domain) and the 2.5 kDa form 
(fragment of the proteinase-inhibiting domain) all are functionally active 
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with respect to elastase inhibition. 
In chapter 3 in vivo and in vitro studies on expression and induction 
are reported. Although data conflict [5-8], we are convinced that hardly 
any anti-elastase activity is present in normal skin. In vivo, a substantial 
induction of SKALP expression can be seen in hyperproliferative 
conditions such as inflammatory skin diseases, and wound healing. The 
time course of expression with a rapid onset of SKALP production by 
keratinocytes makes SKALP a locally produced 'acute phase reactant' 
[7,9]. In vitro, SKALP can be induced in different cell culture systems, 
provided that the media used contain serum factors. The cultured 
keratinocytes mainly produced SKALP in the 9.9 kDa molecule and 
other molecules of relatively high molecular mass, whereas low 
molecular forms of 6 kDa and smaller predominate in tape-stripped or 
psoriatic skin. On Western blots forms with a molecular mass between 
9.9 and 6 kDa are also seen. Heterogeneity at the N-terminus probably 
resulting from proteolysis has been described for the 6 kDa form of 
SKALP [10]. In the different culture systems producing a multilayered 
epidermis, SKALP expression was restricted to the stratum granulosum 
and the outer layers of the stratum spinosum, in accordance with 
previous findings in psoriatic lesionai or tape-stripped skin [11]. 
Different techniques yielded partly conflicting results regarding 
expression levels of SKALP in relation to grade of differentiation of the 
cultured keratinocytes, for which we do not have an explanation yet. The 
fact that SKALP is expressed in keratinocyte culture suggests that PMN 
presence is not required for induction of SKALP synthesis. Of course, 
SKALP production by keratinocytes and elastase release by PMN might 
be triggered by the same stimulus. Recently SKALP was reported to be 
induced in lung cell lines by the cytokines interleukin-1 beta (IL1-B) and 
tumor necrosis factor (TNF), and by the proteinases human neutrophil 
elastase and cathepsin G [9]. The experiments on regulation of SKALP 
expression in cultured keratinocytes will be extented in the near future. 
In chapters 4 and 5, immunohistochemical localization studies are 
described. In psoriatic lesion, the expression of SKALP occurs 
exclusively in the upper layers of spinous and granular cells. Normal 
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skin, uninvolved psoriatic skin and basal cells in the psoriatic lesion did 
not show SKALP production. The presence of SKALP in serum and 
urine of psoriatic patients (chapters 6 and 7) shows that it must pass the 
basement membrane and reaches the dermal vessels, but on histology no 
SKALP presence can be observed in the dermis, probably due to the 
detection level. This might be due to the wash-out of extracellular 
SKALP during staining procedures. Another explanation for this 
discrepancy might be that SKALP in serum and urine is not skin-
derived, but is the result of production elsewhere. As can be read in 
chapter 4, in some normal human tissues SKALP expression was 
observed. SKALP is expessed in normal tongue, gingiva, pharynx, tonsil, 
epiglottis, vocal fold, esophagus, vagina, uterine cervix, and the 
infundibulum of the hair follicle, which are all tissues that are in close 
relation with the outer world and are constantly exposed to inflammatory 
stimuli. When SKALP was expressed, inflammatory cells (PMN in 
particular) could often be observed histologically. Speculatively, SKALP 
might be expressed to limit proteolytic activity of PMN, thus guarding 
tissue integrity. In normal brain, cornea, larynx, lung, bronchus, 
duodenum, colon, liver, kidney, urethra, and skin of various locations no 
expression could be demonstrated. Histological findings were partly 
confirmed by Northern blot analysis. Findings in normal tissue suggest 
that the name SKALP is an unfortunate choice, since skin-derived only 
refers to the origin of SKALP in inflammatory skin disorders. SKALP is 
locally produced in response to mediators in early inflammation, and can 
be regarded as a true local 'acute phase reactant'. The local production 
in several tissues described in chapter 4 may explain SKALP 
concentrations in serum of normal controls (as compared to psoriatics) 
that are reported in chapter 7. 
In the chapters 6 and 7, the application of SKALP as a tool for 
monitoring disease activity is described. In chapter 6 not only the 
presence of SKALP in urine of psoriatics has been demonstrated, but 
also a correlation with the severity of the disease. The most severe cases 
of psoriasis (erythroderma and pustular psoriasis) showed the highest 
urinary SKALP levels. Interestingly, besides free elastase, complexes of 
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SKALP with its target proteinase could be detected using a functional 
assay, which points at an in vivo interaction. However, initially we were 
not able to measure SKALP using a functional assay in the blood, which 
is the linking compartment between epidermis and urine, due to 
interference with other proteinase inhibitors in the circulation. Therefore 
an ELISA was established and used for measuring SKALP in serum and 
urine, as has been described in chapter 7. SKALP levels of serum rather 
than levels in urine correlated with the disease activity as represented by 
the PASI score. SKALP levels did not correlate with sex or age, and a 
circadian rhythm was not observed. It would be favorable if changes in 
SKALP level preceded clinical course, because then therapy could be 
started in advance. To study this, a daily measurement during a 
symptom-free period is indicated, and will be done in the near future. 
For many years, the balance between proteinase and inhibitor has been 
thought to play a role in tissue destruction. The fact that leukocytes 
contain proteolytic enzymes which can be inhibited by normal serum 
was already described in 1905 by Opie [12]. In 1921 the same author 
reported that at the site of an inflammatory reaction anti-enzyme of the 
blood (antileukoprotease) serves to limit the activity of the leukocyte 
enzyme released, thus preventing extracellular proteolysis [13]. However, 
in 1964 Laurell and Eriksson were the first to link emphysema and ctl-
PI deficiency [14], and Dubertret discovered that in psoriasis a 
disbalance between proteolytic and antiproteolytic activity in favor of the 
former was responsible for tissue damage [15]. Proteinases causing tissue 
damage in several bullous diseases have been described by Takamori et 
al. [16]. Interestingly, several proteinase inhibitors have been described 
to be beneficial as they inhibit target enzymes in blistering diseases. In 
skin organ culture, plasminogen activator inhibitor 2 (PAI-2) was able to 
prevent acantholytic changes induced by pemphigus IgG [17]. In organ 
culture of normal human skin, the synthetic serine proteinase inhibitor 
camostat mesylate proved to inhibit blistering induced by dystrophic 
epidermolysis bullosa. Therapeutical use by topical application in 
patients with epidermolysis bullosa seemed promising [18]. 
Unfortunately, contact dermatitis was reported as a side-effect. Another 
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study reported successful treatment of atopic dermatitis with ccl-PI [19]. 
Therefore, therapy based upon the use of proteinase inhibitors in 
(blistering) inflammatory skin diseases might be developed, and SKALP 
might be a candidate for therapeutical use. 
In chapters 8 and 9, studies on tumor biology are reported. Since 
proteinases and their inhibitors play a role in tumor proliferation, 
invasion and metastasis [20-24], SKALP expression was studied in a 
number of epidermal tumors. Interestingly, SKALP appeared to be 
differentially expressed. The study described in chapter 8 proved SKALP 
to be present in squamous cell carcinoma, in Bowen's disease, in actinic 
keratosis, and in keratoacanthoma, but not in basal cell carcinoma. The 
absence of SKALP from basal cell carcinoma is in accordance with 
histological findings in psoriasis (chapter 5) and wound healing where 
SKALP is absent from basal cells [11]. The difference in expression in 
epidermal tumors suggests that SKALP can be used as a tumor marker. 
The expression of SKALP in squamous cell carcinoma appeared to be 
related to the grade of differentiation of the tumor. This was studied in a 
large number of squamous cell carcinomas, as is described in chapter 9. 
This survey showed a clear relation between SKALP expression and 
degree of differentiation of squamous cell carcinoma, SKALP being 
exclusively expressed in nests of well-differentiated tumor cells. Because 
of the heterogeneity of squamous cell carcinoma, some poorly 
differentiated squamous cell carcinoma did show SKALP expression, but 
in well-differentiated cells only. Elastase-positive cells were seen in all 
types of squamous cell carcinoma. A disadvantage of histological studies 
is the fact that they yield a static rather than a dynamic picture. The 
observation of SKALP in close proximity to elastase-positive cells is 
difficult to interpret with respect to in vivo interaction between SKALP 
and PMN. Is it beneficial for the patient because tumor cell detachment 
by PMN [25], possibly enhancing metastasis, is inhibited by SKALP? Or 
is it detrimental because PMN might be cytotoxic to tumor cells as has 
been described for macrophages [26]? Yet another option is that SKALP 
interferes with PMN migration, resulting in a prolonged presence of 
PMN in the tumor fields, thus enabling PMN to fulfill its anti-tumor 
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function better. Studies on effects of implantation of SKALP-expressing 
and SKALP-negative tumors in immunodeficient mice may be used to 
elucidate SKALP function in tumor biology. Also SKALP-deficient mice 
(knock-out for the SKALP gene) might contribute to a better 
understanding of SKALP action in skin cancer. In addition, effects of 
deletion or mutation of the SKALP gene may provide insight into the 
physiological function of SKALP. These studies are scheduled for the 
near future. 
The observations described in this thesis have answered some of the 
questions raised at the start of the project. The exact biological function 
of SKALP is not known, although inhibition of PMN-derived proteinases 
suggests a role in the control of inflammation. However, the fact that 
SKALP can act as a substrate for transglutaminase is not to be ignored, 
and its biological relevance needs to be clarified yet. Clinically it may be 
used for monitoring severe psoriasis by measuring serum levels. 
Moreover it may, owing to its differential expression in human 
epidermal tumors, be used as a tumor marker. Local therapeutical use of 
SKALP as a treatment for downregulation of inflammation in some 
inflammatory skin diseases might be possible. 
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SAMENVATTING 
Ontsteking is de aspecifieke reactie van het lichaam om na een 
schadelijke prikkel weer tot herstel en evenwicht (homeostase) te komen. 
Bij dit ontstekingsproces zijn verschillende ontstekingsmediatoren 
betrokken, o.a. proteolytische (eiwitafbrekende) enzymen of proteïnasen, 
die zelf ook aanleiding kunnen geven tot weefselschade. Om zich te 
beschermen maakt het lichaam remmers tegen deze proteolytische 
enzymen, de zogenaamde anti-proteïnasen. SKALP (skin-derived 
antileukoproteinase) is een proteinase remmer, die recentelijk door onze 
afdeling in de huid ontdekt werd. 
Doel van het project was het nader karakteriseren van het SKALP 
molekuul, en het verruimen van het inzicht in de (patho)fysiologische rol 
van deze proteinase remmer. Hoewel na 4 jaar nog niet alle van de in de 
introductie gestelde vragen beantwoord zijn, biedt dit proefschrift nieuwe 
gegevens wat betreft SKALP op molekulair niveau en wat betreft de 
betekenis van SKALP in de Pathogenese van verschillende 
huidaandoeningen. 
In hoofdstuk 2 wordt de karakterisering van SKALP op molekulair 
niveau beschreven. Het SKALP gen codeert voor een eiwit van 117 
aminozuren, met een molekuul gewicht van 12,3 kDa en dat bestaat uit 2 
functionele domeinen en een signaalpeptide van 22 aminozuren, dat 
duidt op translatie in het ruw endoplasmatisch reticulum. Na afsplitsing 
van het signaalpeptide resteert een molekuul van 95 aminozuren 
bestaande uit een eerste deel met transglutaminase substraat motieven en 
een tweede deel met proteinase remmende eigenschappen. Isolatie uit 
gekweekte cellen levert voornamelijk het uit beide delen bestaande 
SKALP molekuul op, terwijl uit psoriatische huidschilfers vooral het 
tweede deel van 57 aminozuren verkregen wordt. De transglutaminase 
substraat motieven gelegen op het eerste deel kunnen duiden op een nog 
onbekende fuctie van SKALP. Aangetoond is, dat SKALP door 
transglutaminase als substraat 'gecrosslinked' kan worden, hoewel 
precieze plaats(en) waar transglutaminase aangrijpt nog niet bekend zijn. 
Dat in psoriasis transglutaminase en SKALP, zowel op eiwit niveau als 
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op het niveau van het messenger RNA, zich qua lokalisatie in hetzelfde 
(suprabasale) deel van de epidermis bevinden, duidt op een functionele 
interactie. Zowel het uit 2 delen bestaande SKALP molekuul met een 
gewicht van 9,9 kDa als het slechts uit het tweede deel bestaande deel 
met een moleculair gewicht van 6,0 kDa, als het kleinere fragment van 
dit laatste deel met een moleculair gewicht van 2,5 kDa zijn alle 
functioneel actief in het remmen van elastase. 
In hoofdstuk 3 zijn in vivo en in vitro studies t.a.v. expressie en 
inductie van SKALP beschreven. Terwijl normaal vrijwel geen anti-
elastase activiteit in de huid aanwezig is, wordt in vivo onder 
hyperproliferatieve condities, zoals huidziekten gepaard met ontsteking, 
en tijdens het herstel van beschadigde huid, SKALP geproduceerd. 
Omdat deze SKALP productie door keratinocyten snel op gang komt in 
reactie op een inflammatoire prikkel, kan SKALP met recht gezien 
worden als een 'acute fase eiwit'. In vitro kan, mits serum aan het 
kweekmedium is toegevoegd, SKALP door keratinocyten geproduceerd 
worden, en dan vooral de uit 2 delen bestaande grotere vorm van 
SKALP. In de meerlagige epidermis, zowel in vivo als in vitro, is 
SKALP vooral aanwezig in de meest gedifferentieerde (uitgerijpte) 
suprabasale en granulaire cellagen. SKALP expressie lijkt gerelateerd te 
zijn aan een verregaande differentiatiegraad, al zijn de verkregen 
resultaten niet geheel eenduidig. Waardoor de SKALP productie precies 
in gang gezet wordt, is nog niet duidelijk. Ontstekingsmediatoren maar 
ook proteolytische enzymen afkomstig van de polymorfkemige 
granulocyten (PMN) kunnen hiervoor verantwoordelijk zijn. 
In de hoofdstukken 4 en 5 zijn de immunohistologische lokalisatie 
studies beschreven. Bij de psoriatische lesie blijkt SKALP in de 
bovenste, meest gedifferentieerde cellagen voor te komen. In normale 
huid en in basale cellen van de psoriatische plekken is geen SKALP 
zichtbaar. SKALP expressie blijkt niet beperkt tot de beschadigde of 
ontstoken huid, het komt ook voor in andere 'normale' weefsels. In de 
tong, het tandvlees, de achterwand van de keelholte, de amandelen, het 
strotteklepje, de ware stemband, de slokdarm, de vagina, de 
baarmoederhals, en een deel van het haarzakje komt SKALP voor. 
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Interessant is dat in deze weefsels, die alle in direct contact met de 
buitenwereld staan, een bepaalde mate van ontsteking als normaal 
beschouwd moet worden. Bij histologisch onderzoek werden 
ontstekingscellen gezien in de coupes, en SKALP zou aanwezig kunnen 
zijn om weefselbeschadiging t.g.v. deze ontstekingscellen te voorkomen. 
In hersenen, het hoornvlies, de overgang van de keelholte naar de 
luchtwegen, de longblaasjes, de luchtpijp, de dunne- en dikke darm, de 
lever en nier, de urinebuis en in de normale huid komt SKALP niet 
voor. Vooral dit laatste is opmerkelijk: ''skin-derixed 
antileukoproteinase', van de huid afkomstig... De naam is wat 
ongelukkig gekozen, en verwijst naar de plaats van productie in 
ontstoken- of beschadigde huid. De gegevens van het weefselonderzoek 
werden bevestigd door Northern blot analyse. 
In de hoofdstukken 6 en 7 wordt gekeken of SKALP gebruikt kan 
worden als instrument om ziekteactiviteit te meten en te vervolgen. 
Hiervoor zijn concentraties van SKALP in urine en bloed gemeten. Deze 
concentraties bleken bij psoriasis patiënten veel hoger te zijn dan bij 
gezonde vrijwilligers of bij patiënten in een klachtenvrije periode. Verder 
bleken de concentraties in het bloed en de urine van de patiënten samen 
te hangen met de ernst van de huidziekte. Tijdens therapie, waarbij de 
psoriasis afnam, werd een daling van de SKALP concentratie in bloed 
en urine gezien. We concludeerden, dat het meten van SKALP 
concentraties inderdaad gebruikt kan worden om de ziekte-activiteit van 
psoriasis te vervolgen. Tevens is van belang dat SKALP-elastase 
complexen aangetoond werden in urine, wat aangeeft dat SKALP 'іи 
vivo' (dus niet alleen in een laboratorium of 'in vitro' situatie) 
daadwerkelijk het proteolytische enzym elastase remt. Weefselafbraak 
t.g.v. een verstoring van het evenwicht tussen een enzym en zijn remmer 
is niet alleen bij ontstekingsprocessen, maar ook bij tumoren beschreven. 
Er wordt dan ook naar mogelijkheden gezocht om dit evenwicht tussen 
enzym en remmer, door het toedienen van een extra hoeveelheid remmer 
in de vorm van tabletten of zalf, te herstellen. SKALP zou een mogelijke 
kandidaat kunnen zijn om als therapie toegepast te worden. 
In de hoofdstukken 8 en 9 zijn studies beschreven, waarbij de 
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aanwezigheid van SKALP in verschillende huidtumoren werd 
waargenomen. Proteolytische enzymen spelen een rol bij de groei van 
tumoren, bij de ingroei in omringend gezond weefsel en bij de doorgroei 
in bloedvaten, wat tot uitzaaiing van de tumor kan leiden. SKALP bleek 
aanwezig te zijn in sommige goedaardige tumoren en in die vormen van 
plaveiselcel carcinomen, waarvan de cellen goed gedifferentieerd waren. 
SKALP kan dan ook mogelijk gebruikt worden om tumoren te 
classificeren, wat belangrijk kan zijn bij het bepalen van de te volgen 
therapie. Direct contact tussen SKALP en PMN werd gezien in 
verschillende weefselcoupes van plaveiselcel carcinomen, maar de 
precieze betekenis hiervan is moeilijk aan te geven, vooral omdat op 
weefselcoupes een statisch en geen dynamisch beeld gezien wordt. Om 
de betekenis van SKALP in tumoren beter te begrijpen, zullen studies 
worden opgezet, waarbij tumoren met en zonder SKALP expressie 
worden ingebracht bij muizen zonder afweersysteem. Ook kan bij 
muizen het erfelijk materiaal wat codeert voor het SKALP eiwit 
uitgeschakeld worden om meer inzicht te verkrijgen in de fysiologische 
functie van SKALP. 
Hoewel enige vragen gesteld in de introductie beantwoord zijn in dit 
proefschrift, is de precieze biologische functie van SKALP nog niet 
geheel bekend. De remming van enzymen afkomstig van PMN is 
suggestief voor een rol in de controle van ontsteking. Het feit dat 
SKALP ook als substraat voor transglutaminase kan dienen en dus 
betrokken kan zijn bij de vorming van de 'comified envelope', de 
buitenste laag dode cellen van de huid, die het grootste deel van de 
huidbarrière functie vervult, kan duiden op een andere rol. Klinisch kan 
SKALP toegepast worden als maat voor ziekte-activiteit bij psoriasis en 
als tumor merkstof bij verschillende huidtumoren. Lokale therapeutische 
toepassing bij regulatie van ontsteking bij verschillende huidziekten 
behoort ook tot de mogelijkheden. 
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STELLINGEN 
behorende bij het proefschrift 
SKIN-DERIVED ANTILEUKOPROTEINASE 
Expression patterns and clinical applications 
Hans Alkemade, Nijmegen, 16 december 1994 
1. De serine proteinase remmer skin-derived antileukoproteinase 
(SKALP) is aanwezig in lesionale psoriatische huid en is een in 
vivo relevante remmer, aangezien zijn aanwezigheid (in 
gecomplexeerde vorm) in urine van ernstig aangedane psoriasis 
patiënten kan worden aangetoond. Dit proefschrift. 
2. De SKALP concentraties in het serum van patiënten met ernstige 
psoriasis correleren met de klinische ernst van de psoriasis zoals 
weergegeven in de 'Psoriasis Area and Severity Index (PASI)', en 
kunnen gebruikt worden als graadmeter voor de ziekte-activiteit. 
Dit proefschrift. 
3. SKALP kan gebruikt worden als een tumor merkstof vanwege zijn 
verschillende expressie in humane epidermale tumoren. Dit 
proefschrift. 
4. Beauty is averageness. (Symons D. The evolution of human 
sexuality [Oxford University Press, 1979] / Langlois JH and 
Roggman LA. Attractive faces are only average. Psychol Sci 1990; 
1:115-121). 
5. Highly attractive facial configurations are not average, and 
preferences may exert a directional selection pressure on the 
evolution of human face shape. (Perrett DI, May KA and 
Yoshikawa S. Facial shape and judgements of female 
attractiveness. Nature 1994; 368:239-242). 
6. De grootte van een probleem is afhankelijk van je standpunt, zodat 
het probleem kleiner lijkt naarmate je haar van verderaf bekijkt. De 
afstand Italië - Nederland is in dezen een redelijke. 
De toegenomen waarde die aan mooie plaatjes bij 
wetenschappelijke artikelen gehecht wordt, leidt mogelijk tot een 
verschuiving van inhoud naar vorm. Dit is mijns inziens een 
slechte ontwikkeling, waarmee niet gezegd is dat ik ook maar iets 
tegen mooie vormen heb. 
Door de waardering voor een afdeling en de toewijzing van 
(wetenschappelijk) personeel te koppelen aan de door die afdeling 
geproduceerde output, kan het publiceren verworden van middel tot 
doel. 
De kwaliteit van een artikel wordt in het algemeen niet bepaald 
door eerstgenoemde auteur; ook hier geldt 'lest best' of, met enig 
gevoel voor understatement, 'last but not least'. 
De oorzaak van teleurstelling moet niet in het resultaat gezocht 
worden maar in de verwachting. 
Voetbal is een van de weinige denksporten waarbij een zekere 
mate van fysiek geweld is toegestaan. 
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